<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle - Glujovsky, D - 2023 | Cochrane Library</title> <meta content="Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle - Glujovsky, D - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013827.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle - Glujovsky, D - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013827.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013827.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle" name="citation_title"/> <meta content="Demián Glujovsky" name="citation_author"/> <meta content="CEGYR (Centro de Estudios en Genética y Reproducción)" name="citation_author_institution"/> <meta content="demian.glujovsky@gmail.com" name="citation_author_email"/> <meta content="Romina Pesce" name="citation_author"/> <meta content="Hospital Italiano de Buenos Aires" name="citation_author_institution"/> <meta content="Mariana Miguens" name="citation_author"/> <meta content="CEGYR (Centro de Estudios en Genética y Reproducción)" name="citation_author_institution"/> <meta content="Carlos Sueldo" name="citation_author"/> <meta content="CEGYR (Centro de Estudios en Ginecologia y Reproducción)" name="citation_author_institution"/> <meta content="Agustín Ciapponi" name="citation_author"/> <meta content="Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD013827.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/11/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013827.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013827.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013827.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Abortion, Spontaneous; Dydrogesterone; Gonadotropin-Releasing Hormone; Gonadotropins; Live Birth; Luteinizing Hormone; *Ovarian Hyperstimulation Syndrome [prevention &amp; control]; Ovulation Induction [methods]; Pregnancy Rate; Progesterone; Progestins [therapeutic use]; Reproductive Techniques, Assisted" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013827.pub2&amp;doi=10.1002/14651858.CD013827.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="JmNqPX1V";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013827\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013827\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","th","ms","hr","fa","pl","fr","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013827.pub2",title:"Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle",firstPublishedDate:"Nov 30, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013827.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013827.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013827.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013827.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013827.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013827.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013827.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013827.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013827.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013827.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1737 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013827.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/full#CD013827-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/full#CD013827-sec-0064"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/full#CD013827-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/full#CD013827-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/full#CD013827-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/full#CD013827-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/full#CD013827-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/full#CD013827-sec-0058"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/appendices#CD013827-sec-0069"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/supinfo/CD013827-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/supinfo/CD013827-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/information#CD013827-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Demián Glujovsky</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/information#CD013827-cr-0005">Romina Pesce</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/information#CD013827-cr-0006">Mariana Miguens</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/information#CD013827-cr-0007">Carlos Sueldo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013827.pub2/information#CD013827-cr-0008">Agustín Ciapponi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/information/en#CD013827-sec-0077">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 November 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013827.pub2">https://doi.org/10.1002/14651858.CD013827.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013827-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013827-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013827-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013827-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013827-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD013827-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013827-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013827-abs-0001" lang="en"> <section id="CD013827-sec-0001"> <h3 class="title" id="CD013827-sec-0001">Background</h3> <p>Currently, gonadotrophin releasing hormone (GnRH) analogues are used to prevent premature ovulation in ART cycles. However, their costs remain high, the route of administration is invasive and has some adverse effects. Oral progestogens could be cheaper and effective to prevent a premature LH surge. </p> </section> <section id="CD013827-sec-0002"> <h3 class="title" id="CD013827-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and safety of using progestogens to avoid spontaneous ovulation in women undergoing controlled ovarian hyperstimulation (COH). </p> </section> <section id="CD013827-sec-0003"> <h3 class="title" id="CD013827-sec-0003">Search methods</h3> <p>We searched the Cochrane Gynaecology and Fertility Group trials register, CENTRAL, MEDLINE, Embase and PsycINFO in Dec 2021. We contacted study authors and experts to identify additional studies. </p> </section> <section id="CD013827-sec-0004"> <h3 class="title" id="CD013827-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that included progestogens for ovulation inhibition in women undergoing controlled ovarian hyperstimulation (COH). </p> </section> <section id="CD013827-sec-0005"> <h3 class="title" id="CD013827-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures recommended by Cochrane, including the risk of bias (RoB) assessment. The primary review outcomes were live birth rate (LBR) and oocyte pick‐up cancellation rate (OPCR). Secondary outcomes were clinical pregnancy rate (CPR), cumulative pregnancy, miscarriage rate (MR), multiple pregnancies, LH surge, total and MII oocytes, days of stimulation, dose of gonadotropins, and moderate/severe ovarian hyperstimulation syndrome (OHSS) rate. The primary analyses were restricted to studies at overall low and some concerns RoB, and sensitivity analysis included all studies. We used the GRADE approach to assess the certainty of evidence. </p> </section> <section id="CD013827-sec-0006"> <h3 class="title" id="CD013827-sec-0006">Main results</h3> <p>We included 14 RCTs (2643 subfertile women undergoing ART, 47 women used oocyte freezing for fertility preservation and 534 oocyte donors). </p> <p><b>Progestogens versus GnRH antagonists</b> </p> <p>We are very uncertain of the effect of medroxyprogesterone acetate (MPA) 10 mg compared with cetrorelix on the LBR in poor responders (odds ratio (OR) 1.25, 95% confidence interval (CI) 0.73 to 2.13, one RCT, N = 340, very‐low‐certainty evidence), suggesting that if the chance of live birth following GnRH antagonists is assumed to be 18%, the chance following MPA would be 14% to 32%. </p> <p>There may be little or no difference in OPCR between progestogens and GnRH antagonists, but due to wide Cs (CIs), we are uncertain (OR 0.92, 95%CI 0.42 to 2.01, 3 RCTs, N = 648, I² = 0%, low‐certainty evidence), changing the chance of OPCR from 4% with progestogens to 2% to 8%. </p> <p>Given the imprecision found, no conclusions can be retrieved on CPR and MR.</p> <p>Low‐quality evidence suggested that using micronised progesterone in normo‐responders may increase by 2 to 6 the MII oocytes in comparison to GnRH antagonists. </p> <p>There may be little or no differences in gonadotropin doses.</p> <p><b>Progestogens versus GnRH agonists</b> </p> <p>Results were uncertain for all outcomes comparing progestogens with GnRH agonists.</p> <p><b>One progestogen versus another progestogen</b> </p> <p>The analyses comparing one progestogen versus another progestogen for LBR did not meet our criteria for primary analyses. </p> <p>The OPCR was probably lower in the MPA 10 mg in comparison to MPA 4 mg (OR 2.27, 95%CI 0.90 to 5.74, one RCT, N = 300, moderate‐certainty evidence), and MPA 4 mg may be lower than micronised progesterone 100 mg, but due to wide CI, we are uncertain of the effect (OR 0.81, 95%CI 0.43 to 1.53, one RCT, N = 300, low‐certainty evidence), changing the chance of OPCR from 5% with MPA 4 mg to 5% to22%, and from 17% with micronised progesterone 100 mg to 8% to 24%. </p> <p>When comparing dydrogesterone 20 mg to MPA, the OPCR is probably lower in the dydrogesterone group in comparison to MPA 10 mg (OR 1.49, 95%CI 0.80 to 2.80, one RCT, N = 520, moderate‐certainty evidence), and it may be lower in dydrogesterone group in comparison to MPA 4 mg but due to wide confidence interval, we are uncertain of the effect (OR 1.19, 95%CI 0.61 to 2.34, one RCT, N = 300, low‐certainty evidence), changing the chance of OPCR from 7% with dydrogesterone 20 to 6‐17%, and in MPA 4 mg from 12% to 8% to 24%. </p> <p>When comparing dydrogesterone 20 mg to micronised progesterone 100 mg, the OPCR is probably lower in the dydrogesterone group (OR 1.54, 95%CI 0.94 to 2.52, two RCTs, N=550, I² = 0%, moderate‐certainty evidence), changing OPCR from 11% with dydrogesterone to 10% to 24%. </p> <p>We are very uncertain of the effect in normo‐responders of micronised progesterone 100 mg compared with micronised progesterone 200 mg on the OPCR (OR 0.35, 95%CI 0.09 to 1.37, one RCT, N = 150, very‐low‐certainty evidence). </p> <p>There is probably little or no difference in CPR and MR between MPA 10 mg and dydrogesterone 20 mg. </p> <p>There may be little or no differences in MII oocytes and gonadotropins doses.</p> <p>No cases of moderate/severe OHSS were reported in most of the groups in any of the comparisons. </p> </section> <section id="CD013827-sec-0007"> <h3 class="title" id="CD013827-sec-0007">Authors' conclusions</h3> <p>Little or no differences in LBR may exist when comparing MPA 4 mg with GnRH agonists in normo‐responders. OPCR may be slightly increased in the MPA 4 mg group, but MPA 4 mg reduces the doses of gonadotropins in comparison to GnRH agonists. </p> <p>Little or no differences in OPCR may exist between progestogens and GnRH antagonists in normo‐responders and donors. However, micronised progesterone could improve by 2 to 6 MII oocytes. </p> <p>When comparing one progestogen to another, dydrogesterone suggested slightly lower OPCR than MPA and micronised progesterone, and MPA suggested slightly lower OPCR than the micronised progesterone 100 mg. Finally, MPA 10 mg suggests a lower OPCR than MPA 4 mg. </p> <p>There is uncertainty regarding the rest of the outcomes due to imprecision and no solid conclusions can be drawn. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013827-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013827-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013827-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013827-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013827-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013827-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD013827-abs-0015">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013827-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013827-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD013827-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013827-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013827-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013827-abs-0002" lang="en"> <h3>Progestogens versus gonadotrophin‐releasing hormone (GnRH) agonists, GnRH antagonists and other progestogens for women undergoing assisted reproductive technology (ART) </h3> <p><b>Review question</b> </p> <p>Cochrane authors reviewed the evidence about the effect of progestogens versus gonadotrophin‐releasing (GnRH) agonists, GnRH antagonists and other progestogens in women undergoing assisted reproductive technology. </p> <p><b>Background</b> </p> <p>GnRH agonists and antagonists are medications that affect hormones related to fertility. They are commonly used to prevent a hormone called luteinising hormone from causing a premature ovulation in women undergoing assisted reproductive technology treatments. This is important because spontaneous ovulation can lead to the cancellation of egg retrieval. However, these medications can be costly and need to be injected. An alternative approach is to use progestogens, which are steroid hormones, as they may be just as effective but are taken orally, which can reduce costs and increase patient satisfaction. We conducted a comparison of the benefits and risks of these two treatments, using different types of progestogens, such as medroxyprogesterone acetate, dydrogesterone and micronised progesterone. </p> <p><b>Study characteristics</b> </p> <p>We found 14 studies comparing oral progestogens with GnRH agonists, antagonists and other progestogens in a total of 3224 women undergoing assisted reproductive technology. The evidence is current to December 2021. </p> <p><b>Key results</b> </p> <p>Fourteen well‐designed studies were included in the analysis.</p> <p><b>Progestogens versus GnRH antagonists</b> </p> <p>The evidence suggests that if the chance of live birth following GnRH antagonists is assumed to be 18%, the chance following medroxyprogesterone acetate (progestogen) would be between 14% and 32%. </p> <p>Cancellation rates may have no differences between progestogens and GnRH antagonists and may be slightly reduced in GnRH agonists in comparison to medroxyprogesterone acetate 4 mg. </p> <p>No conclusions can be retrieved regarding clinical pregnancy rate and miscarriage rate, when comparing progestogens with GnRH antagonists. </p> <p>In women with normal number of eggs (normo‐responders), micronised progesterone (progestogen) may increase by 2 to 6 the number of MII oocytes in comparison to GnRH antagonists. </p> <p>There may be little or no differences in gonadotropin doses.</p> <p><b>Progestogens versus GnRH agonists</b> </p> <p>There may be no differences in live birth rate when comparing medroxyprogesterone acetate 4 mg (progestogen) to GnRH agonist in normo‐responders undergoing assisted reproductive technology. </p> <p>The evidence suggests that if the chance of cycle cancellation following GnRH agonists is assumed to be 5%, the chance following medroxyprogesterone acetate 4 mg (progestogen) would be between 2% and 16%. </p> <p>No conclusions can be retrieved regarding clinical pregnancy rate and miscarriage rate when comparing progestogens with GnRH agonists. </p> <p>There may be little or no differences in MII oocytes.</p> <p>Medroxyprogesterone acetate 4 mg (progestogen) reduces the doses of gonadotropins in comparison to GnRH agonists. </p> <p><b>One progestogen versus another progestogen</b> </p> <p>None of the studies that reported live birth rate were included in the primary analysis.</p> <p>‐ Dydrogesterone probably decreases the cancellation rate in comparison to medroxyprogesterone acetate and micronised progesterone. </p> <p>‐ Medroxyprogesterone acetate suggested a slightly lower cancellation rate in comparison to micronised progesterone 100 mg. </p> <p>‐ Medroxyprogesterone acetate 10 mg probably suggests lower oocyte pick‐up cancellation rates than in medroxyprogesterone acetate 4 mg. </p> <p>‐ Data were lacking on other unwanted effects.</p> <p>The evidence suggests that:</p> <p>‐ if the chance of cancellation following medroxyprogesterone acetate 10 mg is assumed to be 5%, the chance following medroxyprogesterone acetate 4 mg would be between 5% and 22%; </p> <p>‐ if the chance of cancellation following micronised progesterone 100 mg is assumed to be 17%, the chance following medroxyprogesterone acetate 4 mg would be between 8% and 24%; </p> <p>‐ if the chance of cancellation following dydrogesterone 20 mg is assumed to be 7%, the chance following medroxyprogesterone acetate 10 mg would be between 6% and 17%; </p> <p>‐ if the change of cancellation following dydrogesterone 20 mg is assumed to be 12%, the chance following medroxyprogesterone acetate 4 mg would be between 8% and 24% </p> <p>‐ if the chance of cancellation following dydrogesterone 20 mg is assumed to be 11%, the chance following micronised progesterone 100 mg would be between 10% and 24%. </p> <p>There is probably little or no difference in clinical pregnancy rate and miscarriage rate between medroxyprogesterone acetate 10 mg (progestogen) and dydrogesterone 20 mg (progestogen). </p> <p>There may be little or no differences in MII oocytes and in gonadotropin doses.</p> <p>Evidence about other moderate or severe unwanted events was poorly reported and inconclusive for all the comparisons. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>There remains uncertainty about whether any progestogens compared among them or to GnRH antagonists or GnRH agonists changes the chance of having a baby. However, there may be little or no differences in the egg retrieval cancellation rate when compared to GnRH antagonists and progestogens may increase the risk of cancellation when compared to GnRH agonists. Among progestogens, cancellation rate may be lower in dydrogesterone in comparison to the rest, and medroxyprogesterone acetate 10 mg may be better than medroxyprogesterone acetate 4 mg and micronised progesterone. The certainty of the evidence was assessed as low. The reason for this is that most comparisons included only one study that did not recruit a large enough number of women to provide meaningful results. This means that results must be treated cautiously, and further studies are needed to confirm findings. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013827-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013827-sec-0064"></div> <h3 class="title" id="CD013827-sec-0065">Implications for practice</h3> <section id="CD013827-sec-0065"> <p>We are uncertain whether any progestogens in comparison to gonadotrophin releasing hormone (GnRH) agonists, GnRH antagonists, or other progestogens could have differences in live birth rate (LBR) in any subgroup of women undergoing assisted reproductive technology (ART) treatment. </p> <p>Little or no differences in oocyte pick‐up cancellation rate may exist when comparing progestogens with GnRH antagonists in normo‐responders and donors. Oocyte pick‐up cancellation rate may be slightly decreased in medroxyprogesterone acetate (MPA) 4 mg in comparison to GnRH agonists in normo‐responders. When comparing one progestogen with another one, dydrogesterone suggested slightly lower cancellation rates than MPA and micronised progesterone, and MPA suggested slightly lower cancellation rates than the micronised progesterone 100 mg. Finally, MPA 10 mg suggests a lower cancellation rate than MPA 4 mg. These conclusions are based on currently available data which provided low‐certainty evidence across studies. </p> <p>On the other hand, there is probably little or no difference between MPA 10 mg and dydrogesterone 20 mg in clinical pregnancy rate, but low‐certainty evidence suggests that miscarriage rates could be lowered when using dydrogesterone. When comparing progestogens and GnRH analogs, no conclusion can be retrieved on clinical pregnancy rates yet, given the imprecision that was found. </p> <p>It is remarkable that little or no differences in MII oocytes and in doses of gonadotropins were found when comparing progestogens and GnRH analogs in any of the studied populations. We found low‐certainty evidence coming from a single study that suggested that using micronised progesterone in normo‐responders could improve by 2 to 6 the number of MII oocytes in comparison to GnRH antagonists. </p> <p>MPA 4 mg reduces the doses of gonadotropins in comparison to GnRH agonists.</p> <p>There is uncertainty regarding the rest of the outcomes due to imprecision and thus no solid conclusions can be drawn. </p> </section> <h3 class="title" id="CD013827-sec-0066">Implications for research</h3> <section id="CD013827-sec-0066"> <p>As in most studies in the field, there are scarce or an absence of studies evaluating cumulative live birth rates. This is an outcome that should be included in future research. In terms of complications, moderate and severe ovarian hyperstimulation syndrome (OHSS) is mostly not seen due to the low incidence. Therefore, it is important to keep searching and reporting it to find some results in future meta‐analyses. </p> <p>As we can see in this review, there are many types and doses of progestogens, lots of comparators, and several populations to be analysed. This led to many of the included studies having just one or two per analysis. In the future, it is important to keep researching this topic in order to add more data to each of these analyses and, thus, provide a greater certainty of the evidence. </p> <p>No outcomes related to cost‐effectiveness and patients' preferences were found. It could be important to carry out some research on these outcomes in the future, as it seems to be very important to understand if the use of progestogens is worthwhile or not. Currently, no significant differences were found with GnRH analogs, but this increases the need to perform a deferred embryo transfer, which probably includes an additional cost. More research on this topic is necessary to draw more accurate conclusions. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013827-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013827-sec-0008"></div> <div class="table" id="CD013827-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Progestogens compared to GnRH antagonists for assisted reproduction technology cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progestogens compared to GnRH antagonists for assisted reproduction technology cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> assisted reproduction technology cycles<br/><b>Setting:</b> IVF unit<br/><b>Intervention:</b> Progestogens<br/><b>Comparison:</b> GnRH antagonists </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with GnRH antagonists</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Progestogens</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy ‐ total<br/>follow‐up: mean 40 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for poor‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ total<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b><br/>(19 to 84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.92</b><br/>(0.42 to 2.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>648<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders and oocyte donors.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy ‐ Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>229 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>282 per 1000</b><br/>(194 to 391) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.32</b><br/>(0.81 to 2.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for poor‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage ‐ total<br/>follow‐up: mean 14 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We have also performed a secondary analysis per clinical pregnancy. We are uncertain of the effect of MPA in comparison to cetrorelix on the miscarriage rate in poor responders (OR 0.89, 95% CI 0.31 to 2.59, one RCT, N = 87, very low‐ quality evidence). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy ‐ Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>218 per 1000</b><br/>(140 to 322) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.25</b><br/>(0.73 to 2.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normoresponders (MPA 10 mg versus GnRH antagonists) ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(8 to 65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.84</b><br/>(0.28 to 2.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>534<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normoresponders (micronised progesterone 200 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b><br/>(44 to 300) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.00</b><br/>(0.33 to 3.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Premature LH surge ‐ Donor oocytes ‐ Normoresponders ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Premature LH surge ‐ Own oocytes ‐ PCOS (high‐responders) ‐ Early phase stimulation protocol ‐ Frozen embryo transfer </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total oocytes ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total oocytes ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.88 higher</b><br/>(0.77 lower to 2.54 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>534<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>1.85 higher</b><br/>(1.06 lower to 4.76 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MII oocytes</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to pool the studies for this outcome. See details in the analyses</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total dose of gonadotropins (IU) ‐ total</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total dose of gonadotropins (IU) ‐ total was <b>1775</b> IU </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>40.89 IU lower</b><br/>(107.85 lower to 26.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>952<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>When sub‐groups were analyzed, normo‐responders showed little or no differences between progestogens and GnRH antagonists (MD ‐122.0 95% CI [‐259.42 , 15.49], 2 RCTs, N=492; high certainty of evidence) and poor‐responders showed that progestogens may reduce the dose of gonadotropins (MD ‐6.99 95% CI [‐85.31, 71.33], 2 RCTs, N=492; low certainty of evidence) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MII oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MII oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>1.1 higher</b><br/>(1.51 lower to 3.71 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Moderate or severe OHSS ‐ total</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There were no cases reported of moderate or severe OHSS in either analysed groups.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of stimulation (days) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of stimulation (days) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>1.28 lower</b><br/>(2.73 lower to 0.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total dose of gonadotropins (IU) ‐ Poor responders (MPA 10 mg versus GNrH antagoninsts ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total dose of gonadotropins (IU) ‐ Poor responders (MPA 10 mg versus GNrH antagoninsts ‐ Own oocytes ‐ Early phase stimulation protocol was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>122 lower</b><br/>(259.49 lower to 15.49 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total dose of gonadotropins (IU) ‐ Normoresponders ‐ Donor oocytes ‐ Early ophase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total dose of gonadotropins (IU) ‐ Normoresponders ‐ Donor oocytes ‐ Early ophase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>6.99 lower</b><br/>(85.31 lower to 71.33 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>492<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total dose of gonadotropins (IU) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stumulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total dose of gonadotropins (IU) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stumulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>214 lower</b><br/>(588.33 lower to 160.33 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate or severe OHSS ‐ Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate or severe OHSS ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy sensitivity analysis ‐ Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>218 per 1000</b><br/>(140 to 322) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.25</b><br/>(0.73 to 2.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy sensitivity analysis ‐ PCOS (high‐responders) ‐ own oocytes ‐ early phase stimulation protocol ‐ frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>517 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b><br/>(488 to 807) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.87</b><br/>(0.89 to 3.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy sensitivity analysis ‐ total</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders (MPA 10 mg versus GnRH antagonists) ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(8 to 65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.84</b><br/>(0.28 to 2.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>534<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders (micronised progesterone 200 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b><br/>(44 to 300) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.00</b><br/>(0.33 to 3.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation sensitivity analysis ‐ PCOS (high‐responders)(micronised progesterone 100 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(0 to 122) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.33</b><br/>(0.01 to 8.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation sensitivity analysis ‐ total</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/>(16 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.86</b><br/>(0.40 to 1.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>768<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425213674817892961" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425213674817892961</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded 1 level for some concerns of risk of bias due to the randomization process<br/><sup>b</sup> Downgraded 2 levels for imprecision ‐ due to low number of participants n &lt; 400 and very wide confidence intervals including both substantial benefit and harm<br/><sup>c</sup> Some concerns of risk of bias due to the randomization process and the measurement of the outcome<br/><sup>d</sup> Downgraded 1 level for imprecision ‐ due to low number of participants n &lt; 400 and wide confidence intervals including both benefit and harm<br/><sup>e</sup> Downgraded 1 level for inconsistency I2=50.7% </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013827-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Progestagen compared to GnRH agonist for assisted reproduction technology cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progestagen compared to GnRH agonist for assisted reproduction technology cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> assisted reproduction technology cycles<br/><b>Setting:</b> IVF unit<br/><b>Intervention:</b> Progestagen<br/><b>Comparison:</b> GnRH agonist </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with GnRH agonist</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Progestagen</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy<br/>follow‐up: mean 40 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>469 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>454 per 1000</b><br/>(339 to 575) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.94</b><br/>(0.58 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b><br/>(22 to 163) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.36</b><br/>(0.46 to 4.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Pregnancy<br/>follow‐up: mean 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>531 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>499 per 1000</b><br/>(379 to 620) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.88</b><br/>(0.54 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage<br/>follow‐up: mean 14 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/>(6 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.49</b><br/>(0.12 to 2.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We have also performed a secondary analysis per clinical pregnancy. MPA 4 mg may reduce the miscarriage rate in comparison to GnRH agonists but the confidence interval is large (OR 0.51, 95% CI 0.12 to 2.12, one RCT, N = 134,low‐ quality evidence). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MII oocytes<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MII oocytes was <b>10.1</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.2 higher</b><br/>(1.14 lower to 1.54 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total dose of gonadotropins (IU)<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total dose of gonadotropins (IU) was <b>2673</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>645 lower</b><br/>(763.04 lower to 526.96 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate or severe OHSS<br/>follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b><br/>(0 to 61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.14</b><br/>(0.01 to 2.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425168573456335049" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425168573456335049</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded 2 levels for imprecision ‐ due to low number of participants n &lt; 400 and very wide confidence intervals including both substantial benefit and harm<br/><sup>b</sup> Downgraded 1 level for risk of bias ‐ due to some concerns of risk of bias due to lack of definition of the outcome<br/><sup>c</sup> Downgraded 1 level for imprecision ‐ due to low number of participants n &lt; 400 and wide confidence intervals including both benefit and no clinical difference. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013827-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ Progestogen 1 compared to Progestogen 2 for assisted reproduction technology cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progestogen 1 compared to Progestogen 2 for assisted reproduction technology cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> assisted reproduction technology cycles<br/><b>Setting:</b> IVF unit<br/><b>Intervention:</b> Progestogen 1<br/><b>Comparison:</b> Progestogen 2 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Progestogen 2</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Progestogen 1</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study at low risk or at some concerns of bias reported this outcome in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>139 per 1000</b><br/>(79 to 234) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.81</b><br/>(0.43 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(42 to 219) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.27</b><br/>(0.90 to 5.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>140 per 1000</b><br/>(77 to 242) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.19</b><br/>(0.61 to 2.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(56 to 172) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.49</b><br/>(0.80 to 2.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>520<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normo‐responders (Dydrogesterone 20 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b><br/>(73 to 172) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.65</b><br/>(0.40 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>107 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b><br/>(11 to 141) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.35</b><br/>(0.09 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy ‐ Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>481 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>507 per 1000</b><br/>(422 to 592) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.11</b><br/>(0.79 to 1.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>520<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage ‐ Miscarriage per randomised woman ‐ Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b><br/>(21 to 114) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.66</b><br/>(0.68 to 4.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>520<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We have also performed a secondary analysis per clinical pregnancy. We are uncertain of the effect MPA 10 mg in comparison to dydrogesterone 20 mg on the miscarriage rate (OR 1.60, 95% CI 0.64 to 4.00, one RCT, N = 257 low‐ quality evidence). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MII oocytes</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to pool the studies for this outcome. See details in the analyses</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total dose of gonadotropins</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to pool the studies for this outcome. See details in the analyses</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate or severe OHSS</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to pool the studies for this outcome. See details in the analyses</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425214297148274130" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425214297148274130</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded 2 levels for imprecision ‐ due to low number of participants n &lt; 400 and very wide confidence intervals including both substantial benefit and harm<br/><sup>b</sup> Downgraded 1 level for imprecision ‐ due to low number of participants n &lt; 400 and wide confidence intervals including both benefit and harm<br/><sup>c</sup> Downgraded one level for serious risk of bias: overall some concerns of risk of bias due to the randomisation process </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013827-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013827-sec-0009"></div> <section id="CD013827-sec-0010"> <h3 class="title" id="CD013827-sec-0010">Description of the condition</h3> <p>Infertility remains a highly prevalent global condition, affecting between 8% and 12% of reproductive‐aged couples, and assisted reproductive technology (ART) procedures appear to be a good option for many infertility causes (<a href="./references#CD013827-bbs2-0050" title="InhornMC , PatrizioP . Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. Human Reproduction Update2015;21(4):411-26.">Inhorn 2015</a>). Prognosis depends mainly on the woman's age, and there is evidence showing that it is also related to the number of oocytes retrieved (poor responders, normo‐responders, and high responders) (<a href="./references#CD013827-bbs2-0043" title="GoldmanRH , RacowskyC , FarlandLV , MunnéS , RibustelloL , FoxJH . Predicting the likelihood of live birth for elective oocyte cryopreservation: a counseling tool for physicians and patients. Human Reproduction2017;32(4):853-9.">Goldman 2017</a>). ART is performed not only for women with infertility but also for women donating oocytes to women with infertility. ART involves different steps that are constantly reviewed in order to improve results. In a spontaneous cycle, oestradiol rises to reach a critical point prior to ovulation, exerting positive feedback on the hypothalamus and pituitary gland that triggers the luteinising hormone (LH) surge (<a href="./references#CD013827-bbs2-0049" title="HoleshJE , BassAN , Lord M. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 20 20.">Holesh 2020</a>). In controlled ovarian hyperstimulation (COH), a premature LH surge and its consequences are potential complications of significant concern for both physicians and women undergoing ART; they may result in spontaneous ovulation, leading to ART cycle cancellation. Over the years, several strategies have been developed to prevent premature ovulation and consequent in vitro fertilisation (IVF) cycle cancellation. From the 1980s, the use of gonadotropin‐releasing hormone (GnRH) agonists was the main tool available, through long, short, and ultrashort protocols (<a href="./references#CD013827-bbs2-0038" title="DepaloR , JayakrishanK , GarrutiG , TotaroI , PanzarinoM , GiorginoF , et al. GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). Reproductive and Biological Endocrinology2012;10(1):26.">Depalo 2012</a>). Protocols with GnRH agonists have some disadvantages; for instance, long desensitisation periods in which pituitary gonadotropin secretions are blocked, which could lower the number of retrieved oocytes; the risk of ovarian hyperstimulation syndrome (OHSS); and possible side effects, such as hot flushes and headaches (<a href="./references#CD013827-bbs2-0038" title="DepaloR , JayakrishanK , GarrutiG , TotaroI , PanzarinoM , GiorginoF , et al. GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). Reproductive and Biological Endocrinology2012;10(1):26.">Depalo 2012</a>). They also have other drawbacks: the route of administration is invasive because they are injectable (intramuscular or subcutaneous) and the costs of the medications are high (<a href="./references#CD013827-bbs2-0033" title="BegueríaR , GarcíaD , VassenaR , RodríguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80.">Beguería 2019</a><a href="./references#CD013827-bbs2-0040" title="Ethics Committee of the American Society for Reproductive Medicine. Disparities in access to effective treatment for infertility in the United States: an Ethics Committee opinion. Fertility and Sterility2015;104(5):1104-10.">Ethics 2015</a>). In the late 1990s, GnRH antagonists became available for ART, in order to prevent premature ovulation. As they offer advantages for women undergoing ART, they have been used quite frequently, but costs remain high (<a href="./references#CD013827-bbs2-0052" title="La Marca, CapuzzoM . Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era?Reproductive Biomedicine Online2019;39(2):321-31.">La Marca 2019</a>; <a href="./references#CD013827-bbs2-0063" title="WangR , LinS , WangY , QianW , ZhouL . Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: a systematic review and meta-analysis. PLOS One2017;12(4):e0175985.">Wang 2017</a>). </p> <p>Despite the administration of GnRH analogs, premature progesterone elevation still occurs in around 5% to 38% of cycles (<a href="./references#CD013827-bbs2-0033" title="BegueríaR , GarcíaD , VassenaR , RodríguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80.">Beguería 2019</a>; <a href="./references#CD013827-bbs2-0042" title="EvansMB , ParikhT , DeCherneyAH , CsokmayJM , HealyMW , HillMJ . Evaluation of the cost-effectiveness of ovulation suppression with progestins compared with GnRH analogs in assisted reproduction cycles. Reproductive Biomedicine Online2019;38(5):691-8.">Evans 2019</a>). </p> </section> <section id="CD013827-sec-0011"> <h3 class="title" id="CD013827-sec-0011">Description of the intervention</h3> <p>It is well known that oestradiol and progesterone that are produced by the ovaries regulate hypothalamic function. One of progesterone’s end roles is to inhibit LH secretion (<a href="./references#CD013827-bbs2-0033" title="BegueríaR , GarcíaD , VassenaR , RodríguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80.">Beguería 2019</a>). In ART, progestogens (including both progesterone (synthesised by the human body) and progestins (synthetic progestational agents) are proposed to be used for LH surge inhibition, in both early and late follicular phase stimulation as well as in luteal phase stimulations. A main problem that appears with the use of progestogens in IVF cycles is a prematurely advanced stage endometrium, which leads to an asynchrony between the embryo and the endometrial pattern. For this reason, these protocols should always be used whenever the embryo transfer is not going to be performed in fresh (<a href="./references#CD013827-bbs2-0041" title="EvansMB , HealyMW , DeCherneyAH , HillMJ . Adverse effect of prematurely elevated progesterone in in vitro fertilization cycles: a literature review. Biology of Reproduction2018;99(1):45-51.">Evans 2018</a>), such as in oocyte donor cycles, oocyte freezing cycles, and other conditions that require deferred embryo transfers. In progestogen‐primed COH, it is recommended to administer oral medroxyprogesterone acetate 10 mg/day from early in the follicular phase, throughout the COH protocol (<a href="./references#CD013827-bbs2-0051" title="KuangY , ChenQ , FuY , WangY , HongQ , LyuQ , et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertility and Sterility2015;104(1):62-70.">Kuang 2015</a>; <a href="./references#CD013827-bbs2-0065" title="YuS , LongH , ChangHY , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37.">Yu 2018</a>); when performing a luteal phase stimulation, the progesterone should be administered early in the luteal phase. Medroxyprogesterone acetate has been successfully prescribed, but other progestogens, such as dydrogesterone and micronised progesterone, have also been reported to be effective (<a href="./references#CD013827-bbs2-0051" title="KuangY , ChenQ , FuY , WangY , HongQ , LyuQ , et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertility and Sterility2015;104(1):62-70.">Kuang 2015</a>; <a href="./references#CD013827-bbs2-0056" title="MassinN . New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Human Reproduction Update2017;23(2):211-20.">Massin 2017</a>; <a href="./references#CD013827-bbs2-0065" title="YuS , LongH , ChangHY , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37.">Yu 2018</a>). Additional benefits of progestogens are their oral route of administration and greater affordability (<a href="./references#CD013827-bbs2-0052" title="La Marca, CapuzzoM . Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era?Reproductive Biomedicine Online2019;39(2):321-31.">La Marca 2019</a>). </p> <p>On the other hand, a relevant drawback of using progestogens is the need for a freeze‐all approach, avoiding a fresh embryo transfer due to the presence of an asynchronic endometrium (<a href="./references#CD013827-bbs2-0054" title="LiuL , HuangJ , LiTC , HongXT , LairdS , DaiYD , et al. The effect of elevated progesterone levels before oocyte retrieval in women undergoing ovarian stimulation for IVF treatment on the genomic profile of peri-implantation endometrium. Journal of Reproductive Immunology2017;121:17-25.">Liu 2017</a>; <a href="./references#CD013827-bbs2-0061" title="Van VaerenberghI , FatemiHM , BlockeelC , Van LommelL , In’t VeldP , SchuitF , et al. Progesterone rise on HCG day in GnRH antagonist/rFSH stimulated cycles affects endometrial gene expression. Reproductive Biomedicine Online2011;22(3):263-71.">Van Vaerenbergh 2011</a>). This issue could not only increase the time‐to‐pregnancy, but also increase the total cost of the procedure by adding frozen‐thawed embryo transfer steps. Nevertheless, freeze‐all with delayed transfer is not an unusual approach in ART, as it has multiple indications (i.e. oocyte freezing for cancer or any other reason, oocyte donation, preimplantation genetic testing, in women at risk of OHSS, and in non‐conventional cycles such as double stimulation or random‐start) (<a href="./references#CD013827-bbs2-0042" title="EvansMB , ParikhT , DeCherneyAH , CsokmayJM , HealyMW , HillMJ . Evaluation of the cost-effectiveness of ovulation suppression with progestins compared with GnRH analogs in assisted reproduction cycles. Reproductive Biomedicine Online2019;38(5):691-8.">Evans 2019</a>; <a href="./references#CD013827-bbs2-0051" title="KuangY , ChenQ , FuY , WangY , HongQ , LyuQ , et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertility and Sterility2015;104(1):62-70.">Kuang 2015</a>; <a href="./references#CD013827-bbs2-0056" title="MassinN . New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Human Reproduction Update2017;23(2):211-20.">Massin 2017</a>). It should be noted that evidence about the effectiveness of freeze‐all cycles is still uncertain. Some authors promote routine freeze‐all cycles electively in women with polycystic ovary syndrome (PCOS) (<a href="./references#CD013827-bbs2-0036" title="ChenZJ , ShiY , SunY , ZhangB , LiangX , CaoY , et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. New England Journal of Medicine2016;375(6):523-33.">Chen 2016</a>). Others have shown a benefit in live birth rate, but also an increase in some maternal and perinatal complications (<a href="./references#CD013827-bbs2-0064" title="WeiD , LiuJY , SunY , ShiY , ZhangB , LiuJQ , et al. Frozen versus fresh single blastocyst transfer in ovulatory women: a multicentre, randomised controlled trial. Lancet2019;393(10178):1310-8.">Wei 2019</a>). There are also many publications that show that freeze‐all makes no difference and should not be used routinely (<a href="./references#CD013827-bbs2-0059" title="ShiY , SunY , HaoC , ZhangH , WeiD , ZhangY , et al. Transfer of fresh versus frozen embryos in ovulatory women. New England Journal of Medicine2018;378(2):126-36.">Shi 2018</a>; <a href="./references#CD013827-bbs2-0062" title="VuongLN , DangVQ , HoTM , HuynhBG , HaDT , PhamTD , et al. IVF transfer of fresh or frozen embryos in women without polycystic ovaries. New England Journal of Medicine2018;378(2):137-47.">Vuong 2018</a>) </p> </section> <section id="CD013827-sec-0012"> <h3 class="title" id="CD013827-sec-0012">How the intervention might work</h3> <p>The use of progesterone and its progestogen derivatives (PPOS i.e. progestin‐primed ovarian stimulation) in ART could be considered valid and novel alternatives in controlled ovarian stimulation protocols. The implementation of progestogens is based on effective inhibition of the endogenous LH surge, either with the levels reached in a natural cycle, or when administered exogenously (<a href="./references#CD013827-bbs2-0056" title="MassinN . New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Human Reproduction Update2017;23(2):211-20.">Massin 2017</a>). As the LH surge provokes the initiation of the ovulation process, and given that a spontaneous ovulation could lead to retrieval of no oocytes and, therefore, a cycle cancellation, the LH surge is associated with a reduction of the success rate per initiated cycle. </p> <p>Progestogens are hormones that are involved in many different physiological actions, such as the neuroendocrine influence on ovulation and on the cyclicity of the reproductive tract; they also have an important role in the metabolism of carbohydrates, lipids and proteins (<a href="./references#CD013827-bbs2-0052" title="La Marca, CapuzzoM . Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era?Reproductive Biomedicine Online2019;39(2):321-31.">La Marca 2019</a>). From traditional contraception studies, it is known that progesterone has an inhibitory effect on ovulation, with an ability to block the LH surge (<a href="./references#CD013827-bbs2-0047" title="HeikinheimoO , GordonK , WilliamsRF , HodgenGD . Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions. Contraception1996;53:55-64.">Heikinheimo 1996</a>). The action of progesterone is achieved through its nuclear receptors, and different circulating concentrations significantly change the frequency of the hypothalamic GnRH pulses, modifying the secretion of pituitary LH (<a href="./references#CD013827-bbs2-0046" title="HallJ . Chapter 8: Neuroendocrine control of the menstrual cycle. In: StraussJ , BarbieriR , editors(s). Yen &amp; Jaffe's Reproductive Endocrinology Physiology, Pathophysiology, and Clinical Management. 8th edition. Elsevier, 2013.">Hall 2013</a>). </p> <p>Despite the importance of progesterone in the control of GnRH secretion from the hypothalamus, the neuroendocrine mechanisms through which progesterone interacts with oestradiol to regulate the control of gonadotrophin secretion is not fully understood (<a href="./references#CD013827-bbs2-0052" title="La Marca, CapuzzoM . Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era?Reproductive Biomedicine Online2019;39(2):321-31.">La Marca 2019</a>). Progesterone appears to decrease the frequency of LH pulses and increase their amplitude. This produces a reduction in the circulating concentrations of LH and cessation of its action. The inhibition of the LH surge with progestogens could be a good alternative to GnRH analogues in controlling endogenous LH peak during ovarian stimulation in ART cycles. </p> </section> <section id="CD013827-sec-0013"> <h3 class="title" id="CD013827-sec-0013">Why it is important to do this review</h3> <p>Recent publications have shown that the use of progestogens could be effective in inhibiting the LH surge (<a href="./references#CD013827-bbs2-0056" title="MassinN . New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Human Reproduction Update2017;23(2):211-20.">Massin 2017</a>). They also showed that the results in terms of number of oocytes retrieved, fertilisation rate, clinical pregnancy and live birth rates were not different in comparison to the use of traditional GnRH analogues (<a href="./references#CD013827-bbs2-0051" title="KuangY , ChenQ , FuY , WangY , HongQ , LyuQ , et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertility and Sterility2015;104(1):62-70.">Kuang 2015</a>). Of course, it is also important to assess whether the length of ovarian stimulation and cancellation rates are similar, as these factors will impact on the treatment cost and its effectiveness. </p> <p>These are some potential advantages of using progestogens: their low cost, oral administration, and the likely lower incidence of adverse effects and complications such as a rash, pain or bruising at the site of injection, and abdominal pain or tenderness (<a href="./references#CD013827-bbs2-0039" title="EngmannL , ShakerA , WhiteE . Local side effects of subcutaneous and intramuscular urinary gonadotropins for ovarian stimulation in in vitro fertilization: a prospective, randomized study. Fertility and Sterility1998;69(5):836-40.">Engmann 1998</a>; <a href="./references#CD013827-bbs2-0042" title="EvansMB , ParikhT , DeCherneyAH , CsokmayJM , HealyMW , HillMJ . Evaluation of the cost-effectiveness of ovulation suppression with progestins compared with GnRH analogs in assisted reproduction cycles. Reproductive Biomedicine Online2019;38(5):691-8.">Evans 2019</a>; <a href="./references#CD013827-bbs2-0054" title="LiuL , HuangJ , LiTC , HongXT , LairdS , DaiYD , et al. The effect of elevated progesterone levels before oocyte retrieval in women undergoing ovarian stimulation for IVF treatment on the genomic profile of peri-implantation endometrium. Journal of Reproductive Immunology2017;121:17-25.">Liu 2017</a>; <a href="./references#CD013827-bbs2-0061" title="Van VaerenberghI , FatemiHM , BlockeelC , Van LommelL , In’t VeldP , SchuitF , et al. Progesterone rise on HCG day in GnRH antagonist/rFSH stimulated cycles affects endometrial gene expression. Reproductive Biomedicine Online2011;22(3):263-71.">Van Vaerenbergh 2011</a>). A higher incidence of some mild adverse effects could be expected, such as: feeling light‐headed; vertigo; drowsiness; and bloating (<a href="./references#CD013827-bbs2-0035" title="CheckJH . Luteal phase support in assisted reproductive technology treatment: focus on Endometrin® (progesterone) vaginal insert.. Therapeutics and Clinical Risk Management2009;5(4):403-7.">Check 2009</a>). </p> <p>This review will help to analyse the available evidence on the effectiveness of progestogens in inhibiting the LH surge, in order to prevent spontaneous ovulations in ART treatments. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013827-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013827-sec-0014"></div> <p>To evaluate the effectiveness and safety of using progestogens to avoid spontaneous ovulation in women undergoing controlled ovarian hyperstimulation (COH). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013827-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013827-sec-0015"></div> <section id="CD013827-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013827-sec-0017"> <h4 class="title">Types of studies</h4> <p>We only included parallel‐group randomised controlled trials (RCTs), randomised at the participant level. We planned to include cluster‐randomised trials. We excluded quasi‐RCTs. We also excluded cross‐over trials, unless data were available separately for the phase before the participants crossed over. </p> </section> <section id="CD013827-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies of infertile women undergoing controlled ovarian hyperstimulation (COH) for an ART procedure: all In vitro fertilisation (IVF) procedures were eligible, i.e. with or without intracytoplasmic sperm injection (ICSI); with or without pre‐implantation genetic testing for aneuploidy (PGT‐a); with own or donor sperm. We also included studies in which the participants were oocyte donors. And we included women undergoing controlled ovarian hyperstimulation for oocyte freezing (for fertility preservation). </p> </section> <section id="CD013827-sec-0019"> <h4 class="title">Types of interventions</h4> <p>The interventions of interest were progestogens used in order to prevent a premature LH surge during a controlled ovarian hyperstimulation (COH), versus no intervention, placebo, or any other active intervention (i.e. subcutaneous gonadotropin releasing hormone analogues such as ganirelix acetate or cetrorelix acetate administered in 0.25 mg/day, or triptorelin acetate 0.1 mg/day). Any route of administration was eligible. </p> <p>We also compared different doses and types of progestogens with each other (i.e. medroxyprogesterone acetate at doses 10 mg/day, natural micronised progesterone 100 mg to 200 mg/day orally, or oral administration of dydrogesterone 20 mg/day). </p> </section> <section id="CD013827-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD013827-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013827-list-0001"> <li> <p>Live birth, or ongoing pregnancy rate when live birth is not reported (number of births of one or more living infants or ongoing pregnancies per number of randomised women) at the first embryo transfer. </p> <ul id="CD013827-list-0002"> <li> <p>Live birth is defined as delivery of a live foetus after 20 completed weeks of gestation.</p> </li> <li> <p>Ongoing pregnancy is defined as evidence of a gestational sac with fetal heart motion at 12 weeks, confirmed by ultrasound. </p> </li> </ul> </li> <li> <p>Oocyte pick‐up cancellation rate (number of women with at least one cancelled cycle per number of randomised women) </p> </li> </ol> </p> </section> <section id="CD013827-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013827-list-0003"> <li> <p>Clinical pregnancy, defined as evidence of a gestational sac, confirmed by ultrasound (number of pregnancies with at least one sac, per number of randomised women). </p> </li> <li> <p>Cumulative clinical pregnancy/live birth, defined as the clinical pregnancy or live birth derived from all the embryo transfers performed with all the embryos coming from a single oocyte retrieval. </p> </li> <li> <p>Miscarriage rate (number of pregnancies ending in the spontaneous loss of the embryo or foetus before 20 weeks of gestation) per woman randomised. </p> </li> <li> <p>Multiple pregnancy rate (number of pregnancies with two or more foetuses per woman randomised). </p> </li> <li> <p>LH surge (mean level of LH on the day of ovulation triggering).</p> </li> <li> <p>Number of total oocytes (mean number of total oocytes retrieved).</p> </li> <li> <p>Number of MII oocytes (mean number of MII oocytes retrieved).</p> </li> <li> <p>Number of days of stimulation (mean number of days of stimulation, measured from the first day of gonadotropins/clomiphene citrate/letrozole until the day of triggering). </p> </li> <li> <p>Total dose of gonadotropins (mean dose of follicle stimulating hormone).</p> </li> <li> <p>Other adverse effects (at least one of the following adverse effects: moderate or severe <b>:</b> ovarian; hyperstimulation syndrome (OHSS) (according to the study authors' classification) or any related adverse effect that leads to stopping of the ovarian stimulation. </p> </li> </ol> </p> </section> </section> </section> <section id="CD013827-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all published and unpublished RCTs of progestogens for ovulation inhibition in women undergoing controlled ovarian hyperstimulation, without restrictions on language or publication status and in consultation with the Cochrane Gynaecology and Fertility (CGF) Information Specialist. </p> <section id="CD013827-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases for relevant trials:</p> <p> <ol id="CD013827-list-0004"> <li> <p>The Cochrane Gynaecology and Fertility Group (CGF) Specialised Register of Controlled Trials; PROCITE platform, from inception to December 2021 (<a href="./appendices#CD013827-sec-0070">Appendix 1</a>); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL); via the Cochrane Register of Studies Online (CRSO), web platform, from inception to December 2020 (<a href="./appendices#CD013827-sec-0071">Appendix 2</a>); </p> </li> <li> <p>MEDLINE Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations; Ovid platform, from 1946 to December 2021 (<a href="./appendices#CD013827-sec-0072">Appendix 3</a>); </p> </li> <li> <p>Embase; Ovid platform, from 1980 to December 2021 (<a href="./appendices#CD013827-sec-0073">Appendix 4</a>); and </p> </li> <li> <p>PsycINFO; Ovid platform, from 1806 to December 2021 (<a href="./appendices#CD013827-sec-0074">Appendix 5</a>). </p> </li> </ol> </p> <p>We combined the MEDLINE search with the Cochrane highly sensitive search strategy for identifying randomised trials, which appears in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013827-bbs2-0048" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). </p> <p>Other electronic sources of trials included:</p> <p> <ol id="CD013827-list-0005"> <li> <p>LILACS and other Spanish and Portuguese language databases (Latin American and Caribbean Health Science Information database (from 1982 ongoing), found in the Virtual Health Library Regional Portal (<a href="http://pesquisa.bvsalud.org/portal/" target="_blank">pesquisa.bvsalud.org/portal/</a>); and </p> </li> <li> <p>Google Scholar (for recent trials not yet indexed in the major databases).</p> </li> </ol> </p> </section> <section id="CD013827-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We handsearched reference lists of relevant trials and systematic reviews retrieved by the search, and contact experts in the field to obtain additional data. We also handsearched relevant journals and conference abstracts that are not covered in the CGF register, in liaison with the Information Specialist. We planned toy contact the original authors for clarification and further data if trial reports were unclear. </p> </section> </section> <section id="CD013827-sec-0026"> <h3 class="title" id="CD013827-sec-0026">Data collection and analysis</h3> <section id="CD013827-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Three review authors (DG, MM and RP) independently screened the identified records by title and abstract, and retrieved all the full texts of the potentially eligible studies. Two review authors (DG and RP) independently examined these full‐text articles for compliance with the inclusion criteria and selected eligible studies. We corresponded with study investigators as required, to clarify study eligibility. We resolved any disagreements by discussion. If any reports required translation, we described the process used for data collection. We documented the selection process with a 'PRISMA' flow chart. </p> </section> <section id="CD013827-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Pairs of review authors (from DG, AC, RP, MM) independently extracted data from eligible studies using a data extraction form designed and pilot‐tested by the review authors. We resolved any disagreements by discussion. Extracted data included study characteristics and outcome data. Where studies have multiple publications, the review authors collated multiple reports of the same under a single study ID with multiple references. We corresponded with study investigators for further data on methods or results, as required. </p> </section> <section id="CD013827-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (DG and AC) independently assessed the included studies for risk of bias using the Cochrane Risk of bias 2 '(RoB2) assessment tool (<a href="https://methods.cochrane.org/risk-bias-2" target="_blank">RoB2</a>; <a href="./references#CD013827-bbs2-0060" title="SterneJA , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898.">Sterne 2019</a>). We carried out the risk of bias assessments for the following outcomes: live birth rate/ongoing pregnancy rate, clinical pregnancy rate, cycle cancellation rate, number of days of stimulation and other adverse effects. The effects of interest were the effect of assignment to the intervention at baseline, regardless of whether the interventions are received as intended (the 'intention‐to‐treat' effect). </p> <p>RoB2 assesses five domains:</p> <p> <ul id="CD013827-list-0006"> <li> <p>bias arising from the randomisation process;</p> </li> <li> <p>bias due to deviations from intended interventions;</p> </li> <li> <p>bias due to missing outcome data;</p> </li> <li> <p>bias in measurement of the outcome; and</p> </li> <li> <p>bias in selection of the reported result.</p> </li> </ul> </p> <p>For cluster‐randomised trials, we planned to include an additional domain for bias arising from the timing of identification and recruitment of participants, and included the corresponding signalling questions. </p> <p>These domain‐level judgements provide the basis for an overall risk of bias judgement for the specific trial result being assessed. We classified judgements as 'low risk of bias', 'some concerns' and 'high risk of bias', as suggested by the tool in response to answers to signalling questions for each domain and an algorithm in the tool. We then reached our overall judgement following the algorithm in the tool, as recommended in Chapter 8 of <i>The Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013827-bbs2-0048" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). We resolved any disagreements by discussion. We describe all judgements fully and present the consensus judgements in the main review document (e.g. as a table, or a figure, or within a forest plot of the results). </p> <p>We presented the primary analysis including trials to be judged at overall low risk bias or with some concerns with regard to bias. We pooled all the data for the primary analysis and conducted a sensitivity analysis to assess the effects of restricting the analysis to RCTs with an overall risk of bias rating of 'low/some concerns', for all the outcomes. </p> <p>We sought additional information on trial methodology or actual original trial data from the principal author of trials that appear to meet eligibility criteria but are unclear in aspects of methodology, or where the data were in a form unsuitable for meta‐analysis. We sent reminder correspondence if we did not receive a reply within three weeks. </p> <p>We used the RoB2 Excel tool to implement RoB2 (available on the <a href="https://www.riskofbias.info/welcome/rob-2-0-tool" target="_blank">riskofbias.info</a> website), and stored data for presentation in an online repository in <a href="https://doi.org/10.6084/m9.figshare.17169095.v2" target="_blank">Figshare</a>. </p> </section> <section id="CD013827-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data (e.g. live birth rates), we used the numbers of events in the control and intervention groups of each study to calculate Mantel‐Haenszel odds ratios (ORs) or (where events are very rare) Peto ORs. For continuous data (e.g. total dose of gonadotropins), we calculated mean difference (MD) between treatment groups if all studies report exactly the same outcomes. We treated ordinal data (e.g. number of days of stimulation) as continuous data. We presented 95% confidence intervals (CIs) for all outcomes. Where data to calculate ORs or MDs were not available, we utilised the most detailed numerical data available that may facilitate similar analyses of included studies (e.g. test statistics, P values). We assessed whether the estimates calculated in the review for individual studies were compatible in each case with the estimates reported in the study publications. </p> </section> <section id="CD013827-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The primary analysis was per woman randomised, and we also included per clinical pregnancy data for some outcomes (e.g. miscarriage and multiple pregnancy). We counted multiple births as one live birth event. </p> </section> <section id="CD013827-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We analysed the data on an intention‐to‐treat (ITT) basis as far as possible (i.e. including all randomised participants in the analysis, in the groups to which they were randomised). We attempted to obtain any missing data from the original trialists. Where these were unobtainable, we undertook imputation of individual values for all dichotomous outcomes: we assumed that the outcome did not occur in participants without a reported outcome. </p> <p>Primary outcome oocyte pickup cancellation rate: we note that many studies reporting this outcome in the literature exclude cycles cancelled when reporting this outcome. We were unable to get confirmation from trial authors of studies considered for inclusion in this review. Cancellation cycle rates were usually very low and, therefore, the impact is probably marginal. </p> <p>If studies reported sufficient detail to calculate mean differences but no information on associated standard deviation (SD), we assumed the outcome to have an SD equal to the highest SD from other studies within the same analysis. </p> </section> <section id="CD013827-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether the clinical and methodological characteristics of the included studies are sufficiently similar for meta‐analysis to provide a clinically meaningful summary. We measured statistical heterogeneity using the I<sup>2</sup> statistic. Following <i>The Cochrane Handbook</i> (<a href="./references#CD013827-bbs2-0048" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>), we interpreted an I<sup>2</sup> statistic of over 50% as indicating substantial heterogeneity. </p> </section> <section id="CD013827-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. If there were 10 or more studies in an analysis, we used a funnel plot to explore the possibility of small‐study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies). </p> </section> <section id="CD013827-sec-0035"> <h4 class="title">Data synthesis</h4> <p>If the studies are sufficiently similar, we combined the data using a fixed‐effect model for the following comparisons. </p> <p>1. Progestogens versus GnRH antagonists</p> <p>2. Progestogens versus GnRH agonists</p> <p>3. One progestogen versus another progestogen</p> <p>4. Progestogens versus placebo or no treatment</p> <p>We carried out the statistical analysis using <a href="./references#CD013827-bbs2-0058" title="Review Manager Web (RevMan Web). Version 2.0.1. The Cochrane Collaboration, 2020. Available at: revman.cochrane.org.">RevMan Web 2020</a>. </p> </section> <section id="CD013827-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where data were available, we conducted subgroup analyses to determine the separate evidence within the following subgroups. </p> <p> <ol id="CD013827-list-0007"> <li> <p>Mode of administration (intramuscular, vaginal, subcutaneous or oral)</p> </li> <li> <p>Dose (low or high)</p> </li> <li> <p>Expected ovarian response (poor‐responders, normo‐responders or high‐responders) (as defined by the authors of each study) </p> </li> <li> <p>Phase in which the COH is started (early follicular phase; late follicular phase; luteal phase; random start; not specified) </p> </li> <li> <p>Age (≥ 40 and &lt; 40 years old)</p> </li> <li> <p>Own oocytes versus donor oocytes</p> </li> <li> <p>Fresh or frozen embryo transfer</p> </li> </ol> </p> <p>If we detected substantial heterogeneity, we explored possible explanations in subgroup analyses (e.g. differing populations) or sensitivity analyses (e.g. differing risk of bias). We took any statistical heterogeneity into account when interpreting the results, especially if there is any variation in the direction of effect. </p> </section> <section id="CD013827-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We presented the primary analysis including trials to be judged at overall low risk of bias and with some concerns with regard to bias. </p> <p>The outcomes to be assessed by a sensitivity analysis are live birth/ongoing pregnancy and oocyte pick‐up cancellation. </p> <p>We conducted sensitivity analyses for the primary outcomes to determine whether the conclusions are robust to arbitrary decisions made regarding eligibility and analysis. These analyses included consideration of whether the review conclusions would have differed if we had: </p> <p> <ol id="CD013827-list-0008"> <li> <p>inclusion of studies that were not restricted to those with overall low risk or with some concerns with regard to bias; or </p> </li> <li> <p>used a relative risk rather than odds ratio (OR) as the summary effect measure.</p> </li> </ol> </p> </section> <section id="CD013827-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared a summary of findings table using GRADEpro and Cochrane methods (<a href="./references#CD013827-bbs2-0044" title="GRADEpro GDT 2015. Version accessed 17 April 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>; <a href="./references#CD013827-bbs2-0048" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). This table evaluated the overall certainty of the body of evidence for the main review outcomes (live birth/ongoing pregnancy, cycle cancellation rate, clinical pregnancy rate, miscarriage rate, total number of MII oocytes, total dose of gonadotropins and adverse effects) for the main review comparison (progestogens versus GnRH antagonists). We prepared additional summary of findings' tables with these main review outcomes for other important comparisons (progestogens versus placebo or no treatment, progestogens versus GnRH agonists and one progestogen versus another progestogen). We assessed the certainty of the evidence using GRADE criteria: overall risk of bias (fed by RoB2 assessment), consistency of effect, imprecision, indirectness and publication bias). Two review authors (DG, AC), working independently, made judgements about evidence certainty (high, moderate, low or very low), with disagreements resolved by discussion. We justified the judgements, documented them, and incorporated them into reporting of results for each outcome. </p> <p>When data analyses were reported in only subtotals due to clinical or statistical reasons, we also reported separately in the summary of findings tables. </p> <p>We planned to extract study data, format our comparisons in data tables and prepare the summary of findings tables before writing the results and conclusions of our review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013827-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013827-sec-0039"></div> <section id="CD013827-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD013827-sec-0041"> <h4 class="title">Results of the search</h4> <p>The search retrieved 1273 articles. Forty studies (44 articles) were potentially eligible and were retrieved in full text. Fourteen studies (19 articles) met our inclusion criteria (see <a href="#CD013827-fig-0001">Figure 1</a>). We excluded seven as they were duplicates, five studies did not meet our inclusion criteria (not RCTs), and nine are ongoing. See study tables: Characteristics of included studies, Characteristics of excluded studies, Characteristics of studies awaiting classification. </p> <div class="figure" id="CD013827-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD013827-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD013827-sec-0042"> <h4 class="title">Included studies</h4> <p><b>Study design and setting</b> </p> <p>Fourteen parallel‐design randomised controlled trials (RCTs) were included. All were single‐centre studies conducted in <b>:</b> assisted reproductive technology (ART) clinics in Brazil (<a href="./references#CD013827-bbs2-0003" title="CambiaghiAS , de Barros Ferreira LearioR , Alvarez AV , Martins AraujoPB , NascimentoPF . Dydrogesterone for prevent LH surge yields similar outcomes to ganirelix in a shared oocyte donor cycle with subsequent frozen-thawed embryo transfer: comparison of donors and recipients. Fertility and Sterility. Conference: 75th Scientific Congress of the American Society for Reproductive Medicine, October 12-16, 2019, Philadelphia, Pennsylania2019;112 Suppl:e195. ">Cambiaghi 2019</a>), China (<a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>; <a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>; <a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>; <a href="./references#CD013827-bbs2-0010" title="QianwenX , YanpingK . Outcome of progestin-primed ovarian stimulation protocol vs. ultra-long protocol in patients with a first IVF/ICSI cycle: a randomized clinical trial. Human Reproduction2018;33 Suppl 1:i301. XiQ , TaoY , QiuM , WangY , KuangY . Comparison between ppos and gnrha-long protocol in clinical outcome with the first ivf/ icsi cycle: a randomized clinical trial. Clinical epidemiology2020;12:261-72. ">Xi 2020</a>; <a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>; <a href="./references#CD013827-bbs2-0012" title="ZhuX , YeH , FuY . Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Sterility2017;108(37):505-12. ZhuX , YeH , FuY . The usage of Daphaston and hMG protocol in normalovulatory women undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments in combination with embryo cryopreservation. Human Reproduction2017;32 Suppl 1:i447. ">Zhu 2017a</a>; <a href="./references#CD013827-bbs2-0013" title="FuY , ZhuX , YeH . The comparison of Utrogestan 100 mg or 200 mg per day used for controlled ovarian hyperstimulation in normalovulatory women: a prospective, randomized, controlled trial. Human Reproduction2016;31 Supp1:i421-i422 Abstract no: P. ZhuX , YeH , FuY . The use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a freeze all strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility and Sterility2017;107:379-86. ">Zhu 2017b</a>; <a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>), Iran (<a href="./references#CD013827-bbs2-0006" title="GhasemzadehA , DopourFM , FarzadiL , NavaliN , BahramzadehB , FadaviA , et al. Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: a randomized controlled trial. International Journal of Reproductive BioMedicine2019;18(1):41-6. [DOI: 10.18502/ijrm.v18i1.6197]">Ghasemzadeh 2019</a>), Spain (<a href="./references#CD013827-bbs2-0001" title="BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation cycles stimulated using GnRH antagonist protocol triggered with GnRH agonist: a randomized controlled trial (RCT). In: Human Reproduction. Vol. 33 Suppl 1. 2018:i108. BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80. ">Begueria 2019</a>; <a href="./references#CD013827-bbs2-0007" title="GilesJ , AlamaP , GamizP , VidalC , BadiaP , PellicerA , et al. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial. Fertility and Sterility2021;16(2):404-12. GilesJ , Alama, P, GamizP , VidalC , BadiaP , BoschE . Can serve Medroxiprogesterone acetate (MPA) as pituitary suppressor instead of GnRH antagonist during ovarian stimulation (OS) in oocyte donation (OD) cycles trigger with GnRH agonist? In: Human reproduction. Conference: 36th annual meeting of the european human reproduction and embryology. ESHRE. Virtual meeting 2020;35 Suppl 1():i5. 2020. ">Giles 2021</a>; <a href="./references#CD013827-bbs2-0009" title="Cruz PalominoM , HenzennE , RequenaA . Pituitary supression is not necessary for blocking LH surge during luteal-phase stimulation. Human Reproduction2020;35 Suppl 1:i68-9. ">Palomino 2020</a>), and Tunisia (<a href="./references#CD013827-bbs2-0002" title="BrahamM , KacemK , ZemniZ , AmariS , JaafarW , ChtourouS , et al. The use of dydrogesterone to prevent lh peak in random-start ovarian stimulation for fertility preservation. Fertility and Sterility2020;114(3):e226-e227. ">Braham 2020</a>). </p> <p><b>Participants</b> </p> <p>The studies included 2643 subfertile women undergoing ART, 47 women that did oocyte freezing for fertility preservation and 534 oocyte donors. Their mean age ranged across studies from 24 to 34.9 years. </p> <p><b>Interventions</b> </p> <p>Seven studies compared progestogens with GnRH antagonists (<a href="./references#CD013827-bbs2-0001" title="BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation cycles stimulated using GnRH antagonist protocol triggered with GnRH agonist: a randomized controlled trial (RCT). In: Human Reproduction. Vol. 33 Suppl 1. 2018:i108. BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80. ">Begueria 2019</a>; <a href="./references#CD013827-bbs2-0002" title="BrahamM , KacemK , ZemniZ , AmariS , JaafarW , ChtourouS , et al. The use of dydrogesterone to prevent lh peak in random-start ovarian stimulation for fertility preservation. Fertility and Sterility2020;114(3):e226-e227. ">Braham 2020</a>; <a href="./references#CD013827-bbs2-0003" title="CambiaghiAS , de Barros Ferreira LearioR , Alvarez AV , Martins AraujoPB , NascimentoPF . Dydrogesterone for prevent LH surge yields similar outcomes to ganirelix in a shared oocyte donor cycle with subsequent frozen-thawed embryo transfer: comparison of donors and recipients. Fertility and Sterility. Conference: 75th Scientific Congress of the American Society for Reproductive Medicine, October 12-16, 2019, Philadelphia, Pennsylania2019;112 Suppl:e195. ">Cambiaghi 2019</a>; <a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>; <a href="./references#CD013827-bbs2-0006" title="GhasemzadehA , DopourFM , FarzadiL , NavaliN , BahramzadehB , FadaviA , et al. Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: a randomized controlled trial. International Journal of Reproductive BioMedicine2019;18(1):41-6. [DOI: 10.18502/ijrm.v18i1.6197]">Ghasemzadeh 2019</a>; <a href="./references#CD013827-bbs2-0007" title="GilesJ , AlamaP , GamizP , VidalC , BadiaP , PellicerA , et al. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial. Fertility and Sterility2021;16(2):404-12. GilesJ , Alama, P, GamizP , VidalC , BadiaP , BoschE . Can serve Medroxiprogesterone acetate (MPA) as pituitary suppressor instead of GnRH antagonist during ovarian stimulation (OS) in oocyte donation (OD) cycles trigger with GnRH agonist? In: Human reproduction. Conference: 36th annual meeting of the european human reproduction and embryology. ESHRE. Virtual meeting 2020;35 Suppl 1():i5. 2020. ">Giles 2021</a>; <a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>). </p> <p>One study compared progestogens with GnRH agonists (<a href="./references#CD013827-bbs2-0010" title="QianwenX , YanpingK . Outcome of progestin-primed ovarian stimulation protocol vs. ultra-long protocol in patients with a first IVF/ICSI cycle: a randomized clinical trial. Human Reproduction2018;33 Suppl 1:i301. XiQ , TaoY , QiuM , WangY , KuangY . Comparison between ppos and gnrha-long protocol in clinical outcome with the first ivf/ icsi cycle: a randomized clinical trial. Clinical epidemiology2020;12:261-72. ">Xi 2020</a>). </p> <p>Five studies compared one progestogen with another progestogen (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>; <a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>; <a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>; <a href="./references#CD013827-bbs2-0012" title="ZhuX , YeH , FuY . Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Sterility2017;108(37):505-12. ZhuX , YeH , FuY . The usage of Daphaston and hMG protocol in normalovulatory women undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments in combination with embryo cryopreservation. Human Reproduction2017;32 Suppl 1:i447. ">Zhu 2017a</a>; <a href="./references#CD013827-bbs2-0013" title="FuY , ZhuX , YeH . The comparison of Utrogestan 100 mg or 200 mg per day used for controlled ovarian hyperstimulation in normalovulatory women: a prospective, randomized, controlled trial. Human Reproduction2016;31 Supp1:i421-i422 Abstract no: P. ZhuX , YeH , FuY . The use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a freeze all strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility and Sterility2017;107:379-86. ">Zhu 2017b</a>). </p> <p>One study compared progestogens with no treatment or placebo (<a href="./references#CD013827-bbs2-0009" title="Cruz PalominoM , HenzennE , RequenaA . Pituitary supression is not necessary for blocking LH surge during luteal-phase stimulation. Human Reproduction2020;35 Suppl 1:i68-9. ">Palomino 2020</a>). </p> <p><b>Outcomes</b> </p> <p>Only four studies reported live birth, eight studies reported clinical pregnancy and only three reported cumulative pregnancy. <br/>Eleven studies reported coocyte‐pick cycle cancellation and nine reported adverse effects (mainly moderate or severe ovarian hyperstimulation syndrome (OHSS)). </p> <p>Where data were available for pre‐specified subgroups, we conducted subgroup analyses.</p> </section> <section id="CD013827-sec-0043"> <h4 class="title">Excluded studies</h4> <p>Five studies were excluded from the review, for the following reason:</p> <p> <ul id="CD013827-list-0009"> <li> <p>All five studies were not RCTs (all quasi‐randomised).</p> </li> </ul> </p> </section> </section> <section id="CD013827-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>RoB2 was accessed on 20 March 2021.</p> <p>We made attempts to obtain additional information regarding all aspects of randomisation, blinding, power analysis, and intention‐to‐treat from all trial authors. </p> <p>Risk of bias assessments for each outcome, including all domain judgements and support for judgement, is located within each included study, and at the side of all forest plots. To access further detailed risk of bias assessment data, please use the following <a href="https://figshare.com/articles/dataset/ROB2_progestagenos-2_xlsx/17169095" target="_blank">link</a>. </p> <p>Risk of bias of outcomes across all studies was predominately 'low' and 'some concerns', and it was 'high' only in a few studies, mainly when they were reported as a conference abstract, due to the lack of details in the report and the lack of authors' reply. The most common reason for 'some concerns' of overall risk of bias is the lack of report of the allocation concealment. </p> <p>Detailed risk of bias assessment data (with consensus responses to the 'signalling questions') data are available upon reasonable request to the authors. </p> </section> <section id="CD013827-sec-0045"> <h3 class="title" id="CD013827-sec-0045">Effects of interventions</h3> <p>See: <a href="./full#CD013827-tbl-0001"><b>Summary of findings 1</b> Summary of findings table ‐ Progestogens compared to GnRH antagonists for assisted reproduction technology cycles</a>; <a href="./full#CD013827-tbl-0002"><b>Summary of findings 2</b> Summary of findings table ‐ Progestagen compared to GnRH agonist for assisted reproduction technology cycles</a>; <a href="./full#CD013827-tbl-0003"><b>Summary of findings 3</b> Summary of findings table ‐ Progestogen 1 compared to Progestogen 2 for assisted reproduction technology cycles</a> </p> <section id="CD013827-sec-0046"> <h4 class="title">1 Progestogens versus GnRH antagonists</h4> <p>Seven studies (<a href="./references#CD013827-bbs2-0001" title="BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation cycles stimulated using GnRH antagonist protocol triggered with GnRH agonist: a randomized controlled trial (RCT). In: Human Reproduction. Vol. 33 Suppl 1. 2018:i108. BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80. ">Begueria 2019</a>; <a href="./references#CD013827-bbs2-0002" title="BrahamM , KacemK , ZemniZ , AmariS , JaafarW , ChtourouS , et al. The use of dydrogesterone to prevent lh peak in random-start ovarian stimulation for fertility preservation. Fertility and Sterility2020;114(3):e226-e227. ">Braham 2020</a>; <a href="./references#CD013827-bbs2-0003" title="CambiaghiAS , de Barros Ferreira LearioR , Alvarez AV , Martins AraujoPB , NascimentoPF . Dydrogesterone for prevent LH surge yields similar outcomes to ganirelix in a shared oocyte donor cycle with subsequent frozen-thawed embryo transfer: comparison of donors and recipients. Fertility and Sterility. Conference: 75th Scientific Congress of the American Society for Reproductive Medicine, October 12-16, 2019, Philadelphia, Pennsylania2019;112 Suppl:e195. ">Cambiaghi 2019</a>; <a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>; <a href="./references#CD013827-bbs2-0006" title="GhasemzadehA , DopourFM , FarzadiL , NavaliN , BahramzadehB , FadaviA , et al. Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: a randomized controlled trial. International Journal of Reproductive BioMedicine2019;18(1):41-6. [DOI: 10.18502/ijrm.v18i1.6197]">Ghasemzadeh 2019</a>; <a href="./references#CD013827-bbs2-0007" title="GilesJ , AlamaP , GamizP , VidalC , BadiaP , PellicerA , et al. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial. Fertility and Sterility2021;16(2):404-12. GilesJ , Alama, P, GamizP , VidalC , BadiaP , BoschE . Can serve Medroxiprogesterone acetate (MPA) as pituitary suppressor instead of GnRH antagonist during ovarian stimulation (OS) in oocyte donation (OD) cycles trigger with GnRH agonist? In: Human reproduction. Conference: 36th annual meeting of the european human reproduction and embryology. ESHRE. Virtual meeting 2020;35 Suppl 1():i5. 2020. ">Giles 2021</a>; <a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>) compared the outcomes for women having an ART cycle in which they received progestogens or GnRH antagonists in order to prevent a premature luteinising hormone (LH) surge. </p> <p>Two of them (<a href="./references#CD013827-bbs2-0003" title="CambiaghiAS , de Barros Ferreira LearioR , Alvarez AV , Martins AraujoPB , NascimentoPF . Dydrogesterone for prevent LH surge yields similar outcomes to ganirelix in a shared oocyte donor cycle with subsequent frozen-thawed embryo transfer: comparison of donors and recipients. Fertility and Sterility. Conference: 75th Scientific Congress of the American Society for Reproductive Medicine, October 12-16, 2019, Philadelphia, Pennsylania2019;112 Suppl:e195. ">Cambiaghi 2019</a>; <a href="./references#CD013827-bbs2-0006" title="GhasemzadehA , DopourFM , FarzadiL , NavaliN , BahramzadehB , FadaviA , et al. Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: a randomized controlled trial. International Journal of Reproductive BioMedicine2019;18(1):41-6. [DOI: 10.18502/ijrm.v18i1.6197]">Ghasemzadeh 2019</a>) were performed in 163 normo‐responder women who were stimulated with: a) recombinant‐follicle‐stimulating‐hormone (rFSH) and progestogens (micronised progesterone 200 mg/day) from day 3 of menstruation versus rFSH and cetrorelix 0.25 mg/day in a flexible(odds ratio (OR) 4.23, 95% confidence interval (CI) 1.17 to 15.26) protocol (<a href="./references#CD013827-bbs2-0006" title="GhasemzadehA , DopourFM , FarzadiL , NavaliN , BahramzadehB , FadaviA , et al. Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: a randomized controlled trial. International Journal of Reproductive BioMedicine2019;18(1):41-6. [DOI: 10.18502/ijrm.v18i1.6197]">Ghasemzadeh 2019</a>); or b) human menopausal gonadotropin (hMG) and progestogens (dydrogesterone 20 mg/day) from day 3 of menstruation versus hMG and ganirelix 0.25 mg/day (<a href="./references#CD013827-bbs2-0003" title="CambiaghiAS , de Barros Ferreira LearioR , Alvarez AV , Martins AraujoPB , NascimentoPF . Dydrogesterone for prevent LH surge yields similar outcomes to ganirelix in a shared oocyte donor cycle with subsequent frozen-thawed embryo transfer: comparison of donors and recipients. Fertility and Sterility. Conference: 75th Scientific Congress of the American Society for Reproductive Medicine, October 12-16, 2019, Philadelphia, Pennsylania2019;112 Suppl:e195. ">Cambiaghi 2019</a>). </p> <p>Two studies (<a href="./references#CD013827-bbs2-0001" title="BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation cycles stimulated using GnRH antagonist protocol triggered with GnRH agonist: a randomized controlled trial (RCT). In: Human Reproduction. Vol. 33 Suppl 1. 2018:i108. BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80. ">Begueria 2019</a>; <a href="./references#CD013827-bbs2-0007" title="GilesJ , AlamaP , GamizP , VidalC , BadiaP , PellicerA , et al. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial. Fertility and Sterility2021;16(2):404-12. GilesJ , Alama, P, GamizP , VidalC , BadiaP , BoschE . Can serve Medroxiprogesterone acetate (MPA) as pituitary suppressor instead of GnRH antagonist during ovarian stimulation (OS) in oocyte donation (OD) cycles trigger with GnRH agonist? In: Human reproduction. Conference: 36th annual meeting of the european human reproduction and embryology. ESHRE. Virtual meeting 2020;35 Suppl 1():i5. 2020. ">Giles 2021</a>) were performed on 534 oocyte donors who were stimulated with: a) rFSH and progestogens (medroxyprogesterone acetate (MPA) 10 mg/day) from day 3 of menstruation; or b) rFSH and cetrorelix 0.25 mg/day in a fixed GnRH antagonist protocol. </p> <p>One study (<a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>) was performed on 340 poor‐responders who were stimulated with: a) hMG 150‐225 international units (IU)/day and progestogens (MPA 10 mg/day) from day 3 of menstruation; or b) hMG 150‐225 IU/day and cetrorelix 0.25 mg in a flexible protocol. In the progestin‐primed ovarian stimulation (PPOS) arm, a frozen embryo transfer on day 3 of a subsequent cycle, while in the GnRH antagonist arm, some had a fresh embryo transfer on day 3 (72%) and some had a frozen embryo transfer on day 3 of a subsequent cycle (28%). </p> <p>One study (<a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>) was performed on 120 women with polycystic ovary syndrome (PCOS)who were stimulated with: a) hMG 150 IU/day and progestogens (micronised progesterone 100 mg/day) from day 3 of menstruation; or b) hMG 150 IU/day and cetrorelix 0.25 mg in a flexible protocol. A frozen embryo transfer was performed in both arms. </p> <p>One study (<a href="./references#CD013827-bbs2-0002" title="BrahamM , KacemK , ZemniZ , AmariS , JaafarW , ChtourouS , et al. The use of dydrogesterone to prevent lh peak in random-start ovarian stimulation for fertility preservation. Fertility and Sterility2020;114(3):e226-e227. ">Braham 2020</a>) was performed on 47 women undergoing an oocyte freezing cycle, who were stimulated with a random‐start protocol with: a) rFSH 300 IU/day and progestogens (dydrogesterone 30 mg/day) from the start of the stimulation; or b) rFSH 300 IU/day and cetrorelix 0.25 mg from the start of the stimulation as well. </p> <section id="CD013827-sec-0047"> <h5 class="title">Primary outcome</h5> <p><i>1.1 Live birth rate (</i><a href="./references#CD013827-fig-0002" title="">Analysis 1.1</a><i>)</i> </p> <p>The only study included in this outcome was judged to be of some concerns of risk for bias arising from the randomisation process leading to an overall judgement of some concerns of risk of bias with regard to this study. </p> <p>Live birth rate was analysed in poor‐responders, in one study (<a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>). We are very uncertain of the effect of MPA 10 mg in comparison with cetrorelix on the live birth rate (OR 1.25, 95% CI 0.73 to 2.13, one RCT, N = 340, very low‐certainty evidence). This suggests that if the chance of live birth following GnRH antagonists is assumed to be 18%, the chance following MPA would be between 14% and 32%. </p> <p><i>All studies ‐ Sensitivity analysis</i> (<a href="./references#CD013827-fig-0014" title="">Analysis 1.13</a>) </p> <p>In a sensitivity analysis, there is one study in the subgroup PCOS (<a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>). We are uncertain of the effect of micronised progesterone 100 mg/day compared to GnRH antagonists (OR 1.87, 95% CI 0.89 to 3.91, one RCT, N = 120). </p> <p><i>1.2 Oocyte pick‐up cancellation rate (</i><a href="./references#CD013827-fig-0003" title="">Analysis 1.2</a><i>)</i> </p> <p>Oocyte pick‐up cancellation rate was reported in a total of four studies, of which three were included in the primary analysis. The studies included in this outcome were mostly judged to be of overall low risk of bias. One study with overall some concerns of risk of bias arising from the randomisation process and one was classified as high risk of bias due to missing outcome data </p> <p><i>Oocyte pick‐up</i> cancellation rate was analysed in normo‐responders receiving micronised progesterone 200 mg versus GnRH antagonists (<a href="./references#CD013827-bbs2-0006" title="GhasemzadehA , DopourFM , FarzadiL , NavaliN , BahramzadehB , FadaviA , et al. Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: a randomized controlled trial. International Journal of Reproductive BioMedicine2019;18(1):41-6. [DOI: 10.18502/ijrm.v18i1.6197]">Ghasemzadeh 2019</a>) and oocyte donors receiving MPA 10 mg versus GnRH antagonists (<a href="./references#CD013827-bbs2-0001" title="BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation cycles stimulated using GnRH antagonist protocol triggered with GnRH agonist: a randomized controlled trial (RCT). In: Human Reproduction. Vol. 33 Suppl 1. 2018:i108. BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80. ">Begueria 2019</a>; <a href="./references#CD013827-bbs2-0007" title="GilesJ , AlamaP , GamizP , VidalC , BadiaP , PellicerA , et al. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial. Fertility and Sterility2021;16(2):404-12. GilesJ , Alama, P, GamizP , VidalC , BadiaP , BoschE . Can serve Medroxiprogesterone acetate (MPA) as pituitary suppressor instead of GnRH antagonist during ovarian stimulation (OS) in oocyte donation (OD) cycles trigger with GnRH agonist? In: Human reproduction. Conference: 36th annual meeting of the european human reproduction and embryology. ESHRE. Virtual meeting 2020;35 Suppl 1():i5. 2020. ">Giles 2021</a>), in three studies altogether. There may be little or no difference in o<i>ocyte pick‐up</i> cancellation rate between progestogens and GnRH antagonists but due to wide confidence interval, we are uncertain (OR 0.92, 95% CI 0.42 to 2.01, 3 RCTs, N = 648, I² = 0%, low‐certainty evidence). This suggests that if the chance of cycle cancellation following GnRH antagonists is assumed to be 4%, the chance following progestogens would be between 2% and 8%. </p> <p>No heterogeneity was found in the subgroup analysis (Test for subgroup differences: Chi² = 0.05, df = 1 (P = 0.83), I² = 0%). </p> <p><i>All studies included ‐ Sensitivity analysis (</i><a href="./references#CD013827-fig-0015" title="">Analysis 1.14</a>) </p> <p>In the sensitivity analysis including the study with an overall high risk of bias (<a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>), we are very uncertain of the effect of micronised progesterone 100 mg in comparison to cetrorelix on the o<i>ocyte pick‐up</i> cancellation rate in PCOS (OR 0.86, 95% CI 0.40 to 1.83, 4 RCTs, N = 768, I² = 0%, very low‐certainty evidence). We performed a sensitivity analysis applying RR and a random‐effects model to each comparison, and no differences regarding the primary analysis were found. </p> </section> <section id="CD013827-sec-0048"> <h5 class="title">Secondary outcomes</h5> <p><i>1.3‐ Clinical pregnancy rate (</i><a href="./references#CD013827-fig-0004" title="">Analysis 1.3</a><i>)</i> </p> <p>Clinical pregnancy rate was reported in two studies (<a href="./references#CD013827-bbs2-0003" title="CambiaghiAS , de Barros Ferreira LearioR , Alvarez AV , Martins AraujoPB , NascimentoPF . Dydrogesterone for prevent LH surge yields similar outcomes to ganirelix in a shared oocyte donor cycle with subsequent frozen-thawed embryo transfer: comparison of donors and recipients. Fertility and Sterility. Conference: 75th Scientific Congress of the American Society for Reproductive Medicine, October 12-16, 2019, Philadelphia, Pennsylania2019;112 Suppl:e195. ">Cambiaghi 2019</a>; <a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>), in two different subgroups (poor‐responders and normo‐responders). Only one was included in the primary analysis. </p> <p>For this outcome, one study (<a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>) that analysed poor‐responders was judged to be of some concern about risk for bias arising from the randomisation process, deviations from intended interventions, and measurement of the outcome leading to an overall judgment of some concerns of risk of bias with regard to these studies. However, the study that analysed normo‐responders (<a href="./references#CD013827-bbs2-0003" title="CambiaghiAS , de Barros Ferreira LearioR , Alvarez AV , Martins AraujoPB , NascimentoPF . Dydrogesterone for prevent LH surge yields similar outcomes to ganirelix in a shared oocyte donor cycle with subsequent frozen-thawed embryo transfer: comparison of donors and recipients. Fertility and Sterility. Conference: 75th Scientific Congress of the American Society for Reproductive Medicine, October 12-16, 2019, Philadelphia, Pennsylania2019;112 Suppl:e195. ">Cambiaghi 2019</a>) was not included in the primary analysis as the overall risk of bias was high arising from the missing outcomes and measurement of the outcomes. </p> <p>MPA 10 mg may increase the clinical pregnancy rate in comparison to cetrorelix in poor‐responders, but due to wide confidence interval, we are uncertain of the effect (OR 1.32, 95% CI 0.81 to 2.16, one RCT, N = 340, low‐certainty evidence) This suggests that if the chance of clinical pregnancy following GnRH antagonists is assumed to be 23% in poor responders, the chance following MPA 10 mg would be between 19% and 39%. </p> <p><i>All studies included ‐ Sensitivity analysis</i> </p> <p>In the sensitivity analysis including those studies with an overall high risk of bias, we are very uncertain of the effect of dydrogesterone 20 mg in comparison to cetrorelix on the clinical pregnancy rate in normo‐responders (OR 1.11, 95% CI 0.35 to 3.51, one RCT, N = 49, very low‐certainty evidence). </p> <p><i>1.4 Cumulative pregnancy rate</i> </p> <p>Cumulative pregnancy rate was reported by only one study (<a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>) that evaluated women with PCOS. It was judged to be of high risk of bias or some concerns of risk of bias arising from the missing outcome data. </p> <p>We did not include it in the primary analysis due to the overall risk of bias.</p> <p><i>All studies included ‐ Sensitivity analysis</i> </p> <p>In a secondary analysis, we are also uncertain of the effect of micronised progesterone in women with PCOS (MD 1.85, 95% CI ‐1.06 to 4.76, one RCT, N = 120, very low‐certainty evidence). We performed a sensitivity analysis applying RR and a random‐effects model to each comparison, and no differences with the primary analysis were found. </p> <p><i>1.5 Miscarriage rate (</i><a href="./references#CD013827-fig-0006" title="">Analysis 1.5</a><i>)</i> </p> <p>The only study included in this outcome was judged to be of some concerns of risk for bias arising from the randomisation process and measurement of the outcome leading to an overall judgment of some concerns of risk of bias with regard to this study. </p> <p>Miscarriage rate was analysed in one study (<a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>), in low‐responder women. We are very uncertain of the effect of MPA 10 mg in comparison to cetrorelix on the miscarriage rate in poor‐responders (OR 1.13, 95% CI 0.43 to 3.01, one RCT, N = 340, very low‐certainty evidence). </p> <p>We have also performed a secondary analysis per clinical pregnancy. We are very uncertain of the effect of MPA 10 mg in comparison to cetrorelix on the miscarriage rate in poor‐responders (OR 0.89, 95% CI 0.31 to 2.59, one RCT, N = 87, very low‐certainty evidence). </p> <p>There was only one study, so it was not possible to conduct any planned sensitivity analyses. </p> <p><i>1.6 Multiple pregnancy rate (</i><a href="./references#CD013827-fig-0007" title="">Analysis 1.6</a><i>)</i> </p> <p>The only study included in this outcome was judged to have some concerns of risk for bias arising from the randomisation process, leading to an overall judgement of some concerns of bias with regard to this study. </p> <p>Multiple pregnancy rate was analysed in one study (<a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>), in poor‐responders. The evidence coming from a single study suggests that multiple pregnancy rate may be higher in MPA 10 mg in comparison to cetrorelix in poor‐responders (OR 4.23, 95% CI 1.17 to 15.26, one RCT, N = 340, low‐certainty evidence) but the certainty of this result could be affected by the imbalance in the proportion of embryos transferred in cleavage and blastocyst stage. </p> <p>We have also performed a secondary analysis per clinical pregnancy. In poor‐responders, multiple pregnancy rate may be higher with MPA 10 mg in comparison to cetrorelix (OR 4.00, 95% CI 1.04 to 15.38, one RCT, N = 87, low certainty evidence). </p> <p>There was only one study, so it was not possible to conduct any planned sensitivity analyses. </p> <p><i>1.7 Premature LH surge (</i><a href="./references#CD013827-fig-0008" title="">Analysis 1.7</a><i>)</i><br/>Premature LH surge rate was reported in a total of four studies (in three different subgroups (poor‐responders, PCOS and normo‐responders). Three of them were included in the primary analysis (<a href="./references#CD013827-bbs2-0001" title="BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation cycles stimulated using GnRH antagonist protocol triggered with GnRH agonist: a randomized controlled trial (RCT). In: Human Reproduction. Vol. 33 Suppl 1. 2018:i108. BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80. ">Begueria 2019</a>; <a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>; <a href="./references#CD013827-bbs2-0006" title="GhasemzadehA , DopourFM , FarzadiL , NavaliN , BahramzadehB , FadaviA , et al. Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: a randomized controlled trial. International Journal of Reproductive BioMedicine2019;18(1):41-6. [DOI: 10.18502/ijrm.v18i1.6197]">Ghasemzadeh 2019</a>). The studies included in this outcome were mostly judged to have overall some concerns of risk of bias arising from the randomisation process and the measurement of the outcome, leading to an overall judgment of some concerns of bias with regard to these studies. </p> <p>No cases of premature LH surge were found in any of the normo‐responders that were analysed. In the study that evaluated poor‐responders, premature LH surge rate was probably lower in the MPA 10 mg group in comparison to cetrorelix (OR 0.04, 95% CI 0.00 to 0.77, one RCT, N = 340, moderate‐certainty evidence). </p> <p><i>All studies included ‐ Sensitivity analysis</i> </p> <p>In the sensitivity analysis including those studies with an overall high risk of bias, no cases of premature LH surge were found in the women with PCOS that were analysed. We performed a sensitivity analysis applying RR and a random‐effects model to each comparison, and no differences in the primary analysis were found. </p> <p><i>1.8 Total number of oocytes (</i><a href="./references#CD013827-fig-0009" title="">Analysis 1.8</a><i>)</i><br/>Total number of oocytes was reported in a total of six different studies (<a href="./references#CD013827-bbs2-0001" title="BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation cycles stimulated using GnRH antagonist protocol triggered with GnRH agonist: a randomized controlled trial (RCT). In: Human Reproduction. Vol. 33 Suppl 1. 2018:i108. BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80. ">Begueria 2019</a>; <a href="./references#CD013827-bbs2-0002" title="BrahamM , KacemK , ZemniZ , AmariS , JaafarW , ChtourouS , et al. The use of dydrogesterone to prevent lh peak in random-start ovarian stimulation for fertility preservation. Fertility and Sterility2020;114(3):e226-e227. ">Braham 2020</a>; <a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>; <a href="./references#CD013827-bbs2-0006" title="GhasemzadehA , DopourFM , FarzadiL , NavaliN , BahramzadehB , FadaviA , et al. Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: a randomized controlled trial. International Journal of Reproductive BioMedicine2019;18(1):41-6. [DOI: 10.18502/ijrm.v18i1.6197]">Ghasemzadeh 2019</a>; <a href="./references#CD013827-bbs2-0007" title="GilesJ , AlamaP , GamizP , VidalC , BadiaP , PellicerA , et al. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial. Fertility and Sterility2021;16(2):404-12. GilesJ , Alama, P, GamizP , VidalC , BadiaP , BoschE . Can serve Medroxiprogesterone acetate (MPA) as pituitary suppressor instead of GnRH antagonist during ovarian stimulation (OS) in oocyte donation (OD) cycles trigger with GnRH agonist? In: Human reproduction. Conference: 36th annual meeting of the european human reproduction and embryology. ESHRE. Virtual meeting 2020;35 Suppl 1():i5. 2020. ">Giles 2021</a>; <a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>), in five different subgroups (oocyte freezing for fertility preservation, poor‐responders, normo‐responders, PCOS and oocyte donors). Four of them were included in the primary analysis. As the heterogeneity was high (I² = 84.7%), the results were only described by subgroup. </p> <p>The studies included in this outcome were mostly judged to be of low risk for bias or some concerns of risk of bias arising from the randomisation process. However, we could not include two studies in the primary analysis: one analysed oocyte freezing, and the overall risk of bias was high arising from the randomisation process and missing outcomes (<a href="./references#CD013827-bbs2-0002" title="BrahamM , KacemK , ZemniZ , AmariS , JaafarW , ChtourouS , et al. The use of dydrogesterone to prevent lh peak in random-start ovarian stimulation for fertility preservation. Fertility and Sterility2020;114(3):e226-e227. ">Braham 2020</a>); the second study analysed women with PCOS, and had a high risk of bias due to outcome data missing (<a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>). </p> <p>In the study that evaluated normo‐responders with their own oocytes (<a href="./references#CD013827-bbs2-0006" title="GhasemzadehA , DopourFM , FarzadiL , NavaliN , BahramzadehB , FadaviA , et al. Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: a randomized controlled trial. International Journal of Reproductive BioMedicine2019;18(1):41-6. [DOI: 10.18502/ijrm.v18i1.6197]">Ghasemzadeh 2019</a>), the total number of oocytes may be higher in the micronised progesterone group in comparison to GnRH antagonists (MD 4.70, 95% CI 2.36 to 7.04, one RCT, N = 100, low‐certainty evidence). However, there are probably little or no differences when comparing the effect of MPA 10 mg with GnRH antagonists both in poor responders (MD 0.30, 95% CI ‐0.23 to 0.83, one RCT, N = 340, moderate‐certainty evidence)(<a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>) and in donors (MD 0.88, 95% CI ‐0.77 to 2.54, 2 RCTs, N = 534, moderate‐certainty evidence)(<a href="./references#CD013827-bbs2-0001" title="BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation cycles stimulated using GnRH antagonist protocol triggered with GnRH agonist: a randomized controlled trial (RCT). In: Human Reproduction. Vol. 33 Suppl 1. 2018:i108. BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80. ">Begueria 2019</a>; <a href="./references#CD013827-bbs2-0007" title="GilesJ , AlamaP , GamizP , VidalC , BadiaP , PellicerA , et al. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial. Fertility and Sterility2021;16(2):404-12. GilesJ , Alama, P, GamizP , VidalC , BadiaP , BoschE . Can serve Medroxiprogesterone acetate (MPA) as pituitary suppressor instead of GnRH antagonist during ovarian stimulation (OS) in oocyte donation (OD) cycles trigger with GnRH agonist? In: Human reproduction. Conference: 36th annual meeting of the european human reproduction and embryology. ESHRE. Virtual meeting 2020;35 Suppl 1():i5. 2020. ">Giles 2021</a>). </p> <p><i>All studies included ‐ Sensitivity analysis</i> </p> <p>In the sensitivity analysis including those studies with an overall high risk of bias, we are very uncertain of the effect of dydrogesterone 20 mg in comparison to cetrorelix on the total number of oocytes in oocyte freezing (MD 0.40, 95% CI ‐3.98 to 4.78, one RCT, N = 47, very low‐certainty evidence)(<a href="./references#CD013827-bbs2-0002" title="BrahamM , KacemK , ZemniZ , AmariS , JaafarW , ChtourouS , et al. The use of dydrogesterone to prevent lh peak in random-start ovarian stimulation for fertility preservation. Fertility and Sterility2020;114(3):e226-e227. ">Braham 2020</a>) and we are also uncertain of the effect of micronised progesterone in women with PCOS too (MD 1.85, 95% CI ‐1.06 to 4.76, one RCT, N = 120, very low‐certainty evidence)(<a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>). We performed a sensitivity analysis applying a random‐effects model to each comparison, and no differences in the primary analysis were found. </p> <p><i>1.9 Number of MII oocytes (</i><a href="./references#CD013827-fig-0010" title="">Analysis 1.9</a><i>)</i> </p> <p>Total number of MII oocytes was reported in a total of six different studies (<a href="./references#CD013827-bbs2-0001" title="BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation cycles stimulated using GnRH antagonist protocol triggered with GnRH agonist: a randomized controlled trial (RCT). In: Human Reproduction. Vol. 33 Suppl 1. 2018:i108. BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80. ">Begueria 2019</a>; <a href="./references#CD013827-bbs2-0002" title="BrahamM , KacemK , ZemniZ , AmariS , JaafarW , ChtourouS , et al. The use of dydrogesterone to prevent lh peak in random-start ovarian stimulation for fertility preservation. Fertility and Sterility2020;114(3):e226-e227. ">Braham 2020</a>; <a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>; <a href="./references#CD013827-bbs2-0006" title="GhasemzadehA , DopourFM , FarzadiL , NavaliN , BahramzadehB , FadaviA , et al. Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: a randomized controlled trial. International Journal of Reproductive BioMedicine2019;18(1):41-6. [DOI: 10.18502/ijrm.v18i1.6197]">Ghasemzadeh 2019</a>; <a href="./references#CD013827-bbs2-0007" title="GilesJ , AlamaP , GamizP , VidalC , BadiaP , PellicerA , et al. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial. Fertility and Sterility2021;16(2):404-12. GilesJ , Alama, P, GamizP , VidalC , BadiaP , BoschE . Can serve Medroxiprogesterone acetate (MPA) as pituitary suppressor instead of GnRH antagonist during ovarian stimulation (OS) in oocyte donation (OD) cycles trigger with GnRH agonist? In: Human reproduction. Conference: 36th annual meeting of the european human reproduction and embryology. ESHRE. Virtual meeting 2020;35 Suppl 1():i5. 2020. ">Giles 2021</a>; <a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>), in five different subgroups (oocyte freezing for fertility preservation, poor responders, normo‐responders, PCOS and oocyte donors). Four of them were included in the primary analysis. As the heterogeneity was high (I² = 84.1%), the results were only described by subgroup. </p> <p>The studies included in this outcome were mostly judged to be of low risk for bias or some concerns of risk of bias arising from the randomisation process. However, we could not include two studies in the primary analysis: one analysed oocyte freezing, and the overall risk of bias was high arising from the randomisation process and missing outcomes (<a href="./references#CD013827-bbs2-0002" title="BrahamM , KacemK , ZemniZ , AmariS , JaafarW , ChtourouS , et al. The use of dydrogesterone to prevent lh peak in random-start ovarian stimulation for fertility preservation. Fertility and Sterility2020;114(3):e226-e227. ">Braham 2020</a>); the second study analysed women with PCOS, and had a high risk of bias due to outcome data missing (<a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>). </p> <p>In the study that evaluated normo‐responders with their own oocytes (<a href="./references#CD013827-bbs2-0006" title="GhasemzadehA , DopourFM , FarzadiL , NavaliN , BahramzadehB , FadaviA , et al. Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: a randomized controlled trial. International Journal of Reproductive BioMedicine2019;18(1):41-6. [DOI: 10.18502/ijrm.v18i1.6197]">Ghasemzadeh 2019</a>), the number of MII oocytes may be higher in the micronised progesterone group in comparison to GnRH antagonists (mean difference (MD) 3.80, 95% CI 1.94 to 5.66, one RCT, N = 100, low‐certainty evidence). This suggests that if the number of MII oocytes following GnRH antagonists is assumed to be 7, this number would be between 9 and 13 following micronised progesterone. </p> <p>In poor responders there is probably little or no difference in the number of MII oocytes in the MPA 10 mg group in comparison to GnRH antagonists (MD 0.40, 95% CI ‐0.09 to 0.89, one RCT, N = 340, moderate certainty evidence)(<a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>). This suggests that if the number of MII oocytes following GnRH antagonists is assumed to be 3, the chance following MPA would be between 3 and 4. </p> <p>Finally, in donors, there are little or no differences in the number of MII oocytes in the MPA 10 mg group in comparison to GnRH antagonists (MD 0.07, 95% CI ‐1.30 to 1.44, 2 RCTs, N = 534, high‐certainty evidence)(<a href="./references#CD013827-bbs2-0001" title="BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation cycles stimulated using GnRH antagonist protocol triggered with GnRH agonist: a randomized controlled trial (RCT). In: Human Reproduction. Vol. 33 Suppl 1. 2018:i108. BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80. ">Begueria 2019</a>; <a href="./references#CD013827-bbs2-0007" title="GilesJ , AlamaP , GamizP , VidalC , BadiaP , PellicerA , et al. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial. Fertility and Sterility2021;16(2):404-12. GilesJ , Alama, P, GamizP , VidalC , BadiaP , BoschE . Can serve Medroxiprogesterone acetate (MPA) as pituitary suppressor instead of GnRH antagonist during ovarian stimulation (OS) in oocyte donation (OD) cycles trigger with GnRH agonist? In: Human reproduction. Conference: 36th annual meeting of the european human reproduction and embryology. ESHRE. Virtual meeting 2020;35 Suppl 1():i5. 2020. ">Giles 2021</a>). This suggests that if the number of MII oocytes following GnRH antagonists is assumed to be 15, the chance following MPA 10 mg would be between 14 and 16. </p> <p><i>All studies included ‐ Sensitivity analysis</i> </p> <p>In the sensitivity analysis including those studies with an overall high risk of bias, we are very uncertain of the effect of dydrogesterone 20 mg in comparison to cetrorelix on the total number of MII oocytes in oocyte freezing (MD 0.90, 95% CI ‐2.70 to 4.50, one RCT, N = 47, very low‐certainty evidence)(<a href="./references#CD013827-bbs2-0002" title="BrahamM , KacemK , ZemniZ , AmariS , JaafarW , ChtourouS , et al. The use of dydrogesterone to prevent lh peak in random-start ovarian stimulation for fertility preservation. Fertility and Sterility2020;114(3):e226-e227. ">Braham 2020</a>), and we are also uncertain of the effect of micronised progesterone in women with PCOS too (MD 1.10, 95% CI ‐1.51 to 3.71, one RCT, N = 120, very low‐certainty evidence)(<a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>). We performed a sensitivity analysis applying a random‐effects model to each comparison, and no differences with the primary analysis were found. </p> <p><i>1.10 Duration of stimulation (</i><a href="./references#CD013827-fig-0011" title="">Analysis 1.10</a><i>)</i> </p> <p>Total days of stimulation were reported in a total of six different studies (<a href="./references#CD013827-bbs2-0001" title="BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation cycles stimulated using GnRH antagonist protocol triggered with GnRH agonist: a randomized controlled trial (RCT). In: Human Reproduction. Vol. 33 Suppl 1. 2018:i108. BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80. ">Begueria 2019</a>; <a href="./references#CD013827-bbs2-0002" title="BrahamM , KacemK , ZemniZ , AmariS , JaafarW , ChtourouS , et al. The use of dydrogesterone to prevent lh peak in random-start ovarian stimulation for fertility preservation. Fertility and Sterility2020;114(3):e226-e227. ">Braham 2020</a>; <a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>; <a href="./references#CD013827-bbs2-0006" title="GhasemzadehA , DopourFM , FarzadiL , NavaliN , BahramzadehB , FadaviA , et al. Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: a randomized controlled trial. International Journal of Reproductive BioMedicine2019;18(1):41-6. [DOI: 10.18502/ijrm.v18i1.6197]">Ghasemzadeh 2019</a>; <a href="./references#CD013827-bbs2-0007" title="GilesJ , AlamaP , GamizP , VidalC , BadiaP , PellicerA , et al. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial. Fertility and Sterility2021;16(2):404-12. GilesJ , Alama, P, GamizP , VidalC , BadiaP , BoschE . Can serve Medroxiprogesterone acetate (MPA) as pituitary suppressor instead of GnRH antagonist during ovarian stimulation (OS) in oocyte donation (OD) cycles trigger with GnRH agonist? In: Human reproduction. Conference: 36th annual meeting of the european human reproduction and embryology. ESHRE. Virtual meeting 2020;35 Suppl 1():i5. 2020. ">Giles 2021</a>; <a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>), in five different sub‐groups (oocyte freezing for fertility preservation, poor‐responders, normo‐responders, PCOS and oocyte donors). Four of them were included in the primary analysis. </p> <p>The studies included in this outcome were mostly judged to be of low risk for bias or some concerns of risk of bias arising from the randomisation process. However, the studies that analysed women with PCOS and women undergoing an oocyte freezing cycle were not included in the primary analysis as the overall risk of bias was high arising from the randomisation process and the missing outcomes, leading to an overall judgment of high risk of bias with regard to these studies. </p> <p>Although there is heterogeneity, we reported a pooled result because no important differences were found in the studies. There are probably little or no differences in the number of days of stimulation in the progestogens group in comparison to GnRH antagonists (MD ‐0.30, 95% CI ‐0.52 to ‐0.09, four RCTs, I² = 60%, N = 945, moderate‐certainty evidence). </p> <p><i>All studies included ‐ Sensitivity analysis</i> </p> <p>In the sensitivity analysis including those studies with an overall high risk of bias, we are very uncertain of the effect of dydrogesterone 20 mg in comparison to cetrorelix on the number of days of stimulation in oocyte freezing (MD ‐0.20, 95% CI ‐1.17 to 0.77, one RCT, N = 47, very low‐certainty evidence), and we are also uncertain of the effect of micronised progesterone in women with PCOS too (MD ‐1.28, 95% CI ‐2.73 to 0.17, one RCT, N = 120, very low‐certainty evidence). We performed a sensitivity analysis applying a random‐effects model to each comparison, and we found no differences in the primary analysis. </p> <p><i>1.11 Total dose of gonadotropins (</i><a href="./references#CD013827-fig-0012" title="">Analysis 1.11</a><i>)</i><br/>Total dose of gonadotropins was reported in a total of four different studies (<a href="./references#CD013827-bbs2-0001" title="BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation cycles stimulated using GnRH antagonist protocol triggered with GnRH agonist: a randomized controlled trial (RCT). In: Human Reproduction. Vol. 33 Suppl 1. 2018:i108. BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80. ">Begueria 2019</a>; <a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>; <a href="./references#CD013827-bbs2-0007" title="GilesJ , AlamaP , GamizP , VidalC , BadiaP , PellicerA , et al. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial. Fertility and Sterility2021;16(2):404-12. GilesJ , Alama, P, GamizP , VidalC , BadiaP , BoschE . Can serve Medroxiprogesterone acetate (MPA) as pituitary suppressor instead of GnRH antagonist during ovarian stimulation (OS) in oocyte donation (OD) cycles trigger with GnRH agonist? In: Human reproduction. Conference: 36th annual meeting of the european human reproduction and embryology. ESHRE. Virtual meeting 2020;35 Suppl 1():i5. 2020. ">Giles 2021</a>, <a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>), in three different subgroups (poor‐responders, PCOS and oocyte donors). Three of them were included in the primary analysis. </p> <p>The studies included in this outcome were mostly judged to be of low risk for bias.</p> <p>Although there is heterogeneity, we reported a pooled result because no important clinical differences among the studies were found (<a href="./references#CD013827-bbs2-0001" title="BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation cycles stimulated using GnRH antagonist protocol triggered with GnRH agonist: a randomized controlled trial (RCT). In: Human Reproduction. Vol. 33 Suppl 1. 2018:i108. BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80. ">Begueria 2019</a>; <a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>; <a href="./references#CD013827-bbs2-0007" title="GilesJ , AlamaP , GamizP , VidalC , BadiaP , PellicerA , et al. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial. Fertility and Sterility2021;16(2):404-12. GilesJ , Alama, P, GamizP , VidalC , BadiaP , BoschE . Can serve Medroxiprogesterone acetate (MPA) as pituitary suppressor instead of GnRH antagonist during ovarian stimulation (OS) in oocyte donation (OD) cycles trigger with GnRH agonist? In: Human reproduction. Conference: 36th annual meeting of the european human reproduction and embryology. ESHRE. Virtual meeting 2020;35 Suppl 1():i5. 2020. ">Giles 2021</a>),. Little or no differences in total dose of gonadotropins were found in the MPA 10 mg group in comparison to cetrorelix (MD ‐35.17, 95% CI ‐103.22 to 32.89, three RCTs, I² = 59%, N = 832 moderate‐certainty evidence). This suggests that if the mean dose of gonadotropins following GnRH antagonists is assumed to be 1775 IU, the mean dose of gonadotropins following MPA 10 mg would be between 1672 and 1808 IU. </p> <p><i>All studies included ‐ Sensitivity analysis</i> </p> <p>In the sensitivity analysis including those studies with an overall high risk of bias, we are very uncertain of the effect of micronised progesterone 100 mg in comparison to cetrorelix on the total dose of gonadotropins in women with PCOS(MD ‐0.20, 95% CI ‐1.17 to 0.77, one RCT, N = 47, very low‐certainty evidence)(<a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>). We performed a sensitivity analysis applying a random‐effects model to each comparison, and no differences were found in the primary analysis. </p> <p><i>1.12 Other adverse effects (</i><a href="./references#CD013827-fig-0013" title="">Analysis 1.12</a><i>)</i> </p> <p>Moderate and severe OHSS rate was analysed in four different studies (<a href="./references#CD013827-bbs2-0001" title="BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation cycles stimulated using GnRH antagonist protocol triggered with GnRH agonist: a randomized controlled trial (RCT). In: Human Reproduction. Vol. 33 Suppl 1. 2018:i108. BegueriaR , GarciaD , VassenaR , RodriguezA . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80. ">Begueria 2019</a>; <a href="./references#CD013827-bbs2-0004" title="ChenQ , ChaiW , WangY , CaiR , ZhangS , LuX , et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology2019;10:22. ">Chen 2019</a>, <a href="./references#CD013827-bbs2-0007" title="GilesJ , AlamaP , GamizP , VidalC , BadiaP , PellicerA , et al. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial. Fertility and Sterility2021;16(2):404-12. GilesJ , Alama, P, GamizP , VidalC , BadiaP , BoschE . Can serve Medroxiprogesterone acetate (MPA) as pituitary suppressor instead of GnRH antagonist during ovarian stimulation (OS) in oocyte donation (OD) cycles trigger with GnRH agonist? In: Human reproduction. Conference: 36th annual meeting of the european human reproduction and embryology. ESHRE. Virtual meeting 2020;35 Suppl 1():i5. 2020. ">Giles 2021</a>, <a href="./references#CD013827-bbs2-0014" title="ZhuX , YeH , YeJ , FuY . Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Annals of Translational Medicine2021;9(5):387. [DOI: 10.21037/atm-20-1592]">Zhu 2021</a>), in three different subgroups (poor‐responders, PCOS and oocyte donors). All of them were included in the primary analysis. </p> <p>The studies included in this outcome were mostly judged to be of low risk for bias and some risk of bias arising from the randomisation process and the measurement of the outcome, leading to an overall judgment of some concerns of risk of bias with regard to this study. </p> <p>No cases of moderate and severe OHSS were reported in any of the groups.</p> <p>There was no study that was not included in the primary analysis. Therefore, no sensitivity analysis was performed. </p> </section> </section> <section id="CD013827-sec-0049"> <h4 class="title">2 Progestogens versus GnRH agonists</h4> <p>Only one study (<a href="./references#CD013827-bbs2-0010" title="QianwenX , YanpingK . Outcome of progestin-primed ovarian stimulation protocol vs. ultra-long protocol in patients with a first IVF/ICSI cycle: a randomized clinical trial. Human Reproduction2018;33 Suppl 1:i301. XiQ , TaoY , QiuM , WangY , KuangY . Comparison between ppos and gnrha-long protocol in clinical outcome with the first ivf/ icsi cycle: a randomized clinical trial. Clinical epidemiology2020;12:261-72. ">Xi 2020</a>) compared the outcomes for women having an ART cycle in which they received progestogens or GnRH agonists in order to prevent a premature LH surge. A total of 260 women who were normo‐responders were stimulated with: a) hMG 150 to 225 IU/day and progestogens (MPA 4 mg/day) from day 3 of menstruation, performing a frozen‐embryo transfer on day 3 of a subsequent cycle; or b) hMG 150 to 225 IU/day and the pituitary down‐regulation was obtained with Leuprorelin Acetate 3.75 mg in the previous early follicular phase, performing a fresh or frozen embryo transfer on day 3 of a subsequent cycle. </p> <section id="CD013827-sec-0050"> <h5 class="title">Primary outcome</h5> <p><i>2.1 Live birth rate or ongoing pregnancy (</i><a href="./references#CD013827-fig-0016" title="">Analysis 2.1</a><i>)</i> </p> <p>The only study included in this outcome was judged to be of low risk for bias.</p> <p>There may be little or no difference in live birth rate between MPA 4 mg and GnRH agonists in normo‐responders, but due to wide confidence interval, we are uncertain of the effect (OR 0.94, 95% CI 0.58 to 1.53, one RCT, N = 260, low‐certainty evidence). This suggests that if the chance of ongoing pregnancy following GnRH agonists is assumed to be 47%, the chance following progestogens would be between 34% and 58%. </p> <p>There was only one study, so it was not possible to conduct any planned sensitivity analyses. </p> <p><i>2.2 Oocyte pick‐up cancellation rate (</i><a href="./references#CD013827-fig-0017" title="">Analysis 2.2</a><i>)</i> </p> <p>The only study included in this outcome was judged to be of low risk for bias.</p> <p>MPA 4 mg may increase the cancellation rate in comparison to GnRH agonists in normo‐responders, but due to wide confidence interval, we are uncertain of the effect (OR 1.36, 95% CI 0.46 to 4.02, one RCT, N = 260, low‐certainty evidence). This suggests that if the chance of cycle cancellation following GnRH agonists is assumed to be 5%, the chance following MPA 4 mg would be between 2% and 16%. </p> <p>There was only one study, so it was not possible to conduct any planned sensitivity analyses. </p> <section id="CD013827-sec-0051"> <h6 class="title">Secondary outcomes</h6> <p><i>2.3‐ Clinical pregnancy rate (</i><a href="./references#CD013827-fig-0018" title="">Analysis 2.3</a><i>)</i> </p> <p>The only study included in this outcome was judged to be of low risk for bias.</p> <p>MPA 4 mg may decrease the pregnancy rate in comparison to GnRH agonists in normo‐responders, but due to wide confidence interval, we are uncertain of the effect (OR 0.88, 95% CI 0.54 to 1.44, one RCT, N = 260, low‐certainty evidence). This suggests that if the chance of clinical pregnancy following GnRH agonists is assumed to be 53%, the chance following progestogens would be between 38% and 62%. </p> <p>There was only one study, so it was not possible to conduct any planned sensitivity analyses. </p> <p><i>Cumulative pregnancy rate</i> </p> <p>Not reported.</p> <p><i>2.4 Miscarriage rate (</i><a href="./references#CD013827-fig-0019" title="">Analysis 2.4</a><i>)</i> </p> <p>The only study included in this outcome was judged to be of low risk for bias.</p> <p>MPA 4 mg may decrease the miscarriage rate in comparison to GnRH agonists in normo‐responders, but due to wide confidence interval, we are uncertain of the effect (OR 0.49, 95% CI 0.12 to 2.00, one RCT, N = 260, low‐certainty evidence). This suggests that if the chance of miscarriage following GnRH agonists is assumed to be 5%, the chance following progestogens would be between 1% and 9%. </p> <p>There was only one study, so it was not possible to conduct any planned sensitivity analyses. </p> <p>We also performed a secondary analysis per clinical pregnancy. MPA 4 mg may decrease the miscarriage rate in comparison to GnRH agonists in normo‐responders, but due to wide confidence interval, we are uncertain of the effect (OR 0.51, 95% CI 0.12 to 2.12, one RCT, N = 134, low‐certainty evidence). </p> <p><i>2.5 Multiple pregnancy rate (</i><a href="./references#CD013827-fig-0020" title="">Analysis 2.5</a><i>)</i> </p> <p>The only study included in this outcome was judged to be of low risk for bias.</p> <p>Due to wide confidence interval, we are uncertain of the effect of MPA 4 m compared to GnRH agonists on the multiple pregnancy rate in normo‐responders (OR 0.83, 95% CI 0.42 to 1.65, one RCT, N = 260). </p> <p>We also performed a secondary analysis per clinical pregnancy. We are uncertain of the effect of MPA 4 mg in comparison to GnRH agonists on the miscarriage rate in normo‐responders (OR 0.88, 95% CI 0.41 to 1.85, one RCT, N = 134). </p> <p>There was only one study, so it was not possible to conduct any planned sensitivity analyses. </p> <p><i>2.6‐ Premature LH surge (</i><a href="./references#CD013827-fig-0021" title="">Analysis 2.6</a><i>)</i><br/>The only study included in this outcome was judged to be of overall some concerns of risk of bias arising from the outcome measurement. </p> <p>No cases of premature LH surge were found in any of the normo‐responders women that were analysed. </p> <p><i>2.7 Total number of oocytes (</i><a href="./references#CD013827-fig-0022" title="">Analysis 2.7</a><i>)</i><br/>The only study included in this outcome was judged to be of low risk for bias. </p> <p>In normo‐responders, there is probably little or no difference in the number of oocytes in the MPA 4 mg group in comparison to GnRH agonists (MD 0.50, 95% CI ‐0.97 to 1.97, one RCT, N = 260). </p> <p>There was only one study, so it was not possible to conduct any planned sensitivity analyses. </p> <p><i>2.8 Total number of MII oocytes (</i><a href="./references#CD013827-fig-0023" title="">Analysis 2.8</a><i>)</i><br/>The only study included in this outcome was judged to be of low risk for bias. </p> <p>In normo‐responders, there is little or no difference in the number of MII oocytes in the MPA 4 mg group in comparison to GnRH agonists (MD 0.20, 95% CI ‐1.14 to 1.54, one RCT, N = 260, high‐certainty evidence). This suggests that if the number of MII oocytes following GnRH agonists is assumed to be 10, the number would be between 9 and 12 following MPA. </p> <p>There was only one study, so it was not possible to conduct any planned sensitivity analyses. </p> <p><i>2.9 Number of days of stimulation (</i><a href="./references#CD013827-fig-0024" title="">Analysis 2.9</a><i>)</i> </p> <p>The only study included in this outcome was judged to be of low risk for bias.</p> <p>In normo‐responders, the number of days of stimulation is probably lower in the MPA 4 mg group in comparison to GnRH agonists (MD ‐2.80, 95% CI ‐3.25 to ‐2.35, one RCT, N = 260). </p> <p>There was only one study, so it was not possible to conduct any planned sensitivity analyses. </p> <p><i>2.10 Total dose of gonadotropins (</i><a href="./references#CD013827-fig-0025" title="">Analysis 2.10</a><i>)</i><br/>The only study included in this outcome was judged to be of low risk for bias. </p> <p>In normo‐responders, the total dose of gonadotropins is lower in the MPA 4 mg group in comparison to GnRH agonists (MD ‐645.00, 95% CI ‐763.04 to ‐526.96, one RCT, N = 260, high‐certainty evidence). This suggests that if the number of MII oocytes following GnRH agonists is assumed to be 2670, the chance following MPA would be between 1910 and 2150. </p> <p>There was only one study, so it was not possible to conduct any planned sensitivity analyses. </p> <p><i>2.11 Other adverse effects (</i><a href="./references#CD013827-fig-0026" title="">Analysis 2.11</a><i>)</i> </p> <p>The only study included in this outcome was judged to be of overall some concerns of risk of bias arising from the outcome measurement. </p> <p>Moderate and severe OHSS is the only adverse effect that was analysed. Due to wide confidence interval, we are very uncertain of the effect of GnRH agonists in comparison to MPA 4 mg on moderate or severe OHSS in normo‐responders (OR 0.14, 95% CI 0.01 to 2.73, one RCT, N = 260, very low‐certainty evidence). </p> </section> </section> </section> <section id="CD013827-sec-0052"> <h4 class="title">3 One progestogen versus another progestogen (different types or doses)</h4> <p>Five studies (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>; <a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>; <a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>; <a href="./references#CD013827-bbs2-0012" title="ZhuX , YeH , FuY . Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Sterility2017;108(37):505-12. ZhuX , YeH , FuY . The usage of Daphaston and hMG protocol in normalovulatory women undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments in combination with embryo cryopreservation. Human Reproduction2017;32 Suppl 1:i447. ">Zhu 2017a</a>; <a href="./references#CD013827-bbs2-0013" title="FuY , ZhuX , YeH . The comparison of Utrogestan 100 mg or 200 mg per day used for controlled ovarian hyperstimulation in normalovulatory women: a prospective, randomized, controlled trial. Human Reproduction2016;31 Supp1:i421-i422 Abstract no: P. ZhuX , YeH , FuY . The use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a freeze all strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility and Sterility2017;107:379-86. ">Zhu 2017b</a>) compared the outcomes for women having an ART cycle in which two different types or doses of progestogens were compared, in order to prevent a premature LH surge. All of them were performed in normo‐responders with their own oocytes with an early phase stimulation protocol, but one of them also added as an inclusion criterion to have moderate or severe endometriosis (<a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>). For this reason, the only subgroup analysis that was performed included the comparison of different types of progestogens. </p> <p>Comparisons of different types of progestogens </p> <p><b>MPA versus dydrogesterone</b> </p> <p>One study compared MPA versus dydrogesterone (<a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>). It was performed on 520 normo‐responders who were stimulated with: a) hMG 225 IU/day and MPA 10 mg/day from day 3 of menstruation; or b) hMG 225 IU/day and dydrogesterone 20 mg/day from day 3 of menstruation, performing a frozen embryo transfer on day 3 or 5 of a subsequent cycle. </p> <p>Another study (<a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>) also compared MPA versus dydrogesterone. It was performed on 300 normo‐responders with endometriosis who were stimulated with: a) hMG 150‐225 IU/day and MPA 4 mg/day from day 3 of menstruation; or b) hMG 150‐225 IU/day and dydrogesterone 20 mg/day from day 3 of menstruation. </p> <p><b>Micronised progesterone versus dydrogesterone</b> </p> <p>One study (<a href="./references#CD013827-bbs2-0012" title="ZhuX , YeH , FuY . Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Sterility2017;108(37):505-12. ZhuX , YeH , FuY . The usage of Daphaston and hMG protocol in normalovulatory women undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments in combination with embryo cryopreservation. Human Reproduction2017;32 Suppl 1:i447. ">Zhu 2017a</a>) compared micronised progesterone versus dydrogesterone. It was performed on 250 normo‐responders who were stimulated with: a) hMG 150‐225 IU/day and micronised progesterone 100 mg/day from day 3 of menstruation; or b) hMG 150‐225 IU/day and dydrogesterone 20 mg/day from day 3 of menstruation, performing a frozen embryo transfer on day 3 or 5 of a subsequent cycle. </p> <p>Another study (<a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>) also compared micronised progesterone versus dydrogesterone. It was performed on 300 normo‐responders with endometriosis who were stimulated with: a) hMG 150‐225 IU/day and micronised progesterone 100 mg/day from day 3 of menstruation; or b) hMG 150‐225 IU/day and dydrogesterone 20 mg/day from day 3 of menstruation. </p> <p><b>Micronised progesterone versus MPA</b> </p> <p>And another study (<a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>) compared MPA versus micronised progesterone. It was performed in 300 normo‐responders with endometriosis who were stimulated with: a) hMG 150‐225 IU/day and MPA 4 mg/day from day 3 of menstruation; or b) hMG 150‐225 IU/day and micronised progesterone 100 mg/day from day 3 of menstruation. </p> <p>Comparisons of different doses of the same progestogen type </p> <p><b>MPA 4 mg versus MPA 10 mg</b> </p> <p>One of the studies (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>) compared different doses of MPA, and it was performed on 300 normo‐responders who were stimulated with: a) hMG 225 IU/day and MPA 4 mg/day from day 3 of menstruation; or b) hMG 225 IU/day and MPA 10 mg/day from day 3 of menstruation, performing a frozen embryo transfer on day 3 or 5 of a subsequent cycle. </p> <p><b>Micronised progesterone 100 mg versus micronised progesterone 200 mg</b> </p> <p>Another study (<a href="./references#CD013827-bbs2-0013" title="FuY , ZhuX , YeH . The comparison of Utrogestan 100 mg or 200 mg per day used for controlled ovarian hyperstimulation in normalovulatory women: a prospective, randomized, controlled trial. Human Reproduction2016;31 Supp1:i421-i422 Abstract no: P. ZhuX , YeH , FuY . The use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a freeze all strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility and Sterility2017;107:379-86. ">Zhu 2017b</a>) compared different doses of micronised progesterone, and it was performed on 150 normo‐responders who were stimulated with: a) hMG and micronised progesterone 100 mg/day from day 3 of menstruation; or b) hMG and micronised progesterone 200 mg/day from day 3 of menstruation, performing a frozen embryo transfer on day 3 of a subsequent cycle. </p> <section id="CD013827-sec-0053"> <h5 class="title">Primary outcome</h5> <p><i>3.1 Live birth rate (</i><a href="./references#CD013827-fig-0027" title="">Analysis 3.1</a><i>)</i> </p> <p>Live birth rate was analysed in two different studies (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>; <a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>), in four different comparisons in normo‐responders. </p> <p>The studies included in this outcome were judged to be of very serious risk for bias arising from the missing outcome data, leading to an overall judgement of high risk of bias with regard to these studies. Therefore, none of the studies were included in the primary analysis. </p> <p><i>All studies included ‐ Sensitivity analysis</i> </p> <p>We performed a sensitivity analysis including those studies with an overall high risk of bias. We performed a sensitivity analysis applying risk ratio (RR) and a random‐effects model to each comparison, and no differences in the primary analysis were found. </p> <p><b>MPA versus dydrogesterone</b> </p> <p>We are very uncertain of the effect in normo‐responders of MPA 4 mg in comparison to dydrogesterone 20 mg on the live birth rate (OR 1.09, 95% CI 0.68 to 1.76, one RCT, N = 87, very low‐certainty evidence). </p> <p><b>Micronised progesterone versus dydrogesterone</b> </p> <p>Dydrogesterone 20 mg may increase the live birth rate in comparison to micronised progesterone 100 mg in normo‐responders, but due to wide confidence interval, we are uncertain of the effect (OR 1.42, 95% CI 0.86 to 2.34, one RCT, N = 300, low‐certainty evidence). </p> <p><b>Micronised progesterone versus MPA</b> </p> <p>MPA 10 mg may increase the live birth rate in comparison to micronised progesterone 100 mg in normo‐responders, but due to wide confidence interval, we are uncertain of the effect (OR 1.56, 95% CI 0.95 to 2.55, one RCT, N = 300, low‐certainty evidence). </p> <p><b>MPA 4 mg versus MPA 10 mg</b> </p> <p>MPA 4 mg may decrease the live birth rate in comparison to MPA 10 mg in normo‐responders, but due to wide confidence interval, we are uncertain of the effect (OR 0.76, 95% CI 0.48 to 1.20, one RCT, N = 300, low‐certainty evidence). </p> <p><i>3.2 Oocyte pick‐up cancellation rate (</i><a href="./references#CD013827-fig-0028" title="">Analysis 3.2</a><i>)</i> </p> <p>Cancellation rate was analysed in five different studies (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>; <a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>; <a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>; <a href="./references#CD013827-bbs2-0012" title="ZhuX , YeH , FuY . Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Sterility2017;108(37):505-12. ZhuX , YeH , FuY . The usage of Daphaston and hMG protocol in normalovulatory women undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments in combination with embryo cryopreservation. Human Reproduction2017;32 Suppl 1:i447. ">Zhu 2017a</a>; <a href="./references#CD013827-bbs2-0013" title="FuY , ZhuX , YeH . The comparison of Utrogestan 100 mg or 200 mg per day used for controlled ovarian hyperstimulation in normalovulatory women: a prospective, randomized, controlled trial. Human Reproduction2016;31 Supp1:i421-i422 Abstract no: P. ZhuX , YeH , FuY . The use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a freeze all strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility and Sterility2017;107:379-86. ">Zhu 2017b</a>), in six different comparisons in normo‐responders. All of them were included in the primary analysis. </p> <p>The studies included in this outcome were mostly judged to be of overall low risk of bias and one with overall some concerns of risk of bias arising from the randomisation process. </p> <p><b>MPA versus dydrogesterone</b> </p> <p>When comparing dydrogesterone 20 mg to MPA, oocyte pick‐up cancellation rate is probably lower in the dydrogesterone group in comparison to MPA 10 mg (OR 1.49, 95% CI 0.80 to 2.80, one RCT, N = 520, moderate‐certainty evidence)(<a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>), and it may be lower in dydrogesterone group in comparison to MPA 4 mg (OR 1.19, 95% CI 0.61 to 2.34, one RCT, N = 300, low‐certainty evidence), but due to wide confidence intervals, we are uncertain of the effect (<a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>). This suggests that if the chance of cancellation following dydrogesterone 20 mg is assumed to be 7%, the chance following MPA 10 mg would be between 6% and 17%. And if the change of cancellation following dydrogesterone 20 mg is assumed to be 12%, the chance following MPA 4 mg would be between 8% and 24%. </p> <p><b>Micronised progesterone versus dydrogesterone</b> </p> <p>When comparing dydrogesterone 20 mg to micronised progesterone 100 mg, cancellation rate is probably lower in dydrogesterone group (OR 0.65, 95% CI 0.40 to 1.06, two RCTs, N = 550, I² = 0%, moderate‐certainty evidence) but due to the wide confidence interval, we are uncertain of the effect (<a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>; <a href="./references#CD013827-bbs2-0012" title="ZhuX , YeH , FuY . Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Sterility2017;108(37):505-12. ZhuX , YeH , FuY . The usage of Daphaston and hMG protocol in normalovulatory women undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments in combination with embryo cryopreservation. Human Reproduction2017;32 Suppl 1:i447. ">Zhu 2017a</a>). This suggests that if the chance of cancellation following dydrogesterone 20 mg is assumed to be 11%, the chance following micronised progesterone 100 mg would be between 10% and 24%. </p> <p><b>Micronised progesterone versus MPA</b> </p> <p>MPA 4 mg may be lower than micronised progesterone 100 mg, but due to the wide confidence interval, we are uncertain of the effect (OR 0.81, 95% CI 0.43 to 1.53, one RCT, N = 300, low‐certainty evidence) (<a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>). This suggests that if the chance of cancellation following micronised progesterone 100 mg is assumed to be 17%, the chance following MPA 4 mg would be between 8% and 24%. </p> <p><b>MPA 4 mg versus MPA 10 mg</b> </p> <p>The cancellation rate was probably lower in the MPA 10 mg in comparison to MPA 4 mg (OR 2.27, 95% CI 0.90 to 5.74, one RCT, N = 300, moderate‐certainty evidence) but due to wide confidence interval, we are uncertain of the effect (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>). This suggests that if the chance of cancellation following MPA 10 mg is assumed to be 5%, the chance following MPA 4 mg would be between 5% and 22%. </p> <p><b>Micronised progesterone 100 mg versus micronised progesterone 200 mg</b> </p> <p>We are very uncertain of the effect in normo‐responders of micronised progesterone 100 mg in comparison to micronised progesterone 200 mg on the cancellation rate (OR 0.35, 95% CI 0.09 to 1.37, one RCT, N = 150, very low‐certainty evidence)(<a href="./references#CD013827-bbs2-0013" title="FuY , ZhuX , YeH . The comparison of Utrogestan 100 mg or 200 mg per day used for controlled ovarian hyperstimulation in normalovulatory women: a prospective, randomized, controlled trial. Human Reproduction2016;31 Supp1:i421-i422 Abstract no: P. ZhuX , YeH , FuY . The use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a freeze all strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility and Sterility2017;107:379-86. ">Zhu 2017b</a>). </p> <p>No sensitivity analysis for risk of bias was performed as all the studies were included in the primary analysis for this outcome. We performed a sensitivity analysis applying RR and a random‐effects model to each comparison, and no differences in the the primary analysis were found. </p> <section id="CD013827-sec-0054"> <h6 class="title">Secondary outcomes</h6> <p><i>3.3 Clinical pregnancy rate (</i><a href="./references#CD013827-fig-0029" title="">Analysis 3.3</a><i>)</i> </p> <p>Clinical pregnancy rate was analysed in three different studies (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>; <a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>; <a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>), in five different comparisons in normo‐responders. Only one of them was included in the primary analysis (<a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>). </p> <p>The studies included in this outcome were mostly judged to be of very serious risk for bias arising from the missing outcome data, leading to an overall judgment of high risk of bias with regard to these studies. </p> <p><b>MPA versus dydrogesterone</b> </p> <p>There is probably little or no difference between MPA 10 mg and dydrogesterone 20 mg in clinical pregnancy rate (OR 1.11, 95% CI 0.79 to 1.57, one RCT, N = 520, moderate‐certainty evidence) (<a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>). This suggests that if the chance of clinical pregnancy following dydrogesterone 20 mg is assumed to be 48%, the chance following MPA 10 mg would be between 42% and 59%. There was only one study per comparison to conduct any planned sensitivity analyses. </p> <p><i>All studies included ‐ Sensitivity analysis</i> </p> <p>We performed a sensitivity analysis including those studies with an overall high risk of bias (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>; <a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>). We performed a sensitivity analysis applying RR and a random‐effects model to each comparison, and no differences inh the primary analysis were found. </p> <p>We are uncertain whether MPA 4 mg versus MPA 10 mg or dydrogesterone 20 mg or micronised progesterone 100 mg improves the clinical pregnancy rate in normo‐responders (very low‐certainty evidence). We are uncertain whether micronised progesterone 100 mg versus dydrogesterone 20 mg improves the clinical pregnancy rate in normo‐responders (very low‐certainty evidence). </p> <p><i>3.4 Cumulative pregnancy rate (</i><a href="./references#CD013827-fig-0030" title="">Analysis 3.4</a><i>)</i> </p> <p>Clinical pregnancy rate was analysed in two different studies (<a href="./references#CD013827-bbs2-0012" title="ZhuX , YeH , FuY . Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Sterility2017;108(37):505-12. ZhuX , YeH , FuY . The usage of Daphaston and hMG protocol in normalovulatory women undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments in combination with embryo cryopreservation. Human Reproduction2017;32 Suppl 1:i447. ">Zhu 2017a</a>; <a href="./references#CD013827-bbs2-0013" title="FuY , ZhuX , YeH . The comparison of Utrogestan 100 mg or 200 mg per day used for controlled ovarian hyperstimulation in normalovulatory women: a prospective, randomized, controlled trial. Human Reproduction2016;31 Supp1:i421-i422 Abstract no: P. ZhuX , YeH , FuY . The use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a freeze all strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility and Sterility2017;107:379-86. ">Zhu 2017b</a>), in two different comparisons in normo‐responders. </p> <p>The studies included in this outcome were judged to be of high risk for bias arising from the missing outcome data and some concerns of bias in the randomisation process domain, leading to an overall judgment of high risk of bias with regard to these studies. Therefore, none of the studies were included in the primary analysis. </p> <p><i>All studies included ‐ Sensitivity analysis</i> </p> <p>We performed a sensitivity analysis including those studies with an overall high risk of bias. We performed a sensitivity analysis applying RR and a random‐effects model to each comparison, and no differences in the primary analysis were found. </p> <p>We are uncertain whether micronised progesterone mg versus dydrogesterone 20 mg or versus micronised progesterone 200 mg improves the clinical pregnancy rate in normo‐responders (very low‐certainty evidence). </p> <p><i>3.5 Miscarriage rate (</i><a href="./references#CD013827-fig-0031" title="">Analysis 3.5</a><i>)</i> </p> <p>Miscarriage rate was analysed in five different studies (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>; <a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>; <a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>; <a href="./references#CD013827-bbs2-0012" title="ZhuX , YeH , FuY . Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Sterility2017;108(37):505-12. ZhuX , YeH , FuY . The usage of Daphaston and hMG protocol in normalovulatory women undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments in combination with embryo cryopreservation. Human Reproduction2017;32 Suppl 1:i447. ">Zhu 2017a</a>; <a href="./references#CD013827-bbs2-0013" title="FuY , ZhuX , YeH . The comparison of Utrogestan 100 mg or 200 mg per day used for controlled ovarian hyperstimulation in normalovulatory women: a prospective, randomized, controlled trial. Human Reproduction2016;31 Supp1:i421-i422 Abstract no: P. ZhuX , YeH , FuY . The use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a freeze all strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility and Sterility2017;107:379-86. ">Zhu 2017b</a>), in six different comparisons in normo‐responders. Only one of them was included in the primary analysis (<a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>). </p> <p>The studies included in this outcome were mostly judged to be of very serious risk for bias arising from the missing outcome data, leading to an overall judgment of high risk of bias with regard to these studies. </p> <p><b>MPA versus dydrogesterone</b> </p> <p>Dydrogesterone 20 mg may decrease the miscarriage rate in comparison to MPA 10 mg in normo‐responders, but due to wide confidence interval, we are uncertain of the effect (OR 1.66, 95% CI 0.68 to 4.07, one RCT, N = 520, low‐certainty evidence) (<a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>). This suggests that if the chance of miscarriage following dydrogesterone 20 mg is assumed to be 3%, the chance following MPA 10 mg would be between 2% and 11%. </p> <p><i>All studies included ‐ Sensitivity analysis</i> </p> <p>We performed a sensitivity analysis including those studies with an overall high risk of bias. We performed a sensitivity analysis applying RR and a random‐effects model to each comparison, and no differences inh the primary analysis were found. </p> <p>We are uncertain whether MPA 4 mg versus MPA 10 mg or versus dydrogesterone 20 mg or versus micronised progesterone 100 mg improves the miscarriage rate in normo‐responders (very low‐certainty evidence). We are also uncertain whether micronised progesterone 100 mg versus dydrogesterone 20 mg or versus micronised progesterone 200 mg improves the miscarriage rate in normo‐responders (very low‐certainty evidence). </p> <p>We have also performed a secondary analysis per clinical pregnancy. We are uncertain of the effect of MPA 10 mg in comparison to dydrogesterone 20 mg on the miscarriage rate in normo‐responders (OR 1.60, 95% CI 0.64 to 4.00, one RCT, N = 257). </p> <p><i>3.6 Multiple pregnancy rate</i> </p> <p>Multiple pregnancy rate was analysed in four different studies (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>; <a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>; <a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>; <a href="./references#CD013827-bbs2-0012" title="ZhuX , YeH , FuY . Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Sterility2017;108(37):505-12. ZhuX , YeH , FuY . The usage of Daphaston and hMG protocol in normalovulatory women undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments in combination with embryo cryopreservation. Human Reproduction2017;32 Suppl 1:i447. ">Zhu 2017a</a>), in five different comparisons in normo‐responders. Only one of them was included in the primary analysis (<a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>). </p> <p>The studies included in this outcome were mostly judged to be of very serious risk for bias arising from the missing outcome data leading to an overall judgment of high risk of bias with regard to these studies. </p> <p><b>MPA versus dydrogesterone</b> </p> <p>Dydrogesterone 20 mg may decrease the multiple pregnancy rate in comparison to MPA 10 mg in normo‐responders, but due to wide confidence interval, we are uncertain of the effect (OR 1.50, 95% CI 0.95 to 2.36, one RCT, N = 520, low‐certainty evidence) (<a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>). </p> <p><i>All studies included ‐ Sensitivity analysis</i> </p> <p>We performed a senstivity analysis including those studies with an overall high risk of bias. We performed a sensitivity analysis applying RR and a random‐effects model to each comparison, and no differences with the primary analysis were found. </p> <p>We are uncertain whether MPA 4 mg versus MPA 10 mg or versus dydrogesterone 20 mg or versus micronised progesterone 100 mg improves the multiple pregnancy rate in normo‐responders. We are also uncertain whether micronised progesterone 100 mg versus dydrogesterone 20 mg improves the miscarriage rate in normo‐responders (very low‐certainty evidence). </p> <p>We also performed a secondary analysis per clinical pregnancy. We are uncertain of the effect of MPA 10 mg in comparison to dydrogesterone 20 mg on the miscarriage rate in normo‐responders (OR 1.56, 95% CI 0.88 to 2.76, one RCT, N = 257). </p> <p><i>3.7 Premature LH surge (</i><a href="./references#CD013827-fig-0033" title="">Analysis 3.7</a><i>)</i><br/>The studies included in this outcome were mostly judged to be of overall low risk of bias. All of them were included in the primary analysis. </p> <p>Premature LH surge rate was analysed in five different studies (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>; <a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>; <a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>; <a href="./references#CD013827-bbs2-0012" title="ZhuX , YeH , FuY . Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Sterility2017;108(37):505-12. ZhuX , YeH , FuY . The usage of Daphaston and hMG protocol in normalovulatory women undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments in combination with embryo cryopreservation. Human Reproduction2017;32 Suppl 1:i447. ">Zhu 2017a</a>; <a href="./references#CD013827-bbs2-0013" title="FuY , ZhuX , YeH . The comparison of Utrogestan 100 mg or 200 mg per day used for controlled ovarian hyperstimulation in normalovulatory women: a prospective, randomized, controlled trial. Human Reproduction2016;31 Supp1:i421-i422 Abstract no: P. ZhuX , YeH , FuY . The use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a freeze all strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility and Sterility2017;107:379-86. ">Zhu 2017b</a>). No cases of premature LH surge were found in any of the normo‐responders women that were analysed. </p> <p>No secondary analysis for risk of bias was performed as all the studies were included in the primary analysis for this outcome. We performed a sensitivity analysis applying RR and a random‐effects model to each comparison, and no differences in the primary analysis were found. </p> <p><i>3.8 Total number of oocytes (</i><a href="./references#CD013827-fig-0034" title="">Analysis 3.8</a><i>)</i><br/>Total number of oocytes was analysed in five different studies (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>; <a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>; <a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>; <a href="./references#CD013827-bbs2-0012" title="ZhuX , YeH , FuY . Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Sterility2017;108(37):505-12. ZhuX , YeH , FuY . The usage of Daphaston and hMG protocol in normalovulatory women undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments in combination with embryo cryopreservation. Human Reproduction2017;32 Suppl 1:i447. ">Zhu 2017a</a>; <a href="./references#CD013827-bbs2-0013" title="FuY , ZhuX , YeH . The comparison of Utrogestan 100 mg or 200 mg per day used for controlled ovarian hyperstimulation in normalovulatory women: a prospective, randomized, controlled trial. Human Reproduction2016;31 Supp1:i421-i422 Abstract no: P. ZhuX , YeH , FuY . The use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a freeze all strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility and Sterility2017;107:379-86. ">Zhu 2017b</a>), in six different comparisons in normo‐responders. All of them were included in the primary analysis. </p> <p>The studies included in this outcome were mostly judged to be of low risk for bias.</p> <p><b>MPA versus dydrogesterone</b> </p> <p>There is probably little or no differences in the total number of oocytes when comparing MPA 4 mg to dydrogesterone (MD 1.30, 95% CI 0.14 to 2.46, one RCT, N = 300). The analysis ruled out a clinically relevant difference in the number of total oocytes when comparing MPA 10 mg to dydrogesterone 20 mg (MD 0.30, 95% CI ‐0.74 to 1.34, one RCT, N = 520). </p> <p><b>Micronised progesterone versus dydrogesterone</b> </p> <p>The analysis ruled out a clinically relevant difference in the number of total oocytes when comparing micronised progesterone 100 mg to dydrogesterone 20 mg (MD ‐0.36, 95% CI ‐1.22 to 0.50). </p> <p><b>Micronised progesterone versus MPA</b> </p> <p>There is probably little or no difference in the total number of oocytes when comparing MPA 4 mg to micronised progesterone 100 mg (MD 1.50, 95% CI 0.27 to 2.73, one RCT, N = 300). </p> <p><b>MPA 4 mg versus MPA 10 mg</b> </p> <p>The analysis ruled out a clinically relevant difference in the number of total oocytes when comparing MPA 10 mg to MPA 4 mg (MD ‐0.20, 95% CI ‐1.58 to 1.18, one RCT, N = 300). </p> <p><b>Micronised progesterone 100 mg versus micronised progesterone 200 mg</b> </p> <p>The analysis ruled out a clinically relevant difference in the number of total oocytes when comparing micronised progesterone 100 mg to micronised progesterone 200 mg (MD ‐0.40, 95% CI ‐2.19 to 1.39) or to dydrogesterone 20 mg (MD ‐0.36, 95% CI ‐1.22 to 0.50). </p> <p>No secondary analysis for risk of bias was performed as all the studies were included in the primary analysis for this outcome. We performed a sensitivity analysis applying RR and a random‐effects model to each comparison, and no differences in the primary analysis were found. </p> <p><i>3.9 Total number of MII oocytes (</i><a href="./references#CD013827-fig-0035" title="">Analysis 3.9</a><i>)</i><br/>Total number of oocytes was analysed in five different studies (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>; <a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>; <a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>; <a href="./references#CD013827-bbs2-0012" title="ZhuX , YeH , FuY . Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Sterility2017;108(37):505-12. ZhuX , YeH , FuY . The usage of Daphaston and hMG protocol in normalovulatory women undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments in combination with embryo cryopreservation. Human Reproduction2017;32 Suppl 1:i447. ">Zhu 2017a</a>; <a href="./references#CD013827-bbs2-0013" title="FuY , ZhuX , YeH . The comparison of Utrogestan 100 mg or 200 mg per day used for controlled ovarian hyperstimulation in normalovulatory women: a prospective, randomized, controlled trial. Human Reproduction2016;31 Supp1:i421-i422 Abstract no: P. ZhuX , YeH , FuY . The use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a freeze all strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility and Sterility2017;107:379-86. ">Zhu 2017b</a>), in six different comparisons in normo‐responders. All of them were included in the primary analysis. </p> <p>The studies included in this outcome were mostly judged to be of low risk for bias.</p> <p><b>MPA versus dydrogesterone</b> </p> <p>There are probably little or no differences in the total number of MII oocytes when comparing MPA 4 mg to dydrogesterone (MD 0.90, 95% CI ‐0.15 to 1.95, one RCT, N = 300, moderate‐certainty evidence). This suggests that if the number of MII oocytes following dydrogesterone 20 mg is assumed to be 7, the number of MII oocytes following MPA 4 mg would be between 6 and 8. </p> <p>There is little or no difference in the number of total MII oocytes when comparing dydrogesterone 20 mg to MPA 10 mg (MD 0.30, 95% CI ‐0.65 to 1.25, one RCT, N = 520, high‐certainty evidence). This suggests that if the number of MII oocytes following dydrogesterone 20 mg is assumed to be 7, the number of MII oocytes following MPA 10 mg would be close to 7. </p> <p><b>Micronised progesterone versus dydrogesterone</b> </p> <p>There are little or no differences in the number of total MII oocytes when comparing dydrogesterone 20 mg to micronised progesterone 100 mg (MD ‐0.16, 95% CI ‐0.90 to 0.58, two RCTs, I<sup>2</sup> = 0% N = 550, high‐certainty evidence). This suggests that if the number of MII oocytes following dydrogesterone 20 mg is assumed to be 9, the number of MII oocytes following micronised progesterone 100 mg would be close to 9. </p> <p><b>Micronised progesterone versus MPA</b> </p> <p>There is probably little or no difference in the total number of MII oocytes when comparing MPA 4 mg to micronised progesterone 100 mg (MD 1.30, 95% CI 0.21 to 2.39, one RCT, N = 300, moderate certainty evidence). This suggests that if the number of MII oocytes following micronised progesterone 100 mg is assumed to be 7, the number of MII oocytes following MPA 4 mg would be between 6 and 8. </p> <p><b>Micronised progesterone 100 mg versus micronised progesterone 200 mg</b> </p> <p>The analysis ruled out a clinically relevant difference between micronised progesterone 100 mg and micronised progesterone 200 mg on the total number of MII oocytes, but the certainty of the evidence was low (MD ‐0.80, 95% CI ‐2.37 to 0.77, one RCT, N = 150, low‐certainty evidence). This suggests that if the number of MII oocytes following micronised progesterone 200 mg is assumed to be 9, the number of MII oocytes following micronised progesterone 200 mg would be between 8 and 10. </p> <p>No secondary analysis for risk of bias was performed as all the studies were included in the primary analysis for this outcome. We performed a sensitivity analysis applying RR and a random‐effects model to each comparison, and no differences in the primary analysis were found. </p> <p><i>3.10 Number of days of stimulation (</i><a href="./references#CD013827-fig-0036" title="">Analysis 3.10</a><i>)</i> </p> <p>Number of days of stimulation was analysed in five different studies (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>; <a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>; <a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>; <a href="./references#CD013827-bbs2-0012" title="ZhuX , YeH , FuY . Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Sterility2017;108(37):505-12. ZhuX , YeH , FuY . The usage of Daphaston and hMG protocol in normalovulatory women undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments in combination with embryo cryopreservation. Human Reproduction2017;32 Suppl 1:i447. ">Zhu 2017a</a>; <a href="./references#CD013827-bbs2-0013" title="FuY , ZhuX , YeH . The comparison of Utrogestan 100 mg or 200 mg per day used for controlled ovarian hyperstimulation in normalovulatory women: a prospective, randomized, controlled trial. Human Reproduction2016;31 Supp1:i421-i422 Abstract no: P. ZhuX , YeH , FuY . The use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a freeze all strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility and Sterility2017;107:379-86. ">Zhu 2017b</a>), in six different comparisons in normo‐responders. All of them were included in the primary analysis. </p> <p>The studies included in this outcome were mostly judged to be of low risk for bias.</p> <p><b>MPA versus dydrogesterone</b> </p> <p>There was probably little or no difference in the number of days of stimulation when comparing MPA 4 mg to dydrogesterone 20 mg (MD 0.10, 95% CI ‐0.24 to 0.44, one RCT, N = 300). There was probably little or no difference in the number of days of stimulation when comparing dydrogesterone 20 mg to MPA 10 mg (MD 0.20, 95% CI 0.01 to 0.39, one RCT, N = 520). </p> <p>There was probably little or no difference in the number of days of stimulation when comparing dydrogesterone 20 mg to MPA 10 mg (MD 0.20, 95% CI 0.01 to 0.39, one RCT, N = 520). </p> <p><b>Micronised progesterone versus dydrogesterone</b> </p> <p>There was probably little or no difference in the number of days of stimulation when comparing dydrogesterone 20 mg to micronised progesterone 100 mg (MD 0.08, 95% CI ‐0.18 to 0.33, two RCTs, I<sup>2</sup> = 81% N = 550) or MPA 10 mg (MD 0.20, 95% CI 0.01 to 0.39, one RCT, N = 520). </p> <p><b>Micronised progesterone versus MPA</b> </p> <p>There was probably little or no difference in the number of days of stimulation when comparing MPA 4 mg to micronised progesterone 100 mg (MD ‐0.30, 95% CI ‐0.67 to 0.07, one RCT, N = 300). </p> <p><b>Micronised progesterone 100 mg versus micronised progesterone 200 mg</b> </p> <p>There was probably little or no difference in the number of days of stimulation when comparing micronised progesterone 100 mg to micronised progesterone 200 mg (MD ‐0.50, 95% CI ‐0.97 to ‐0.03, one RCT, N = 150) </p> <p>No secondary analysis for risk of bias was performed as all the studies were included in the primary analysis for this outcome. We performed a sensitivity analysis applying RR and a random‐effects model to each comparison, and no differences in the primary analysis were found. </p> <p><i>3.11 Total dose of gonadotropins (</i><a href="./references#CD013827-fig-0037" title="">Analysis 3.11</a><i>)</i><br/>Total dose of gonadotropins was analysed in five different studies (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>; <a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>; <a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>; <a href="./references#CD013827-bbs2-0012" title="ZhuX , YeH , FuY . Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Sterility2017;108(37):505-12. ZhuX , YeH , FuY . The usage of Daphaston and hMG protocol in normalovulatory women undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments in combination with embryo cryopreservation. Human Reproduction2017;32 Suppl 1:i447. ">Zhu 2017a</a>; <a href="./references#CD013827-bbs2-0013" title="FuY , ZhuX , YeH . The comparison of Utrogestan 100 mg or 200 mg per day used for controlled ovarian hyperstimulation in normalovulatory women: a prospective, randomized, controlled trial. Human Reproduction2016;31 Supp1:i421-i422 Abstract no: P. ZhuX , YeH , FuY . The use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a freeze all strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility and Sterility2017;107:379-86. ">Zhu 2017b</a>), in six different comparisons in normo‐responders. All of them were included in the primary analysis. </p> <p>The studies included in this outcome were mostly judged to be of low risk for bias.</p> <p><b>MPA versus dydrogesterone</b> </p> <p>There were probably little or no differences in the total dose of gonadotropins when comparing MPA 4 mg to dydrogesterone 20 mg (MD 127.00, 95% CI 41.74 to 212.26, one RCT, N = 300, moderate‐certainty evidence). This suggests that if the total dose of gonadotropins following dydrogesterone 20 mg is assumed to be 1750, the total dose of gonadotropins following MPA 4 mg would be between 1800 and 1970. </p> <p>There were little or no differences in the total dose of gonadotropins when comparing dydrogesterone 20 mg to MPA 10 mg (MD 47.00, 95% CI 5.91 to 88.09, one RCT, N = 520, high‐certainty evidence). This suggests that if the total dose of gonadotropins following dydrogesterone 20 mg is assumed to be 1700 IU, the total dose of gonadotropins following MPA 10 mg would be between 1705 and 1780. </p> <p><b>Micronised progesterone versus dydrogesterone</b> </p> <p>There were little or no differences in the total dose of gonadotropins when comparing dydrogesterone 20 mg to micronised progesterone 100 mg (MD ‐28.14, 95% CI ‐84.02 to 27.75, two RCTs, I<sup>2</sup> = 81% N = 550, high‐certainty evidence). This suggests that if the total dose of gonadotropins following dydrogesterone 20 mg is assumed to be 1700 IU, the total dose of gonadotropins following micronised progesterone 100 mg would be between 1620 and 1730 IU. </p> <p><b>Micronised progesterone versus MPA</b> </p> <p>There were little or no differences in the total dose of gonadotropins when comparing MPA 4 mg to micronised progesterone 100 mg (MD 162.00, 95% CI 68.25 to 255.75, one RCT, N = 300, moderate certainty evidence). This suggests that if the total dose of gonadotropins following micronised progesterone 100 is assumed to be 1720 IU, the total dose of gonadotropins following MPA 4 mg would be between 1790 and 1970 IU. </p> <p><b>MPA 4 mg versus MPA 10 mg</b> </p> <p>There were little or no differences when comparing MPA 4 mg to MPA 10 mg (MD 22.00, 95% CI ‐48.26 to 92.26, one RCT, N = 300, high‐certainty evidence). This suggests that if the total dose of gonadotropins following MPA 10 mg is assumed to be 1990, the total dose of gonadotropins following MPA 4 mg would be between 1940 and 2080. </p> <p><b>Micronised progesterone 100 mg versus micronised progesterone 200 mg</b> </p> <p>The analysis ruled out a clinically relevant difference in the total dose of gonadotropins when comparing micronised progesterone 100 mg to micronised progesterone 200 mg, but the quality of the evidence was low (MD ‐28.14, 95% CI ‐84.02 to 27.75, one RCT, N = 150, low‐certainty evidence). This suggests that if the total dose of gonadotropins following micronised progesterone 200 mg is assumed to be 1750 IU, the total dose of gonadotropins following micronised progesterone 100 mg would be between 1550 and 1745 IU. </p> <p>No secondary analysis for risk of bias was performed as all the studies were included in the primary analysis for this outcome. We performed a sensitivity analysis applying RR and a random‐effects model to each comparison, and no differences with the primary analysis were found. </p> <p><i>3.12 Other adverse effects (</i><a href="./references#CD013827-fig-0038" title="">Analysis 3.12</a><i>)</i> </p> <p>Moderate and severe OHSS rate was analysed in five different studies (<a href="./references#CD013827-bbs2-0005" title="DongJ , WangY , ChaiWR , HongQQ , WangNL , Sun LH , et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(7):1048-55. ">Dong 2017</a>; <a href="./references#CD013827-bbs2-0008" title="GuoH , LiJ , ShenX , CongY , WangY , WuL , LiB , et al. Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-a single-center non-inferiority randomized controlled trial. Frontiers in Endocrinology2020;11:129. ">Guo 2020</a>; <a href="./references#CD013827-bbs2-0011" title="YuS , LongH , Ya-Ning ChangH , LiuY , GaoH , ZhuJ , et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction2018;33(2):229-37. ">Yu 2018</a>; <a href="./references#CD013827-bbs2-0012" title="ZhuX , YeH , FuY . Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Sterility2017;108(37):505-12. ZhuX , YeH , FuY . The usage of Daphaston and hMG protocol in normalovulatory women undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments in combination with embryo cryopreservation. Human Reproduction2017;32 Suppl 1:i447. ">Zhu 2017a</a>; <a href="./references#CD013827-bbs2-0013" title="FuY , ZhuX , YeH . The comparison of Utrogestan 100 mg or 200 mg per day used for controlled ovarian hyperstimulation in normalovulatory women: a prospective, randomized, controlled trial. Human Reproduction2016;31 Supp1:i421-i422 Abstract no: P. ZhuX , YeH , FuY . The use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a freeze all strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility and Sterility2017;107:379-86. ">Zhu 2017b</a>), in six different comparisons in normo‐responders. All of them were included in the primary analysis. </p> <p>The studies included in this outcome were mostly judged to be of some risk of bias arising from the randomisation process and the measurement of the outcome leading to an overall judgment of some concerns of risk of bias with regard to this study. </p> <p>No cases of moderate and severe OHSS were reported in any of the groups.</p> <p>No secondary analysis for risk of bias was performed as all the studies were included in the primary analysis for this outcome. We performed a sensitivity analysis applying RR and a random‐effects model to each comparison, and no differences in the primary analysis were found. </p> </section> </section> </section> <section id="CD013827-sec-0055"> <h4 class="title">4 Progestogens versus no treatment or placebo</h4> <p>Only one study (<a href="./references#CD013827-bbs2-0009" title="Cruz PalominoM , HenzennE , RequenaA . Pituitary supression is not necessary for blocking LH surge during luteal-phase stimulation. Human Reproduction2020;35 Suppl 1:i68-9. ">Palomino 2020</a>) compared the outcomes for women having an ART cycle in which they received progestogens or nothing in order to prevent a premature LH surge. A total of 20 oocyte donors underwent double‐ovarian stimulation. The study was performed in the luteal phase, and the participants received: a) rFSH 225 IU/day and progestogens (MPA 10 mg/day) from the initial day of stimulation; or b) rFSH 225 IU/day. In both cases, the ovulation was triggered by GnRH agonists. </p> <section id="CD013827-sec-0056"> <h5 class="title">Primary outcome</h5> <p><i>Live birth rate</i> </p> <p>Not reported.</p> <p><i>Oocyte pick‐up cancellation rate</i> </p> <p>Not reported.</p> </section> <section id="CD013827-sec-0057"> <h5 class="title">Secondary outcomes</h5> <p><i>Clinical pregnancy rate</i> </p> <p>Not reported.</p> <p><i>Cumulative pregnancy rate</i> </p> <p>Not reported.</p> <p><i>Miscarriage rate</i> </p> <p>Not reported.</p> <p><i>Multiple pregnancy rate</i> </p> <p>Not reported.</p> <p><i>Premature LH surge</i><br/>Not reported. </p> <p><i>4.1 Total number of oocytes (</i><a href="./references#CD013827-fig-0039" title="">Analysis 4.1</a><i>)</i> </p> <p>The only study included in this outcome (<a href="./references#CD013827-bbs2-0009" title="Cruz PalominoM , HenzennE , RequenaA . Pituitary supression is not necessary for blocking LH surge during luteal-phase stimulation. Human Reproduction2020;35 Suppl 1:i68-9. ">Palomino 2020</a>) was judged to be of high risk for bias arising from the missing outcome data, leading to an overall judgment of high risk of bias with regard to this study. Therefore, it was included in the primary analysis. </p> <p><i>All studies included ‐ Sensitivity analysis</i> </p> <p>We performed a sensitivity analysis including those studies with an overall high risk of bias. </p> <p>In oocyte donors that are stimulated in the luteal phase, we are uncertain whether progestogens increase the total number of oocytes in comparison to no treatment (MD 1.70, 95% CI 0.06 to 3.34, one RCT, N = 20, very low‐certainty evidence). </p> <p><i>4.2 Total number of MII oocytes (</i><a href="./references#CD013827-fig-0040" title="">Analysis 4.2</a><i>)</i> </p> <p>The only study included in this outcome (<a href="./references#CD013827-bbs2-0009" title="Cruz PalominoM , HenzennE , RequenaA . Pituitary supression is not necessary for blocking LH surge during luteal-phase stimulation. Human Reproduction2020;35 Suppl 1:i68-9. ">Palomino 2020</a>) was judged to be of high risk for bias arising from the missing outcome data, leading to an overall judgment of high risk of bias with regard to this study. Therefore, it was included in the primary analysis. </p> <p><i>All studies included ‐ Sensitivity analysis</i> </p> <p>We performed a sensitivity analysis including those studies with an overall high risk of bias. </p> <p>In oocyte donors that are stimulated in the luteal phase, we are uncertain whether progestogens increase the total number of MII oocytes in comparison to no treatment (MD 1.30, 95% CI ‐0.25 to 2.85, one RCT, N = 20, very low‐certainty evidence). </p> <p><i>Number of days of stimulation</i> </p> <p>Not reported.</p> <p><i>Total dose of gonadotropins</i><br/>Not reported. </p> <p><i>Other adverse effects</i> </p> <p>Not reported.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013827-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013827-sec-0058"></div> <section id="CD013827-sec-0059"> <h3 class="title" id="CD013827-sec-0059">Summary of main results</h3> <p>Different types of progestogens were analysed and compared to GnRH agonists, GnRH antagonists, to no treatment and to other types and doses of progestogens. Additionally, these comparisons were made in different subgroups of women, including oocyte donors, women undergoing oocyte freezing, and women undergoing an assisted reproductive technology (ART) treatment, who were normo‐responders and low responders. </p> <p>Considering applicability issues, we discuss here only those comparisons that were classified as low or some concerns risk of bias and that had low, moderate or high certainty of evidence (See <a href="./full#CD013827-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013827-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD013827-tbl-0003">summary of findings Table 3</a>. </p> <p><b>Live birth rate</b> was evaluated in one study in normo‐responders undergoing ART treatment. It compared MPA 4 mg with GnRH agonists and the evidence suggests that there may be little or no differences between them. This outcome was also evaluated in one study that compared medroxyprogesterone acetate (MPA) with GnRH antagonists in poor‐responders, but the certainty of the evidence was very low. The rest of the studies that analysed this outcome were not included in the primary analysis as the overall risk of bias was high. Our primary effectiveness outcome is 'live birth or ongoing pregnancy'. We can confirm that all studies reported live birth. </p> <p><b>Oocyte pick‐up cancellation rate</b> was evaluated by comparing progestogens to GnRH antagonists in normo‐responders and donors, and the certainty of the evidence was low for all the comparisons, mainly due to very serious imprecision. There may be little or no differences between the progestogens and GnRH antagonists for this outcome. When comparing MPA 4 mg with GnRH agonists in normo‐responders, only one study was included, and it suggested that GnRH agonists may slightly decrease the o<i>ocyte pick‐up</i> cancellation rate. When comparing one progestogen with another one, dydrogesterone probably suggested lower cancellation rates than MPA and micronised progesterone, and MPA suggested slightly lower cancellation rates than the micronised progesterone 100 mg. Besides MPA 10 mg probably suggested lower o<i>ocyte pick‐up</i> cancellation rates than MPA 4 mg. However, due to wide confidence intervals, we are uncertain of the effect of progestogens in comparison to all the analysed comparators. </p> <p><b>Clinical pregnancy rate</b> was evaluated by comparing progestogens with GnRH agonists and antagonists, but the certainty of the evidence was low in both cases, mainly due to imprecision. One study suggested that progestogens may increase the clinical pregnancy rate in comparison to GnRH antagonists in poor‐responders, and another study that evaluated normo‐responders suggested that the GnRH agonists may slightly increase the clinical pregnancy rate in comparison to progestogens. However, due to wide confidence intervals, we are uncertain of the effect of progestogens in comparison to GnRH analogs in clinical pregnancy rates. There is probably little or no difference between MPA 10 mg and dydrogesterone 20 mg in clinical pregnancy rate. </p> <p><b>Miscarriage rate</b> was evaluated in only one study, comparing dydrogesterone 20 mg to MPA 10 mg in normo‐responders undergoing ART treatment, and the evidence suggests that miscarriage rate may be lower in the dydrogesterone group. </p> <p>One study suggested that the <b>number of MII oocytes</b> was 2 to 5 higher when using micronised progesterone versus GnRH antagonists in normo‐responders. On the other hand, other studies showed little or no differences when comparing MPA versus GnRH antagonists or versus GnRH agonists, or when comparing one progestogen versus another one. </p> <p><b>Doses of gonadotropins</b> were lower when using MPA 4 mg in comparison to GnRH agonists. Little or no differences were found when comparing progestogens to GnRH antagonists or when comparing one progestogen versus another progestogen. </p> <p>There was not enough evidence to draw any conclusions about <b>cumulative pregnancy rate</b> and <b>moderate or severe OHSS</b> in any of the analysed comparisons. </p> </section> <section id="CD013827-sec-0060"> <h3 class="title" id="CD013827-sec-0060">Overall completeness and applicability of evidence</h3> <p>Most studies included important outcomes and lots of different types and doses of progestogens were used. In the comparison between progestogens and GnRH antagonists, several types of participants were included: normo‐responders, low responders, oocyte donors, and women undergoing oocyte freezing. However, as we analysed each comparison by subgroups of participants, current conclusions are applicable specifically to each of those subgroups. On the other hand, when progestogens were compared with GnRH agonists or with another type of progestogen, the analysed studies only included normo‐responders. Therefore, the applicability remains for that specific subgroup. </p> <p>The included studies did answer the review questions but the quantity and certainty of the evidence is low in general. For live birth rate, the highest certainty of evidence came from a single study that compared progestogens with GnRH agonists. There was also another study comparing progestogens with GnRH antagonists in poor‐responders and four studies that compared one type of progestogen with another, but the overall risk of bias was high for all these comparisons. In all these cases, there were no important differences. For the other primary outcome, the oocyte pick‐up cancellation rate, the evidence is more complete and applicable, coming from several trials, which suggested little differences that could slightly benefit GnRH agonists in comparison with progestogens and that dydrogesterone and MPA 10 mg may be slightly better than MPA 4 mg and micronised progesterone. </p> <p>When analysing the secondary outcomes, clinical pregnancy results came from a few low‐quality studies and, therefore, the evidence is not completely applicable. A remarkable result is that, in normo‐responders (but not in poor‐responders), the number of oocytes could be higher in the micronised progesterone group in comparison with the GnRH antagonist group. Again, the applicability is limited as it comes from a single trial with a low number of participants. And no other differences were found in other comparisons in terms of the number of oocytes. Finally, the doses of gonadotropins were not different between those that received progestogens and those that received GnRH analogs. </p> <p>Current practice is supported by the evidence that was found in this review, as progestogens are usually proposed in order to keep the same success rates as with GnRH analogs but to reduce the costs and patients' discomfort by using oral medication instead of injections. In this review, most outcomes show no differences for most comparisons. Still, more effectiveness studies for each of the subgroups and comparisons, and an evaluation of costs and patients' preferences have to be performed to draw definitive conclusions. </p> </section> <section id="CD013827-sec-0061"> <h3 class="title" id="CD013827-sec-0061">Quality of the evidence</h3> <p>The primary analysis of this review was restricted to studies with low or some concerns about the overall risk of bias, and the most common reason for 'some concerns' was the lack of report of the allocation concealment. When the certainty of the evidence was analysed with the GRADE approach, most of the conclusions were based on low‐certainty evidence, mainly due to large imprecision, except conclusions about the number of MII oocytes and the doses of gonadotropins that were based on moderate‐ or high‐certainty evidence. </p> <p>We have included several studies in this review. However, as we compared progestogens versus different types of comparators, and as they were evaluated in different types of populations, each of the analyses finally had only one or two studies. Therefore, one of the main limitations of the evidence is that most of the analyses were based on a single study with a small sample size, which prevented us from doing further sensitivity analyses. </p> <p>This review has important limitations to conclude on most of the important outcomes, such as live birth rate, cumulative pregnancy rate, clinical pregnancy rate, and cancellation rates. However, the evidence is significant differences between progestogens and GnRH analogs in these outcomes or among progestogens. </p> </section> <section id="CD013827-sec-0062"> <h3 class="title" id="CD013827-sec-0062">Potential biases in the review process</h3> <p>We searched on multiple databases and trial registries to identify unpublished and ongoing studies in order to reduce the risk of publication bias. When any information in any of the screened studies was missing, we contacted the trial authors for additional information or clarification; however, only one author responded. For example, we are not sure if authors counted zero retrieved oocytes when a cycle cancellation occurred, which could mean that the mean number could be lower than reported. Cancellation cycle rates were usually very low and, therefore, the impact is probably marginal. It is possible that our searches did not identify unpublished studies. Although we had planned sensitivity analyses, it was possible only for the risk of bias, excluding in the primary analysis those with overall high risk of bias, and including them in a secondary analysis. However, no other sensitivity analyses could be performed due to the lack of data to do so. Subgroups analysis by population (mainly, normo‐responders, poor‐responders and donors), and also by type and dose of progestogen and by type of comparison, made that most of the analysis had only one study. We were unable to conduct a funnel plot given the small number of included studies in each analysis. </p> </section> <section id="CD013827-sec-0063"> <h3 class="title" id="CD013827-sec-0063">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review, that was published in 2020 (<a href="./references#CD013827-bbs2-0031" title="AlexandruP , CekicSG , YildizS , TurkgeldiE , AtaB . Progestins versus GnRH analogues for pituitary suppression during ovarian stimulation for assisted reproductive technology: a systematic review and meta-analysis. Reproductive BioMedicine Online2020;40(6):894-903.">Alexandru 2020</a>), included not only two randomised controlled trials (RCTs), but also one quasi‐randomised and four non‐randomised studies, and compared progestogens with GnRH analogs. Their analysis was not per randomised woman but per embryo transfer. Apart from the mentioned differences, the only important difference they found was that live birth rate or ongoing pregnancy rate were higher in the progestogen group in comparison with GnRH agonists short protocol (risk ratio (RR) 1.49, 95% confidence interval (CI) 1.16 to 1.91) in their review, but we did not find that difference. The rest of the results were similar to ours. The authors found, as we did, little or no differences between progestogens and GnRH antagonists. The only exception is the number of MII oocytes, which we found that there could be some benefit from using progestogens in normo‐responders. Safety parameters were similar in all groups and cancellation rates were similar as well. </p> <p>Another systematic review, that was published in 2021 (<a href="./references#CD013827-bbs2-0032" title="AtaB , CapuzzoM , TurkgeldiE , YildizS , La MarcaA . Progestins for pituitary suppression during ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses. Human Reproduction Update 2021/01/04;27(1):48-66.">Ata 2021</a>), included RCTs as well as non‐RCTs. This review agrees with our review that a cycle with progestin‐primed ovarian stimulation (PPOS) protocol could be shorter than a long GnRH agonist protocol. Regarding women with polycystic ovary syndrome (PCOS), our review did not include any study that evaluated this population; however, Ata and colleagues found that using PPOS could increase the clinical pregnancy rate in comparison with GnRH agonists in women with polycystic ovary syndrome (PCOS). In that review, the only evaluation among progestogens was dydrogesterone versus medroxyprogesterone acetate (MPA), while in ours we found several comparisons among different types and doses of progestogens; although they found little or no differences between dydrogesterone and MPA, we noted a slightly lower cancellation rate in the dydrogesterone group. An interesting outcome that was not evaluated in our review is the euploidy of the embryos, showing no differences between progestogens and conventional cycles. Finally, in terms of cost‐effectiveness, the authors show that PPOS may increase the cost per live birth when compared to conventional cycles with fresh embryo transfers, mainly because of the need for a deferred embryo transfer when using progestogens. </p> <p>Another systematic review of RCTs was published (<a href="./references#CD013827-bbs2-0045" title="GuanS , FengY , HuangY , Huang. Progestin-primed ovarian stimulation protocol for patients in assisted reproductive technology: a meta-analysis of randomized controlled trials. Frontiers in Endocrinology2021;12:1082.">Guan 2021</a>), including nine studies. Out of those included studies, three were also included in our review; five are listed in our excluded studies list mainly due to randomisation issues, and one study is in our awaiting classification list. As in our review, one study did not find any important difference in live birth or clinical pregnancy between PPOS and conventional stimulation. Although the authors conclude that the number of oocytes retrieved was higher in PPOS, the difference is not clinically important. Finally, that review found a lower incidence of OHSS, but our review only considered moderate and severe ovarian hyperstimulation syndrome (OHSS), and no cases were reported. </p> <p>We also found a systematic review (<a href="./references#CD013827-bbs2-0037" title="CuiL , LinY , WangF , ChenC . Effectiveness of progesterone-primed ovarian stimulation in assisted reproductive technology: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics2021;303(3):615630.">Cui 2021</a>) that included five RCTs, other non‐randomised trials, and retrospective studies. Two of those RCTs were also included in our review while the three others were excluded or in the awaiting classification list. The same as in our review, the authors did not find important differences between PPOS and the comparators, but as Guan and colleagues did, they mention the lower incidence of ovarian hyperstimulation syndrome (OHSS). </p> <p>Another systematic review (<a href="./references#CD013827-bbs2-0055" title="MartinezF , RaccaA , RodríguezI , PolyzosNP . Ovarian stimulation for oocyte donation: a systematic review and meta-analysis. Human Reproduction Update 2021/08/01;27(4):673-96.">Martinez 2021</a>) evaluated different types of controlled ovarian stimulation protocols on oocyte donors and included two RCTs that we also included in the PPOS section, and, as we did, no differences were described between the progestogens and the comparators. </p> <p>In 2021, another systematic review (<a href="./references#CD013827-bbs2-0034" title="CaiR , ZhengB , LinQ , DengJ , ZengX , LinW , et al. A meta-analysis of the efficacy of progestin-primed ovarian stimulation with medroxyprogesterone acetate in ovulation induction in poor ovarian responders. Journal of Gynecology Obstetrics and Human Reproduction2021;50(7):102049.">Cai 2021</a>). It included 15 case‐control studies and one RCT (that was included in our review). The authors found a lower cancellation rate when comparing PPOS with the Chinese minimal stimulation and with the ultra‐short protocol with GnRH agonists. As in our review, the authors did not find differences in other outcomes. </p> <p>Our systematic review did not assess either obstetric and neonatal outcomes or cost‐effectiveness analysis. However, some other authors did. A retrospective study (<a href="./references#CD013827-bbs2-0066" title="ZhangJ , MaoX , WangY , ChenQ , LuX , HongQ , et al. Neonatal outcomes and congenital malformations in children born after human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles. Archives of Gynecology and Obstetrics2017;296(6):1207-17. [DOI: 10.1007/s00404-017-4537-z]">Zhang 2017</a>) was performed on more than 4500 women who received PPOS, a short protocol with GnRH agonists, or a mild stimulation protocol. No significant differences were found either in mean birth weight and length, gestational age, and the frequency of preterm birth, both in singletons and in twins. A logistic multivariable analysis did not show any significant difference in congenital malformations either. Another study published in 2020 (<a href="./references#CD013827-bbs2-0053" title="LiangZ , WangY , KuangY . Live-birth outcomes and congenital malformations after progestin-primed ovarian stimulation in maternal endometriosis. Drug Design Development and Therapy2020;14:5459-67.">Liang 2020</a>), analysed 1495 newborns from women who had undergone in vitro fertilisation (IVF) cycle with GnRH agonist long protocol, GnRH antagonist, or PPOS. No differences were found in congenital malformations among the three groups. A cost‐effectiveness study was published in France in 2020 (<a href="./references#CD013827-bbs2-0057" title="Mathieu d’ArgentE , FerrierC , ZacharopoulouC , Ahdad-Yata, Boudy AS et al, . Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols. Journal of Ovarian Research2020;13(1):18.">Mathieu 2020</a>), and it analysed 108 women with endometriosis who underwent an oocyte freezing cycle and received PPOS or GnRH antagonists. No differences were found between the two groups. In the multiple regression model, the number of oocytes was associated with age, prior ovarian surgery, and anti‐Mullerian hormone levels. In the cost‐effectiveness analysis, the PPOS protocol was strongly dominant over the antagonist protocol. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013827-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013827-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/full#CD013827-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progestogens versus GnRH antagonists, Outcome 1: Live birth or ongoing pregnancy" data-id="CD013827-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Progestogens versus GnRH antagonists, Outcome 1: Live birth or ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progestogens versus GnRH antagonists, Outcome 2: Oocyte pick‐up cancellation" data-id="CD013827-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Progestogens versus GnRH antagonists, Outcome 2: Oocyte pick‐up cancellation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progestogens versus GnRH antagonists, Outcome 3: Clinical pregnancy" data-id="CD013827-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Progestogens versus GnRH antagonists, Outcome 3: Clinical pregnancy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progestogens versus GnRH antagonists, Outcome 4: Cumulative pregnancy rate" data-id="CD013827-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Progestogens versus GnRH antagonists, Outcome 4: Cumulative pregnancy rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progestogens versus GnRH antagonists, Outcome 5: Miscarriage" data-id="CD013827-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Progestogens versus GnRH antagonists, Outcome 5: Miscarriage</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progestogens versus GnRH antagonists, Outcome 6: Multiple pregnancy" data-id="CD013827-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Progestogens versus GnRH antagonists, Outcome 6: Multiple pregnancy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progestogens versus GnRH antagonists, Outcome 7: Premature LH surge" data-id="CD013827-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Progestogens versus GnRH antagonists, Outcome 7: Premature LH surge</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progestogens versus GnRH antagonists, Outcome 8: Total oocytes" data-id="CD013827-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Progestogens versus GnRH antagonists, Outcome 8: Total oocytes</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progestogens versus GnRH antagonists, Outcome 9: MII oocytes" data-id="CD013827-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Progestogens versus GnRH antagonists, Outcome 9: MII oocytes</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progestogens versus GnRH antagonists, Outcome 10: Duration of stimulation (days)" data-id="CD013827-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Progestogens versus GnRH antagonists, Outcome 10: Duration of stimulation (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progestogens versus GnRH antagonists, Outcome 11: Total dose of gonadotropins (IU)" data-id="CD013827-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Progestogens versus GnRH antagonists, Outcome 11: Total dose of gonadotropins (IU) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progestogens versus GnRH antagonists, Outcome 12: Moderate or severe OHSS" data-id="CD013827-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Progestogens versus GnRH antagonists, Outcome 12: Moderate or severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progestogens versus GnRH antagonists, Outcome 13: Live birth or ongoing pregnancy sensitivity analysis" data-id="CD013827-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Progestogens versus GnRH antagonists, Outcome 13: Live birth or ongoing pregnancy sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progestogens versus GnRH antagonists, Outcome 14: Oocyte pick‐up cancellation sensitivity analysis" data-id="CD013827-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Progestogens versus GnRH antagonists, Outcome 14: Oocyte pick‐up cancellation sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progestogens versus GnRH agonists, Outcome 1: Live birth or ongoing pregnancy" data-id="CD013827-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Progestogens versus GnRH agonists, Outcome 1: Live birth or ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progestogens versus GnRH agonists, Outcome 2: Oocyte pick‐up cancellation" data-id="CD013827-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Progestogens versus GnRH agonists, Outcome 2: Oocyte pick‐up cancellation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progestogens versus GnRH agonists, Outcome 3: Clinical Pregnancy" data-id="CD013827-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Progestogens versus GnRH agonists, Outcome 3: Clinical Pregnancy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progestogens versus GnRH agonists, Outcome 4: Miscarriage" data-id="CD013827-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Progestogens versus GnRH agonists, Outcome 4: Miscarriage</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progestogens versus GnRH agonists, Outcome 5: Multiple pregnancy" data-id="CD013827-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Progestogens versus GnRH agonists, Outcome 5: Multiple pregnancy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progestogens versus GnRH agonists, Outcome 6: Premature LH surge" data-id="CD013827-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Progestogens versus GnRH agonists, Outcome 6: Premature LH surge</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progestogens versus GnRH agonists, Outcome 7: Total oocytes" data-id="CD013827-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Progestogens versus GnRH agonists, Outcome 7: Total oocytes</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progestogens versus GnRH agonists, Outcome 8: MII oocytes" data-id="CD013827-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Progestogens versus GnRH agonists, Outcome 8: MII oocytes</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progestogens versus GnRH agonists, Outcome 9: Duration of stimulation (days)" data-id="CD013827-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Progestogens versus GnRH agonists, Outcome 9: Duration of stimulation (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progestogens versus GnRH agonists, Outcome 10: Total dose of gonadotropins (IU)" data-id="CD013827-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Progestogens versus GnRH agonists, Outcome 10: Total dose of gonadotropins (IU) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progestogens versus GnRH agonists, Outcome 11: Moderate or severe OHSS" data-id="CD013827-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Progestogens versus GnRH agonists, Outcome 11: Moderate or severe OHSS</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Progestogen versus another progestogen, Outcome 1: Live birth or ongoing pregnancy" data-id="CD013827-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Progestogen versus another progestogen, Outcome 1: Live birth or ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Progestogen versus another progestogen, Outcome 2: Oocyte pick‐up cancellation" data-id="CD013827-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Progestogen versus another progestogen, Outcome 2: Oocyte pick‐up cancellation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Progestogen versus another progestogen, Outcome 3: Clinical pregnancy" data-id="CD013827-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Progestogen versus another progestogen, Outcome 3: Clinical pregnancy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Progestogen versus another progestogen, Outcome 4: Cumulative pregnancy" data-id="CD013827-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Progestogen versus another progestogen, Outcome 4: Cumulative pregnancy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Progestogen versus another progestogen, Outcome 5: Miscarriage" data-id="CD013827-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Progestogen versus another progestogen, Outcome 5: Miscarriage</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Progestogen versus another progestogen, Outcome 6: Multiple pregnancy" data-id="CD013827-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Progestogen versus another progestogen, Outcome 6: Multiple pregnancy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Progestogen versus another progestogen, Outcome 7: Premature LH surge" data-id="CD013827-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Progestogen versus another progestogen, Outcome 7: Premature LH surge</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Progestogen versus another progestogen, Outcome 8: Total oocytes" data-id="CD013827-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Progestogen versus another progestogen, Outcome 8: Total oocytes</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Progestogen versus another progestogen, Outcome 9: MII oocytes" data-id="CD013827-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Progestogen versus another progestogen, Outcome 9: MII oocytes</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Progestogen versus another progestogen, Outcome 10: Duration of stimulation" data-id="CD013827-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Progestogen versus another progestogen, Outcome 10: Duration of stimulation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Progestogen versus another progestogen, Outcome 11: Total dose of gonadotropins" data-id="CD013827-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Progestogen versus another progestogen, Outcome 11: Total dose of gonadotropins</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Progestogen versus another progestogen, Outcome 12: Moderate or severe OHSS" data-id="CD013827-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Progestogen versus another progestogen, Outcome 12: Moderate or severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Progestogens versus no intervention or placebo, Outcome 1: Total oocytes" data-id="CD013827-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Progestogens versus no intervention or placebo, Outcome 1: Total oocytes</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013827-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/urn:x-wiley:14651858:media:CD013827:CD013827-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Progestogens versus no intervention or placebo, Outcome 2: MII oocytes" data-id="CD013827-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_t/tCD013827-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Progestogens versus no intervention or placebo, Outcome 2: MII oocytes</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/media/CDSR/CD013827/image_n/nCD013827-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013827-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Progestogens compared to GnRH antagonists for assisted reproduction technology cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progestogens compared to GnRH antagonists for assisted reproduction technology cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> assisted reproduction technology cycles<br/><b>Setting:</b> IVF unit<br/><b>Intervention:</b> Progestogens<br/><b>Comparison:</b> GnRH antagonists </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with GnRH antagonists</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Progestogens</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy ‐ total<br/>follow‐up: mean 40 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for poor‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ total<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b><br/>(19 to 84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.92</b><br/>(0.42 to 2.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>648<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders and oocyte donors.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy ‐ Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>229 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>282 per 1000</b><br/>(194 to 391) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.32</b><br/>(0.81 to 2.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for poor‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage ‐ total<br/>follow‐up: mean 14 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We have also performed a secondary analysis per clinical pregnancy. We are uncertain of the effect of MPA in comparison to cetrorelix on the miscarriage rate in poor responders (OR 0.89, 95% CI 0.31 to 2.59, one RCT, N = 87, very low‐ quality evidence). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy ‐ Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>218 per 1000</b><br/>(140 to 322) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.25</b><br/>(0.73 to 2.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normoresponders (MPA 10 mg versus GnRH antagonists) ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(8 to 65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.84</b><br/>(0.28 to 2.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>534<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normoresponders (micronised progesterone 200 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b><br/>(44 to 300) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.00</b><br/>(0.33 to 3.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Premature LH surge ‐ Donor oocytes ‐ Normoresponders ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Premature LH surge ‐ Own oocytes ‐ PCOS (high‐responders) ‐ Early phase stimulation protocol ‐ Frozen embryo transfer </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total oocytes ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total oocytes ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.88 higher</b><br/>(0.77 lower to 2.54 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>534<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>1.85 higher</b><br/>(1.06 lower to 4.76 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MII oocytes</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to pool the studies for this outcome. See details in the analyses</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total dose of gonadotropins (IU) ‐ total</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total dose of gonadotropins (IU) ‐ total was <b>1775</b> IU </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>40.89 IU lower</b><br/>(107.85 lower to 26.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>952<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>When sub‐groups were analyzed, normo‐responders showed little or no differences between progestogens and GnRH antagonists (MD ‐122.0 95% CI [‐259.42 , 15.49], 2 RCTs, N=492; high certainty of evidence) and poor‐responders showed that progestogens may reduce the dose of gonadotropins (MD ‐6.99 95% CI [‐85.31, 71.33], 2 RCTs, N=492; low certainty of evidence) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MII oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MII oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>1.1 higher</b><br/>(1.51 lower to 3.71 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Moderate or severe OHSS ‐ total</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There were no cases reported of moderate or severe OHSS in either analysed groups.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of stimulation (days) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of stimulation (days) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>1.28 lower</b><br/>(2.73 lower to 0.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total dose of gonadotropins (IU) ‐ Poor responders (MPA 10 mg versus GNrH antagoninsts ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total dose of gonadotropins (IU) ‐ Poor responders (MPA 10 mg versus GNrH antagoninsts ‐ Own oocytes ‐ Early phase stimulation protocol was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>122 lower</b><br/>(259.49 lower to 15.49 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total dose of gonadotropins (IU) ‐ Normoresponders ‐ Donor oocytes ‐ Early ophase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total dose of gonadotropins (IU) ‐ Normoresponders ‐ Donor oocytes ‐ Early ophase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>6.99 lower</b><br/>(85.31 lower to 71.33 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>492<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total dose of gonadotropins (IU) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stumulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total dose of gonadotropins (IU) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stumulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>214 lower</b><br/>(588.33 lower to 160.33 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate or severe OHSS ‐ Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate or severe OHSS ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy sensitivity analysis ‐ Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>218 per 1000</b><br/>(140 to 322) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.25</b><br/>(0.73 to 2.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy sensitivity analysis ‐ PCOS (high‐responders) ‐ own oocytes ‐ early phase stimulation protocol ‐ frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>517 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b><br/>(488 to 807) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.87</b><br/>(0.89 to 3.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy sensitivity analysis ‐ total</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders (MPA 10 mg versus GnRH antagonists) ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(8 to 65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.84</b><br/>(0.28 to 2.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>534<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders (micronised progesterone 200 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b><br/>(44 to 300) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.00</b><br/>(0.33 to 3.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation sensitivity analysis ‐ PCOS (high‐responders)(micronised progesterone 100 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(0 to 122) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.33</b><br/>(0.01 to 8.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation sensitivity analysis ‐ total</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/>(16 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.86</b><br/>(0.40 to 1.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>768<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425213674817892961" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425213674817892961</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded 1 level for some concerns of risk of bias due to the randomization process<br/><sup>b</sup> Downgraded 2 levels for imprecision ‐ due to low number of participants n &lt; 400 and very wide confidence intervals including both substantial benefit and harm<br/><sup>c</sup> Some concerns of risk of bias due to the randomization process and the measurement of the outcome<br/><sup>d</sup> Downgraded 1 level for imprecision ‐ due to low number of participants n &lt; 400 and wide confidence intervals including both benefit and harm<br/><sup>e</sup> Downgraded 1 level for inconsistency I2=50.7% </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Progestogens compared to GnRH antagonists for assisted reproduction technology cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/full#CD013827-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013827-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Progestagen compared to GnRH agonist for assisted reproduction technology cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progestagen compared to GnRH agonist for assisted reproduction technology cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> assisted reproduction technology cycles<br/><b>Setting:</b> IVF unit<br/><b>Intervention:</b> Progestagen<br/><b>Comparison:</b> GnRH agonist </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with GnRH agonist</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Progestagen</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy<br/>follow‐up: mean 40 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>469 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>454 per 1000</b><br/>(339 to 575) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.94</b><br/>(0.58 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b><br/>(22 to 163) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.36</b><br/>(0.46 to 4.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Pregnancy<br/>follow‐up: mean 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>531 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>499 per 1000</b><br/>(379 to 620) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.88</b><br/>(0.54 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage<br/>follow‐up: mean 14 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/>(6 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.49</b><br/>(0.12 to 2.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We have also performed a secondary analysis per clinical pregnancy. MPA 4 mg may reduce the miscarriage rate in comparison to GnRH agonists but the confidence interval is large (OR 0.51, 95% CI 0.12 to 2.12, one RCT, N = 134,low‐ quality evidence). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MII oocytes<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MII oocytes was <b>10.1</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.2 higher</b><br/>(1.14 lower to 1.54 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total dose of gonadotropins (IU)<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total dose of gonadotropins (IU) was <b>2673</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>645 lower</b><br/>(763.04 lower to 526.96 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate or severe OHSS<br/>follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b><br/>(0 to 61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.14</b><br/>(0.01 to 2.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425168573456335049" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425168573456335049</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded 2 levels for imprecision ‐ due to low number of participants n &lt; 400 and very wide confidence intervals including both substantial benefit and harm<br/><sup>b</sup> Downgraded 1 level for risk of bias ‐ due to some concerns of risk of bias due to lack of definition of the outcome<br/><sup>c</sup> Downgraded 1 level for imprecision ‐ due to low number of participants n &lt; 400 and wide confidence intervals including both benefit and no clinical difference. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Progestagen compared to GnRH agonist for assisted reproduction technology cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/full#CD013827-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013827-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ Progestogen 1 compared to Progestogen 2 for assisted reproduction technology cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progestogen 1 compared to Progestogen 2 for assisted reproduction technology cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> assisted reproduction technology cycles<br/><b>Setting:</b> IVF unit<br/><b>Intervention:</b> Progestogen 1<br/><b>Comparison:</b> Progestogen 2 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Progestogen 2</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Progestogen 1</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study at low risk or at some concerns of bias reported this outcome in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>139 per 1000</b><br/>(79 to 234) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.81</b><br/>(0.43 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(42 to 219) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.27</b><br/>(0.90 to 5.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>140 per 1000</b><br/>(77 to 242) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.19</b><br/>(0.61 to 2.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(56 to 172) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.49</b><br/>(0.80 to 2.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>520<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normo‐responders (Dydrogesterone 20 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b><br/>(73 to 172) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.65</b><br/>(0.40 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oocyte pick‐up cancellation ‐ Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>107 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b><br/>(11 to 141) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.35</b><br/>(0.09 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy ‐ Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>481 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>507 per 1000</b><br/>(422 to 592) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.11</b><br/>(0.79 to 1.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>520<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are for women normo‐responders.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage ‐ Miscarriage per randomised woman ‐ Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol<br/>follow‐up: mean 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b><br/>(21 to 114) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.66</b><br/>(0.68 to 4.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>520<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We have also performed a secondary analysis per clinical pregnancy. We are uncertain of the effect MPA 10 mg in comparison to dydrogesterone 20 mg on the miscarriage rate (OR 1.60, 95% CI 0.64 to 4.00, one RCT, N = 257 low‐ quality evidence). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MII oocytes</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to pool the studies for this outcome. See details in the analyses</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total dose of gonadotropins</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to pool the studies for this outcome. See details in the analyses</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate or severe OHSS</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to pool the studies for this outcome. See details in the analyses</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425214297148274130" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_425214297148274130</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded 2 levels for imprecision ‐ due to low number of participants n &lt; 400 and very wide confidence intervals including both substantial benefit and harm<br/><sup>b</sup> Downgraded 1 level for imprecision ‐ due to low number of participants n &lt; 400 and wide confidence intervals including both benefit and harm<br/><sup>c</sup> Downgraded one level for serious risk of bias: overall some concerns of risk of bias due to the randomisation process </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ Progestogen 1 compared to Progestogen 2 for assisted reproduction technology cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/full#CD013827-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013827-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Progestogens versus GnRH antagonists</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.73, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Oocyte pick‐up cancellation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.42, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Normoresponders (MPA 10 mg versus GnRH antagonists) ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.28, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Normoresponders (micronised progesterone 200 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.33, 3.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.81, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Cumulative pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Miscarriage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Miscarriage per randomised woman ‐ Poor Ovarian Reserve (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.43, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Miscarriage per clinical pregnancy ‐ Poor Ovarian Reserve (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.31, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Multiple pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Multiple pregnancy per randomised woman ‐ Poor Ovarian Reserve (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.23 [1.17, 15.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Multiple pregnancy per clinical pregnancy ‐ Poor Ovarian Reserve (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [1.04, 15.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Premature LH surge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Own oocytes ‐ Normoresponders ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Donor oocytes ‐ Normoresponders ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Own oocytes ‐ PCOS (high‐responders) ‐ Early phase stimulation protocol ‐ Frozen embryo transfer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 Poor‐responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.00, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Total oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Normoresponders ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (Micronised progesterone versus GnRH antagonists) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.70 [2.20, 7.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [‐0.77, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.23, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [‐1.06, 4.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.5 Oocyte freezing ‐ random start (Dydrogesterone 10 mg versus GnRH antagonists)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐3.98, 4.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 MII oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Normoresponders ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (Micronised progesterone versus GnRH antagonists) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [1.82, 5.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐1.30, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.09, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.4 PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [‐1.51, 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.5 Oocyte freezing ‐ random start (Dydrogesterone 10 mg versus GnRH antagonists)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐2.70, 4.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Duration of stimulation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Normoresponders ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (Micronised progesterone versus GnRH antagonists) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐1.25, ‐0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.36, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.92, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.4 PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.28 [‐2.73, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.5 Oocyte freezing ‐ Random start (Dydrogesterone 10 mg versus GnRH antagonists)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.17, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Total dose of gonadotropins (IU) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>952</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐40.89 [‐107.85, 26.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Poor responders (MPA 10 mg versus GNrH antagoninsts ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐122.00 [‐259.49, 15.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Normoresponders ‐ Donor oocytes ‐ Early ophase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.99 [‐85.31, 71.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stumulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐214.00 [‐588.33, 160.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Moderate or severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Live birth or ongoing pregnancy sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.73, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 PCOS (high‐responders) ‐ own oocytes ‐ early phase stimulation protocol ‐ frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.89, 3.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Oocyte pick‐up cancellation sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.40, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Normoresponders (MPA 10 mg versus GnRH antagonists) ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.28, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Normoresponders (micronised progesterone 200 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.33, 3.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 PCOS (high‐responders)(micronised progesterone 100 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.21]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Progestogens versus GnRH antagonists</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013827-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Progestogens versus GnRH agonists</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Normo‐responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.58, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Oocyte pick‐up cancellation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.46, 4.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Clinical Pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.54, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Miscarriage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Miscarriage rate per randomised woman ‐ Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.12, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Miscarriage rate per clinical pregnancy ‐ Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.12, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Multiple pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Multiple pregnancy per randomised woman ‐ Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.42, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Multiple pregnancy per clinical pregnancy ‐ Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.41, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Premature LH surge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Total oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐0.97, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 MII oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐1.14, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Duration of stimulation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.80 [‐3.25, ‐2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Total dose of gonadotropins (IU) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐645.00 [‐763.04, ‐526.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Moderate or severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.73]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Progestogens versus GnRH agonists</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013827-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Progestogen versus another progestogen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Normo‐responders with endometriosis (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.95, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.48, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Normo‐responders with endometriosis (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.68, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 Normo‐responders with endometriosis (Dydrogesterone 20 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.86, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Oocyte pick‐up cancellation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.43, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.27 [0.90, 5.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.61, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.4 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.80, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.5 Normo‐responders (Dydrogesterone 20 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.40, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.6 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.09, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.00, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.44, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.64, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.4 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.79, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.5 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.39, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Cumulative pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.51, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.37, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.56, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Miscarriage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Miscarriage per randomised woman ‐ Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.08 [0.45, 36.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Miscarriage per randomised woman ‐ Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.11, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.3 Miscarriage per randomised woman ‐ Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.25, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.4 Miscarriage per randomised woman ‐ Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.68, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.5 Miscarriage per randomised woman ‐ Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.17, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.6 Miscarriage per randomised woman ‐ Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.03, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.7 Miscarriage per clinical pregnancy ‐ Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.02 [0.32, 28.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.8 Miscarriage per clinical pregnancy ‐ Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.12, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.9 Miscarriage per clinical pregnancy ‐ Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.23, 4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.10 Miscarriage per clinical pregnancy ‐ Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.64, 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.11 Miscarriage per clinical pregnancy ‐ Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.20, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.12 Miscarriage per clinical pregnancy ‐ Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.03, 3.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Multiple pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Multiple pregnancy per randomised woman ‐ Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.46, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 Multiple pregnancy per randomised woman ‐ Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.60, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.3 Multiple pregnancy per randomised woman ‐ Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.53, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.4 Multiple pregnancy per randomised woman ‐ Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.95, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.5 Multiple pregnancy per randomised woman ‐ Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.64, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.6 Multiple pregnancy per clinical pregnancy ‐ Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.26, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.7 Multiple pregnancy per clinical pregnancy ‐ Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.74, 3.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.8 Multiple pregnancy per clinical pregnancy ‐ Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.50, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.9 Multiple pregnancy per clinical pregnancy ‐ Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.92, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.10 Multiple pregnancy per clinical pregnancy ‐ Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.88, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Premature LH surge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.3 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.4 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.5 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.6 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Total oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.27, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.58, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.3 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.14, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.4 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.74, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.5 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐1.22, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.6 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐2.19, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 MII oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.21, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.2 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐0.15, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.3 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.65, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.4 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.90, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.5 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐2.37, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Duration of stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.67, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.31, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.3 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.24, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.4 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.5 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.18, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.6 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.97, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Total dose of gonadotropins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>162.00 [68.25, 255.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>22.00 [‐48.26, 92.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.3 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>127.00 [41.74, 212.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.4 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>47.00 [5.91, 88.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.5 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐28.14 [‐84.02, 27.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.6 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐101.00 [‐198.31, ‐3.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Moderate or severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.3 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.4 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.5 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.6 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Progestogen versus another progestogen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013827-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Progestogens versus no intervention or placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Total oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Oocyte donors (MPA 10 mg versus nothing) ‐ Luteal phase in a double stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.06, 3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 MII oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Oocyte donors (MPA 10 mg versus nothing) ‐ Luteal phase in a double stimulation protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [‐0.25, 2.85]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Progestogens versus no intervention or placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#CD013827-tbl-0007">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Live birth or ongoing pregnancy</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.1 Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chen 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "The allocation sequences were generated by investigators utilizing computer‐generated random number. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information if there was a deviation from the intended protocols. Number of transferred embryos was similar. Quote “The numbers of viable embryos used for transfer were comparable between the two groups (1.4 ± 1.3 vs. 1.6 ± 1.7, P &gt; 0.05).” All randomised women were analysed. All the randomized women were analyzed. Quote: "Live birth was defined as the delivery of an infant after 28 weeks of gestation.". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Live birth or ongoing pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Oocyte pick‐up cancellation</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.2.1 Normoresponders (MPA 10 mg versus GnRH antagonists) ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begueria 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and it outcome assessors were not aware of the assigned intervention </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced.". . Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was not different between the groups (p=0.17). Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and outcome assessors were not aware of the assigned intervention. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Giles 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "A randomization table was obtained using a computer application (www.randomization.com)"</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and carers were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The study was registered with EudraCT (number 2017‐002341‐ 30)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "A randomization table was obtained using a computer application (www.randomization.com)". Participants and carers were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. There is only one method to measure this outcome. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "The study was registered with EudraCT (number 2017‐002341‐ 30)." </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.2.2 Normoresponders (micronised progesterone 200 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Ghasemzadeh 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomisation process was performed, but there were no differences in baseline characteristics </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. Not clear if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Registration ID in IRCT: IRCT20110301005942N6"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomization process was performed, but there were no differences in baseline characteristics. . Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. Not clear if there was a deviation from the intended protocols. All randomised women were analysed. All the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "Registration ID in IRCT: IRCT20110301005942N6" </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Oocyte pick‐up cancellation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Clinical pregnancy</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.3.1 Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chen 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "The allocation sequences were generated by investigators utilizing computer‐generated random number. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "Clinical pregnancy was defined as the presence of intrauterine gestation sac at 7 weeks of gestation." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. . . Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information if there was a deviation from the intended protocols. Number of transferred embryos was similar. Quote “The numbers of viable embryos used for transfer were comparable between the two groups (1.4 ± 1.3 vs. 1.6 ± 1.7, P &gt; 0.05).” All randomised women were analysed. All the randomized women were analyzed. Quote: "Clinical pregnancy was defined as the presence of intrauterine gestation sac at 7 weeks of gestation.". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Clinical pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Cumulative pregnancy rate</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Zhu 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "ChiCTR‐IOR‐15006633"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number.". . Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. There is only one method to measure this outcome. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "ChiCTR‐IOR‐15006633" </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Cumulative pregnancy rate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Miscarriage</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.5.1 Miscarriage per randomised woman ‐ Poor Ovarian Reserve (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chen 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "The allocation sequences were generated by investigators utilizing computer‐generated random number. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information if there was a deviation from the intended protocols. Number of transferred embryos was similar. Quote “The numbers of viable embryos used for transfer were comparable between the two groups (1.4 ± 1.3 vs. 1.6 ± 1.7, P &gt; 0.05).” All randomised women were analysed. All the randomized women were analyzed. Definition of this outcome was not stated.. Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.5.2 Miscarriage per clinical pregnancy ‐ Poor Ovarian Reserve (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chen 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "The allocation sequences were generated by investigators utilizing computer‐generated random number. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information if there was a deviation from the intended protocols. Number of transferred embryos was similar. Quote “The numbers of viable embryos used for transfer were comparable between the two groups (1.4 ± 1.3 vs. 1.6 ± 1.7, P &gt; 0.05).” All randomised women were analysed. All the randomized women were analyzed. Definition of this outcome was not stated.. Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Miscarriage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-6"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Multiple pregnancy</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.6.1 Multiple pregnancy per randomised woman ‐ Poor Ovarian Reserve (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chen 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "The allocation sequences were generated by investigators utilizing computer‐generated random number. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. . . Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information if there was a deviation from the intended protocols. Number of transferred embryos was similar. Quote “The numbers of viable embryos used for transfer were comparable between the two groups (1.4 ± 1.3 vs. 1.6 ± 1.7, P &gt; 0.05).” All randomised women were analysed. All the randomized women were analyzed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.6.2 Multiple pregnancy per clinical pregnancy ‐ Poor Ovarian Reserve (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chen 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "The allocation sequences were generated by investigators utilizing computer‐generated random number. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. . . Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information if there was a deviation from the intended protocols. Number of transferred embryos was similar. Quote “The numbers of viable embryos used for transfer were comparable between the two groups (1.4 ± 1.3 vs. 1.6 ± 1.7, P &gt; 0.05).” All randomised women were analysed. All the randomized women were analyzed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Multiple pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-6">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-7"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Premature LH surge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.7.1 Own oocytes ‐ Normoresponders ‐ Early phase stimulation protocol ‐ Fresh embryo transfer</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Ghasemzadeh 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomisation process was performed, but there were no differences in baseline characteristics </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. Not clear if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information about the method of measuring the outcome but it was not different between groups. Measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Registration ID in IRCT: IRCT20110301005942N6"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomization process was performed, but there were no differences in baseline characteristics. . Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. Not clear if there was a deviation from the intended protocols. All randomised women were analysed. All the randomized women were analysed. Definition of this outcome was not stated.. There is no information about the method of measuring the outcome but it was not different between groups. Measurement of this outcome depends on the assessors evaluation. Quote: "Registration ID in IRCT: IRCT20110301005942N6" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.7.2 Donor oocytes ‐ Normoresponders ‐ Early phase stimulation protocol ‐ Fresh embryo transfer</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begueria 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and it outcome assessors were not aware of the assigned intervention </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced.". . Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was not different between the groups (p=0.17). Nearly all the randomized women were analysed.. Definition of this outcome was not stated.. Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and outcome assessors were not aware of the assigned intervention. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.7.3 Own oocytes ‐ PCOS (high‐responders) ‐ Early phase stimulation protocol ‐ Frozen embryo transfer</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "ChiCTR‐IOR‐15006633"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number.". . Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "A premature LH rise was defined as a serum LH ≥10 IU/L". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "ChiCTR‐IOR‐15006633" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.7.4 Poor‐responders</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chen 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "The allocation sequences were generated by investigators utilizing computer‐generated random number. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. All the randomized women were analyzed. Quote: "serum LH &gt;15 mIU/ml on the trigger day, with or without dominant follicle rupture and increased serum progesterone". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Premature LH surge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-7">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-8"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Total oocytes</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.8.1 Normoresponders ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (Micronised progesterone versus GnRH antagonists)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Ghasemzadeh 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomisation process was performed, but there were no differences in baseline characteristics </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. Not clear if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Registration ID in IRCT: IRCT20110301005942N6"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomization process was performed, but there were no differences in baseline characteristics. . Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. Not clear if there was a deviation from the intended protocols. All randomised women were analysed. All the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "Registration ID in IRCT: IRCT20110301005942N6" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.8.2 Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begueria 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and it outcome assessors were not aware of the assigned intervention </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced.". . Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was not different between the groups (p=0.17). Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and outcome assessors were not aware of the assigned intervention. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Giles 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "A randomization table was obtained using a computer application (www.randomization.com)"</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and carers were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The study was registered with EudraCT (number 2017‐002341‐ 30)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "A randomization table was obtained using a computer application (www.randomization.com)". Participants and carers were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. There is only one method to measure this outcome. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "The study was registered with EudraCT (number 2017‐002341‐ 30)." </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.8.3 Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chen 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "The allocation sequences were generated by investigators utilizing computer‐generated random number. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. All the randomized women were analyzed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.8.4 PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "ChiCTR‐IOR‐15006633"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number.". . Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. There is only one method to measure this outcome. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "ChiCTR‐IOR‐15006633" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.8.5 Oocyte freezing ‐ random start (Dydrogesterone 10 mg versus GnRH antagonists)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Braham 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomization process was performed, but there were no differences in baseline characteristics </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were probably aware of their assigned intervention. Not stated if carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information about the number of randomised participants and no information about the reason for the potential missingness </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol registration was found</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomization process was performed, but there were no differences in baseline characteristics. . Participants were probably aware of their assigned intervention. Not stated if carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. There is no information about the number of randomised participants and no information about the reason for the potential missingness. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. No protocol registration was found </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Total oocytes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-8">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-9"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.9 MII oocytes</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.9.1 Normoresponders ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (Micronised progesterone versus GnRH antagonists)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Ghasemzadeh 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomisation process was performed, but there were no differences in baseline characteristics </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. Not clear if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Registration ID in IRCT: IRCT20110301005942N6"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomization process was performed, but there were no differences in baseline characteristics. . Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. Not clear if there was a deviation from the intended protocols. All randomised women were analysed. All the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "Registration ID in IRCT: IRCT20110301005942N6" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.9.2 Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begueria 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and it outcome assessors were not aware of the assigned intervention </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced.". . Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was not different between the groups (p=0.17). Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and outcome assessors were not aware of the assigned intervention. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Giles 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "A randomization table was obtained using a computer application (www.randomization.com)"</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and carers were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The study was registered with EudraCT (number 2017‐002341‐ 30)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "A randomization table was obtained using a computer application (www.randomization.com)". Participants and carers were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. There is only one method to measure this outcome. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "The study was registered with EudraCT (number 2017‐002341‐ 30)." </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.9.3 Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chen 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "The allocation sequences were generated by investigators utilizing computer‐generated random number. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. All the randomized women were analyzed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.9.4 PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "ChiCTR‐IOR‐15006633"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number.". . Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. There is only one method to measure this outcome. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "ChiCTR‐IOR‐15006633" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.9.5 Oocyte freezing ‐ random start (Dydrogesterone 10 mg versus GnRH antagonists)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Braham 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomization process was performed, but there were no differences in baseline characteristics </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were probably aware of their assigned intervention. Not stated if carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information about the number of randomised participants and no information about the reason for the potential missingness </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol registration was found</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomization process was performed, but there were no differences in baseline characteristics. . Participants were probably aware of their assigned intervention. Not stated if carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. There is no information about the number of randomised participants and no information about the reason for the potential missingness. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. No protocol registration was found </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.9 MII oocytes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-9">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-10"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.10 Duration of stimulation (days)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.10.1 Normoresponders ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (Micronised progesterone versus GnRH antagonists)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Ghasemzadeh 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomisation process was performed, but there were no differences in baseline characteristics </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. Not clear if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Registration ID in IRCT: IRCT20110301005942N6"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomization process was performed, but there were no differences in baseline characteristics. . Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. Not clear if there was a deviation from the intended protocols. All randomised women were analysed. All the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "Registration ID in IRCT: IRCT20110301005942N6" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.10.2 Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begueria 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and it outcome assessors were not aware of the assigned intervention </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced.". . Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was not different between the groups (p=0.17). Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and outcome assessors were not aware of the assigned intervention. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Giles 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "A randomization table was obtained using a computer application (www.randomization.com)"</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and carers were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The study was registered with EudraCT (number 2017‐002341‐ 30)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "A randomization table was obtained using a computer application (www.randomization.com)". Participants and carers were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. There is only one method to measure this outcome. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "The study was registered with EudraCT (number 2017‐002341‐ 30)." </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.10.3 Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chen 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "The allocation sequences were generated by investigators utilizing computer‐generated random number. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. All the randomized women were analyzed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.10.4 PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "ChiCTR‐IOR‐15006633"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number.". . Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. There is only one method to measure this outcome. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "ChiCTR‐IOR‐15006633" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.10.5 Oocyte freezing ‐ Random start (Dydrogesterone 10 mg versus GnRH antagonists)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Braham 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomization process was performed, but there were no differences in baseline characteristics </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were probably aware of their assigned intervention. Not stated if carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information about the number of randomised participants and no information about the reason for the potential missingness </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol registration was found</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomization process was performed, but there were no differences in baseline characteristics. . Participants were probably aware of their assigned intervention. Not stated if carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. There is no information about the number of randomised participants and no information about the reason for the potential missingness. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. No protocol registration was found </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.10 Duration of stimulation (days)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-10">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-11"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.11 Total dose of gonadotropins (IU)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.11.1 Poor responders (MPA 10 mg versus GNrH antagoninsts ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chen 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "The allocation sequences were generated by investigators utilizing computer‐generated random number. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. All the randomized women were analyzed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.11.2 Normoresponders ‐ Donor oocytes ‐ Early ophase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begueria 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and it outcome assessors were not aware of the assigned intervention </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced.". . Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was not different between the groups (p=0.17). Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and outcome assessors were not aware of the assigned intervention. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Giles 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "A randomization table was obtained using a computer application (www.randomization.com)"</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and carers were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The study was registered with EudraCT (number 2017‐002341‐ 30)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "A randomization table was obtained using a computer application (www.randomization.com)". Participants and carers were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. There is only one method to measure this outcome. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "The study was registered with EudraCT (number 2017‐002341‐ 30)." </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.11.3 PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stumulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "ChiCTR‐IOR‐15006633"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number.". . Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. There is only one method to measure this outcome. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "ChiCTR‐IOR‐15006633" </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.11 Total dose of gonadotropins (IU)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-11">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-12"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.12 Moderate or severe OHSS</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.12.1 Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chen 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "The allocation sequences were generated by investigators utilizing computer‐generated random number. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. All the randomized women were analyzed. Definition of this outcome was not stated.. Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.12.2 Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begueria 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and it outcome assessors were not aware of the assigned intervention </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced.". . Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was not different between the groups (p=0.17). Nearly all the randomized women were analysed.. Definition of this outcome was not stated.. Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and outcome assessors were not aware of the assigned intervention. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Giles 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "A randomization table was obtained using a computer application (www.randomization.com)"</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and carers were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The study was registered with EudraCT (number 2017‐002341‐ 30)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "A randomization table was obtained using a com‐ puter application (www.randomization.com)". . Participants and carers were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated.. Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The study was registered with EudraCT (number 2017‐002341‐ 30)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.12 Moderate or severe OHSS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-12">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-13"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.13 Live birth or ongoing pregnancy sensitivity analysis</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.13.1 Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Chen 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "The allocation sequences were generated by investigators utilizing computer‐generated random number. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information if there was a deviation from the intended protocols. Number of transferred embryos was similar. Quote “The numbers of viable embryos used for transfer were comparable between the two groups (1.4 ± 1.3 vs. 1.6 ± 1.7, P &gt; 0.05).” All randomised women were analysed. All the randomized women were analyzed. Quote: "Live birth was defined as the delivery of an infant after 28 weeks of gestation.". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The trial was registered in China Clinical Trial Registry on 18 March 2017 (Number: ChiCTR‐IPR‐17010906). </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.13.2 PCOS (high‐responders) ‐ own oocytes ‐ early phase stimulation protocol ‐ frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "ChiCTR‐IOR‐15006633"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number.". . Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. There is only one method to measure this outcome. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "ChiCTR‐IOR‐15006633" </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.13 Live birth or ongoing pregnancy sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-13">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-14"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.14 Oocyte pick‐up cancellation sensitivity analysis</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.14.1 Normoresponders (MPA 10 mg versus GnRH antagonists) ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begueria 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and it outcome assessors were not aware of the assigned intervention </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated sequence of blocks of 10 subjects to ensure balanced distributions within the study arms was used. Allocation was performed by the pharmacist of the center using a password‐protected program." Quote: "The characteristics of oocyte donors and recipients at baseline were well‐balanced.". . Participants, carers and people delivering the intervention were probably aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was not different between the groups (p=0.17). Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was not stated, but it is unlikely that it was different between groups and outcome assessors were not aware of the assigned intervention. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Giles 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "A randomization table was obtained using a computer application (www.randomization.com)"</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and carers were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The study was registered with EudraCT (number 2017‐002341‐ 30)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "A randomization table was obtained using a computer application (www.randomization.com)". Participants and carers were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. There is only one method to measure this outcome. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "The study was registered with EudraCT (number 2017‐002341‐ 30)." </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.14.2 Normoresponders (micronised progesterone 200 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Ghasemzadeh 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomisation process was performed, but there were no differences in baseline characteristics </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. Not clear if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Registration ID in IRCT: IRCT20110301005942N6"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated how randomization process was performed, but there were no differences in baseline characteristics. . Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. Not clear if there was a deviation from the intended protocols. All randomised women were analysed. All the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "Registration ID in IRCT: IRCT20110301005942N6" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.14.3 PCOS (high‐responders)(micronised progesterone 100 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "ChiCTR‐IOR‐15006633"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients who met the eligibility were randomly allocated to the study group or the control group at a ratio of 1:1 using a computer‐generated random number.". . Participants were aware of their assigned intervention. People delivering the intervention were not aware of their assigned intervention.No information if there was a deviation from the intended protocols. All randomised women were analysed. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. There is only one method to measure this outcome. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "ChiCTR‐IOR‐15006633" </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.14 Oocyte pick‐up cancellation sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-14">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-15"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 Live birth or ongoing pregnancy</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.1.1 Normo‐responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Xi 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Eligible volunteers were randomized using a computer‐generated random number to either treatment group; treatment allocation was generated and then given to researchers in a sealed envelope by an administration. Each patient was enrolled by a physician. After signing the written informed consent form, they were allocated to a specific treatment arm by opening the sealed envelope.". Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. Quote:"In total, nine patients in the study group and seven patients in the control group had a single embryo transfer. Meanwhile, 106 patients in the study group and 114 ones in the control group had a double embryo transfer, and no difference was found between two groups (P = 0.53)." All randomised women were analysed.. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 Live birth or ongoing pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-15">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-16"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.2 Oocyte pick‐up cancellation</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.2.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Xi 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed.. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.2 Oocyte pick‐up cancellation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-16">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-17"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.3 Clinical Pregnancy</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.3.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Xi 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: The definition of clinical pregnancy is the existence of a gestational sac whether there is a fetal heart activity or not under transvaginal 4 weeks after embryo transfer." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed.. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. Quote:"In total, nine patients in the study group and seven patients in the control group had a single embryo transfer. Meanwhile, 106 patients in the study group and 114 ones in the control group had a double embryo transfer, and no difference was found between two groups (P = 0.53)." All randomised women were analysed.. Almost all the randomized women were analysed. Quote: The definition of clinical pregnancy is the existence of a gestational sac whether there is a fetal heart activity or not under transvaginal 4 weeks after embryo transfer.". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: The definition of clinical pregnancy is the existence of a gestational sac whether there is a fetal heart activity or not under transvaginal 4 weeks after embryo transfer.". Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.3 Clinical Pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-17">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-18"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.4 Miscarriage</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.4.1 Miscarriage rate per randomised woman ‐ Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Xi 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "spontaneous abortion rate was defined as the number of patients with spontaneous loss before 12 weeks gestation divided by those with a clinical pregnancy." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed.. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. Quote:"In total, nine patients in the study group and seven patients in the control group had a single embryo transfer. Meanwhile, 106 patients in the study group and 114 ones in the control group had a double embryo transfer, and no difference was found between two groups (P = 0.53)." All randomised women were analysed.. Almost all the randomized women were analysed. Quote: "spontaneous abortion rate was defined as the number of patients with spontaneous loss before 12 weeks gestation divided by those with a clinical pregnancy.". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "spontaneous abortion rate was defined as the number of patients with spontaneous loss before 12 weeks gestation divided by those with a clinical pregnancy.". Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)." </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.4.2 Miscarriage rate per clinical pregnancy ‐ Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Xi 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "spontaneous abortion rate was defined as the number of patients with spontaneous loss before 12 weeks gestation divided by those with a clinical pregnancy." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed.. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. Quote:"In total, nine patients in the study group and seven patients in the control group had a single embryo transfer. Meanwhile, 106 patients in the study group and 114 ones in the control group had a double embryo transfer, and no difference was found between two groups (P = 0.53)." All randomised women were analysed.. Almost all the randomized women were analysed. Quote: "spontaneous abortion rate was defined as the number of patients with spontaneous loss before 12 weeks gestation divided by those with a clinical pregnancy.". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "spontaneous abortion rate was defined as the number of patients with spontaneous loss before 12 weeks gestation divided by those with a clinical pregnancy.". Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.4 Miscarriage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-18">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-19"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.5 Multiple pregnancy</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.5.1 Multiple pregnancy per randomised woman ‐ Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Xi 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed.. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. Quote:"In total, nine patients in the study group and seven patients in the control group had a single embryo transfer. Meanwhile, 106 patients in the study group and 114 ones in the control group had a double embryo transfer, and no difference was found between two groups (P = 0.53)." All randomised women were analysed.. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)." </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.5.2 Multiple pregnancy per clinical pregnancy ‐ Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Xi 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed.. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. Quote:"In total, nine patients in the study group and seven patients in the control group had a single embryo transfer. Meanwhile, 106 patients in the study group and 114 ones in the control group had a double embryo transfer, and no difference was found between two groups (P = 0.53)." All randomised women were analysed.. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.5 Multiple pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-19">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-20"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.6 Premature LH surge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.6.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Xi 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, was probably not different between groups but the measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed.. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated.. Method of measuring the outcome was not stated, was probably not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.6 Premature LH surge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-20">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-21"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.7 Total oocytes</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.7.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Xi 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed.. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.7 Total oocytes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-21">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-22"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.8 MII oocytes</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.8.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Xi 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed.. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.8 MII oocytes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-22">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-23"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.9 Duration of stimulation (days)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.9.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Xi 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed.. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.9 Duration of stimulation (days)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-23">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-24"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.10 Total dose of gonadotropins (IU)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.10.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Xi 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed.. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.10 Total dose of gonadotropins (IU)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-24">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-25"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.11 Moderate or severe OHSS</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.11.1 Normo responders (MPA 4 mg versus GnRH agonists) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Xi 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, was probably not different between groups but the measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed.. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated.. Method of measuring the outcome was not stated, was probably not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐INR‐17012089)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.11 Moderate or severe OHSS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-25">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-26"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 Live birth or ongoing pregnancy</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.1.1 Normo‐responders with endometriosis (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.1.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Dong 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is was probably blinded for the assessors. Quote: "The live birth was defined as delivery infant after the age of gestation 28 weeks." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer.". . Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups). Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "The live birth was defined as delivery infant after the age of gestation 28 weeks.". Method of measuring the outcome was appropriate, was not different between groups and it is was probably blinded for the assessors. Quote: "The live birth was defined as delivery infant after the age of gestation 28 weeks.". Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127 </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.1.3 Normo‐responders with endometriosis (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.1.4 Normo‐responders with endometriosis (Dydrogesterone 20 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 Live birth or ongoing pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-26">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-27"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 Oocyte pick‐up cancellation</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.2.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote:"The criterion for cycle cancellation was no viable embryos for cryopreservation" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Quote: "The criterion for cycle cancelation was no viable embryos for cryopreservation". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote:"The criterion for cycle cancelation was no viable embryos for cryopreservation". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.2.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Dong 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is was probably blinded for the assessors. Quote: "The criterion for cycle cancelation was no viable embryos for cryopreservation" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed.Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer.". . Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups). All the randomized women were analysed.. Quote: "The criterion for cycle cancelation was no viable embryos for cryopreservation". Method of measuring the outcome was appropriate, was not different between groups and it is was probably blinded for the assessors. Quote: "The criterion for cycle cancelation was no viable embryos for cryopreservation". Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127 </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.2.3 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote:"The criterion for cycle cancellation was no viable embryos for cryopreservation" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Quote: "The criterion for cycle cancelation was no viable embryos for cryopreservation". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote:"The criterion for cycle cancelation was no viable embryos for cryopreservation". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.2.4 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Yu 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and outcome assessors were not aware of the intervention received by the participants. Quote: "Cycle cancellation was defined as having no viable embryos that were frozen for later transfer." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. Quote: "Cycle cancellation was defined as having no viable embryos that were frozen for later transfer.". Method of measuring the outcome was appropriate, was not different between groups and outcome assessors were not aware of the intervention received by the participants. Quote: "Cycle cancellation was defined as having no viable embryos that were frozen for later transfer.". Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.2.5 Normo‐responders (Dydrogesterone 20 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote:"The criterion for cycle cancellation was no viable embryos for cryopreservation" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Quote: "The criterion for cycle cancelation was no viable embryos for cryopreservation". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote:"The criterion for cycle cancelation was no viable embryos for cryopreservation". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols but it was unlikely. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "Cycle cancellation referred to patients who completed oocyte retrieval without viable embryos, including requested cancellation after oocyte retrieval for personal reasons." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols but it was unlikely. All randomised women were analysed. Almost all the randomized women were analysed. Quote: "Cycle cancellation referred to patients who completed oocyte retrieval without viable embryos, including requested cancellation after oocyte retrieval for personal reasons.". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "Cycle cancellation referred to patients who completed oocyte retrieval without viable embryos, including requested cancellation after oocyte retrieval for personal reasons.". Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.2.6 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed.. All the randomized women were analyzed. Quote: "Cycle cancellation referred to patients who completed oocyte retrieval without viable embryos.". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 Oocyte pick‐up cancellation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-27">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-28"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.3 Clinical pregnancy</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.3.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation.Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation.Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.3.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Dong 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is was probably blinded for the assessors. Quote: "Clinical pregnancy was defined as the presence of at least one fetus with heart activity, as assessed at least 35 days after FET" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer.". . Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups). Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "Clinical pregnancy was defined as the presence of at least one fetus with heart activity, as assessed at least 35 days after FET". Method of measuring the outcome was appropriate, was not different between groups and it is was probably blinded for the assessors. Quote: "Clinical pregnancy was defined as the presence of at least one fetus with heart activity, as assessed at least 35 days after FET". Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127 </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.3.3 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation.Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation.Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.3.4 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Yu 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.9 in each group) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and outcome assessors were not aware of the intervention received by the participants. Quote: "Clinical pregnancy was defined as the presence of a gestational sac with or without fetal heart activity, as assessed by ultrasound examination 4 weeks after embryo transfer." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.9 in each group). Almost all the randomized women were analysed. Quote: "Clinical pregnancy was defined as the presence of a gestational sac with or without fetal heart activity, as assessed by ultrasound examination 4 weeks after embryo transfer.". Method of measuring the outcome was appropriate, was not different between groups and outcome assessors were not aware of the intervention received by the participants. Quote: "Clinical pregnancy was defined as the presence of a gestational sac with or without fetal heart activity, as assessed by ultrasound examination 4 weeks after embryo transfer.". Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.3.5 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation.Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation.Quote: "Clinical pregnancy and ongoing pregnancy were considered to be the presence of a gestational sac with fetal heart activity, as assessed by ultrasound at 7 and 12 weeks of gestation, respectively". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.3 Clinical pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-28">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-29"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.4 Cumulative pregnancy</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.4.1 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, was probably not different between groups but the measurement of this outcome depends on the assessors evaluation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols (for example, no information about the number of transferred embryos or the embryo stage). All randomised women were analysed. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Definition of this outcome was not stated.. Method of measuring the outcome was not stated, was probably not different between groups but the measurement of this outcome depends on the assessors evaluation.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.4.2 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar. Quote “The transfer of day 3 embryos or blastocysts was scheduled based on the embryo and endometrium synchronization....The numbers of top‐quality embryos (4.15±3.17 vs. 3.73±2.34; P&gt;.05) showed no significant difference between the two groups.” All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "Clinical pregnancy was defined as the presence of a gestational sac with fetal heart activity during ultra‐ sound examination 7 weeks after FET.". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.4 Cumulative pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-29">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-30"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.5 Miscarriage</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.5.1 Miscarriage per randomised woman ‐ Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.5.2 Miscarriage per randomised woman ‐ Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Dong 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, was probably not different between groups and it is was probably blinded for the assessors </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer.". . Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups). Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Definition of this outcome was not stated.. Method of measuring the outcome was not stated, was probably not different between groups and it is was probably blinded for the assessors. Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127 </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.5.3 Miscarriage per randomised woman ‐ Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.5.4 Miscarriage per randomised woman ‐ Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Yu 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.9 in each group) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and outcome assessors were not aware of the intervention received by the participants. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous preg‐ nancy termination before the gestational age of 12 weeks." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.9 in each group). Almost all the randomized women were analysed. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous preg‐ nancy termination before the gestational age of 12 weeks.". Method of measuring the outcome was appropriate, was not different between groups and outcome assessors were not aware of the intervention received by the participants. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous preg‐ nancy termination before the gestational age of 12 weeks.". Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.5.5 Miscarriage per randomised woman ‐ Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols (for example, no information about the number of transferred embryos or the embryo stage). All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "The miscarriage rate was defined as the proportion of patients with spontaneous termination of pregnancy. " </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols (for example, no information about the number of transferred embryos or the embryo stage). All randomised women were analysed. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "The miscarriage rate was defined as the proportion of patients with spontaneous termination of pregnancy. ". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "The miscarriage rate was defined as the proportion of patients with spontaneous termination of pregnancy. ". Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.5.6 Miscarriage per randomised woman ‐ Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar. Quote “The transfer of day 3 embryos or blastocysts was scheduled based on the embryo and endometrium synchronization....The numbers of top‐quality embryos (4.15±3.17 vs. 3.73±2.34; P&gt;.05) showed no significant difference between the two groups.” All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "The miscarriage rate was defined as the proportion of patients with spontaneous termination of pregnancy". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)." </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.5.7 Miscarriage per clinical pregnancy ‐ Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.5.8 Miscarriage per clinical pregnancy ‐ Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Dong 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, was probably not different between groups and it is was probably blinded for the assessors </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer.". . Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups). Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Definition of this outcome was not stated.. Method of measuring the outcome was not stated, was probably not different between groups and it is was probably blinded for the assessors. Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127 </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.5.9 Miscarriage per clinical pregnancy ‐ Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.5.10 Miscarriage per clinical pregnancy ‐ Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Yu 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.9 in each group) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and outcome assessors were not aware of the intervention received by the participants. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous preg‐ nancy termination before the gestational age of 12 weeks." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.9 in each group). Almost all the randomized women were analysed. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous preg‐ nancy termination before the gestational age of 12 weeks.". Method of measuring the outcome was appropriate, was not different between groups and outcome assessors were not aware of the intervention received by the participants. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous preg‐ nancy termination before the gestational age of 12 weeks.". Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.5.11 Miscarriage per clinical pregnancy ‐ Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The early miscarriage rate was defined as the proportion of patients with spontaneous pregnancy termination before the gestational age of 12 weeks". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols (for example, no information about the number of transferred embryos or the embryo stage). All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "The miscarriage rate was defined as the proportion of patients with spontaneous termination of pregnancy. " </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols (for example, no information about the number of transferred embryos or the embryo stage). All randomised women were analysed. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "The miscarriage rate was defined as the proportion of patients with spontaneous termination of pregnancy. ". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "The miscarriage rate was defined as the proportion of patients with spontaneous termination of pregnancy. ". Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.5.12 Miscarriage per clinical pregnancy ‐ Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar. Quote “The transfer of day 3 embryos or blastocysts was scheduled based on the embryo and endometrium synchronization....The numbers of top‐quality embryos (4.15±3.17 vs. 3.73±2.34; P&gt;.05) showed no significant difference between the two groups.” All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "The miscarriage rate was defined as the proportion of patients with spontaneous termination of pregnancy". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.5 Miscarriage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-30">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-31"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.6 Multiple pregnancy</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.6.1 Multiple pregnancy per randomised woman ‐ Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.6.2 Multiple pregnancy per randomised woman ‐ Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Dong 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was probably not different between groups and it is was probably blinded for the assessors </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer.". . Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups). Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was probably not different between groups and it is was probably blinded for the assessors. Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127 </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.6.3 Multiple pregnancy per randomised woman ‐ Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.6.4 Multiple pregnancy per randomised woman ‐ Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Yu 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.9 in each group) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.9 in each group). Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.6.5 Multiple pregnancy per randomised woman ‐ Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols (for example, no information about the number of transferred embryos or the embryo stage). All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols (for example, no information about the number of transferred embryos or the embryo stage). All randomised women were analysed. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "The multiple pregnancy rate was defined as the number of cycles with more than one intrauterine sac divided by the total number of pregnant cycles.". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.6.6 Multiple pregnancy per clinical pregnancy ‐ Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.6.7 Multiple pregnancy per clinical pregnancy ‐ Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Dong 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was probably not different between groups and it is was probably blinded for the assessors </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer.". . Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups). Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was probably not different between groups and it is was probably blinded for the assessors. Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127 </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.6.8 Multiple pregnancy per clinical pregnancy ‐ Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.6.9 Multiple pregnancy per clinical pregnancy ‐ Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Yu 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.9 in each group) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.9 in each group). Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.6.10 Multiple pregnancy per clinical pregnancy ‐ Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols (for example, no information about the number of transferred embryos or the embryo stage). All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols (for example, no information about the number of transferred embryos or the embryo stage). All randomised women were analysed. Missing outcome data is too much in relation with the observed number of events and there is no information if missingness in the outcome is likely to depend on its true value.. Quote: "The multiple pregnancy rate was defined as the number of cycles with more than one intrauterine sac divided by the total number of pregnant cycles.". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)" </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.6 Multiple pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-31">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-32"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.7 Premature LH surge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.7.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The criteria of LH surge was serum LH &gt;15.0 mIU/ml on the trigger day" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Quote: "The criteria of LH surge was serum LH &gt;15.0 mIU/ml on the trigger day". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The criteria of LH surge was serum LH &gt;15.0 mIU/ml on the trigger day". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.7.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Dong 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is was probably blinded for the assessors. Quote: "The criteria of LH surge was serum LH &gt; 15.0 mIU/ml on the trigger day." </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer.". . Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups). All the randomized women were analysed.. Quote: "The criteria of LH surge was serum LH &gt; 15.0 mIU/ml on the trigger day.". Method of measuring the outcome was appropriate, was not different between groups and it is was probably blinded for the assessors. Quote: "The criteria of LH surge was serum LH &gt; 15.0 mIU/ml on the trigger day.". Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127 </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.7.3 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The criteria of LH surge was serum LH &gt;15.0 mIU/ml on the trigger day" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Quote: "The criteria of LH surge was serum LH &gt;15.0 mIU/ml on the trigger day". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The criteria of LH surge was serum LH &gt;15.0 mIU/ml on the trigger day". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.7.4 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Yu 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, was probably not different between groups and it is was probably blinded for the assessors </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated.. Method of measuring the outcome was not stated, was probably not different between groups and it is was probably blinded for the assessors. Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.7.5 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The criteria of LH surge was serum LH &gt;15.0 mIU/ml on the trigger day" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Quote: "The criteria of LH surge was serum LH &gt;15.0 mIU/ml on the trigger day". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The criteria of LH surge was serum LH &gt;15.0 mIU/ml on the trigger day". The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols but it was unlikely. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "The cutoff level for a premature LH surge was 10 IU/L" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols but it was unlikely. All randomised women were analysed. Almost all the randomized women were analysed. Quote: "The cutoff level for a premature LH surge was 10 IU/L". Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. Quote: "The cutoff level for a premature LH surge was 10 IU/L". Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.7.6 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed.. All the randomized women were analyzed. Quote: "The cutoff level of premature LH surge was 10 IU/L". Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.7 Premature LH surge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-32">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-33"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.8 Total oocytes</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.8.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.8.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Dong 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was probably not different between groups and it is was probably blinded for the assessors </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer.". . Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups). All the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was probably not different between groups and it is was probably blinded for the assessors. Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127 </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.8.3 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.8.4 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Yu 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.8.5 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols but it was unlikely. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols but it was unlikely. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.8.6 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed.. All the randomized women were analyzed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.8 Total oocytes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-33">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-34"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.9 MII oocytes</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.9.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.9.2 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.9.3 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Yu 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.9.4 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols but it was unlikely. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols but it was unlikely. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.9.5 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed.. All the randomized women were analyzed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.9 MII oocytes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-34">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-35"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.10 Duration of stimulation</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.10.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.10.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Dong 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was probably not different between groups and it is was probably blinded for the assessors </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer.". . Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups). All the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was probably not different between groups and it is was probably blinded for the assessors. Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127 </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.10.3 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.10.4 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Yu 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.10.5 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols but it was unlikely. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols but it was unlikely. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.10.6 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed.. All the randomized women were analyzed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.10 Duration of stimulation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-35">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-36"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.11 Total dose of gonadotropins</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.11.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.11.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Dong 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was probably not different between groups and it is was probably blinded for the assessors </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer.". . Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups). All the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was probably not different between groups and it is was probably blinded for the assessors. Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127 </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.11.3 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.11.4 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Yu 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.11.5 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Definition of this outcome was not stated, but the definition of this outcome is usually unique, and was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols but it was unlikely. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols but it was unlikely. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.11.6 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed.. All the randomized women were analyzed. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was appropriate, was not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.11 Total dose of gonadotropins</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-36">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-37"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.12 Moderate or severe OHSS</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.12.1 Normo‐responders (MPA 4 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was nos stated and was probably not different between groups. The measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Definition of this outcome was not stated.. Definition of this outcome was not stated and was probably not different between groups, Not stated if assessors were aware of the assigned intervention but it is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.12.2 Normo‐responders (MPA 4 mg versus MPA 10 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Dong 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, was probably not different between groups and it is was probably blinded for the assessors </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "Subjects were randomly assigned in a 1: 1 ratio to receive treatment with either a high dose (group A: 10 mg of MPA per day) or low dose (groupB: 4mg of MPA per day) via a sealed envelope with random numbers generated by computer.". . Participants were aware of their assigned intervention. Carers and people delivering the intervention were not aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. Number of transferred embryos was similar (1.8 in both groups). All the randomized women were analysed.. Definition of this outcome was not stated.. Method of measuring the outcome was not stated, was probably not different between groups and it is was probably blinded for the assessors. Chinese clinical trial registration number: ChiCTR‐ONRC‐14005127 </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.12.3 Normo‐responders (MPA 4 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was nos stated and was probably not different between groups. The measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Definition of this outcome was not stated.. Definition of this outcome was not stated and was probably not different between groups, Not stated if assessors were aware of the assigned intervention but it is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.12.4 Normo‐responders (MPA 10 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Yu 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was not stated, was probably not different between groups and it is was probably blinded for the assessors </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "A computer‐generated list was used for randomization, patients were assigned via numbered sealed envelopes at a ratio of 1:1.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated.. Method of measuring the outcome was not stated, was probably not different between groups and it is was probably blinded for the assessors. Quote: "TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR‐IPR‐15007251" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.12.5 Normo‐responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Nearly all the randomized women were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was nos stated and was probably not different between groups. The measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation sequence was random and concealed. Quote: "The randomized sequence was generated by the randomization program in SPSS 16.0 statistical software. The randomization process was prepared by an independent statistician. An envelope was opened after confirmation of the inclusion/exclusion factors and after signing the informed consent." Quote: "There were no significant differences among the three groups in terms of age, BMI, AFC, duration of infertility, previous failed FET cycles, and the rate of ovarian advanced endometriomas that were treated surgically by laparoscopy or laparotomy. There were higher basal LH levels in the MPA+hMG group compared with the dydrogesterone +hMG and progesterone +hMG groups (4.14 IU/L vs. 3.48 IU/L vs. 3.24 IU/L, P &lt; 0.001)". However, the LH difference is not clinically significant.<br/>. . No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. Number of transferred embryos was similar (1.9 vs 1.8 vs 1.9). All randomised women were analysed.. Nearly all the randomized women were analysed.. Definition of this outcome was not stated.. Definition of this outcome was not stated and was probably not different between groups, Not stated if assessors were aware of the assigned intervention but it is unlikely to be influenced by the knowledge of the assigned intervention.. The study was registered with EudraCT Number 2015‐004328‐73 and under the ClinicalTrials.gov Identifier: NCT02796105. </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols but it was unlikely. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all the randomized women were analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was nos stated and was probably not different between groups. The measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)"</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited in a 1:1 ratio to receive treatment with either the Utrogestan + hMG protocol or the Duphaston + hMG protocol via the use of a random number table based on a computer‐generated drawing of numbers.". . Participants, carers and people delivering the intervention were aware of their assigned intervention. No information if there was a deviation from the intended protocols but it was unlikely. All randomised women were analysed. Almost all the randomized women were analysed. Definition of this outcome was not stated.. Method of measuring the outcome was nos stated and was probably not different between groups. The measurement of this outcome depends on the assessors evaluation. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐IOR‐15007265)" </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.12.6 Normo‐responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) ‐ Own oocytes ‐ Early phase stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Zhu 2017b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All the randomized women were analyzed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)."</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not stated if the allocation sequence was concealed, but sequence was random and there were no differences in baseline characteristics. Quote: "Patients were recruited with the use of a random number table based on a computer‐generated drawing of numbers.". Quote: "No significant differences were observed between the two groups regarding baseline characteristics, indication for IVF, previous IVF failures, and basal hormonal profile.". No information if participants, carers and people delivering the intervention were aware of their assigned intervention. No information about a deviation from the intended protocols. All randomised women were analysed.. All the randomized women were analyzed. Definition of this outcome was not stated.. Method of measuring the outcome was appropriate, was not different between groups but the measurement of this outcome depends on the assessors evaluation. Quote: "The trial was registered with the Chinese Clinical Trial Registry (ChiCTR‐OOC‐14005277)." </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.12 Moderate or severe OHSS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-37">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-38"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.1 Total oocytes</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 4.1.1 Oocyte donors (MPA 10 mg versus nothing) ‐ Luteal phase in a double stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Palomino 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with a computer (AleatorMetod.xsl) but not stated if the allocation sequence was concealed. And no information about the baseline characteristics. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information about the number of randomised participants and no information about the reason for the potential missingness </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol has not been registered</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with a computer (AleatorMetod.xsl) but not stated if the allocation sequence was concealed. And no information about the baseline characteristics. Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. All randomised women were analysed. There is no information about the number of randomised participants and no information about the reason for the potential missingness. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The protocol has not been registered </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.1 Total oocytes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-38">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-39"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.2 MII oocytes</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 4.2.1 Oocyte donors (MPA 10 mg versus nothing) ‐ Luteal phase in a double stimulation protocol</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Palomino 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with a computer (AleatorMetod.xsl) but not stated if the allocation sequence was concealed. And no information about the baseline characteristics. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. All randomised women were analysed </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information about the number of randomised participants and no information about the reason for the potential missingness </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method of measuring the outcome was probably appropriate, was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol has not been registered</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with a computer (AleatorMetod.xsl) but not stated if the allocation sequence was concealed. And no information about the baseline characteristics. Participants were probably aware of their assigned intervention. Carers and people delivering the intervention were probably not aware of their assigned intervention. All randomised women were analysed. There is no information about the number of randomised participants and no information about the reason for the potential missingness. Definition of this outcome was not stated, but the definition of this outcome is usually unique. Method of measuring the outcome was probably appropriate, was probably not different between groups and it is an objective outcome that is unlikely to be influenced by the knowledge of the assigned intervention.. The protocol has not been registered </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.2 MII oocytes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013827.pub2/references#riskOfBias2Table-39">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013827.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013827-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013827-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013827-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013827-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD013827-note-0016">Magyar</a> </li> <li class="section-language"> <a class="" href="ms#CD013827-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013827-note-0014">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD013827-note-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013827-note-0008">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013827-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013827\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013827\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013827\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013827\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013827\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013827.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013827.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013827.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013827.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013827.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716106260"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013827.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716106264"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013827.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d97641d4ff409',t:'MTc0MDcxNjEwNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 